

**POISONS STANDARD 2013**

I, ANTHONY GILL, a delegate of the Secretary to the Department of Health and Ageing for the purposes of paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the Act) and acting in accordance with the Secretary’s power under that paragraph of the Act, prepare this new Poisons Standard, in substitution for the current Poisons Standard.

(signed by)

ANTHONY GILL

Delegate of the Secretary to the Department of Health and Ageing

Dated this 22nd day of July 2013

1. **Citation**

This instrument is the *Poisons Standard 2013*.

1. **The New Poisons Standard**

The Poisons Standard 2013 consists of the Standard for the Uniform Scheduling of Medicines and Poisons No. 4 (the SUSMP 4) as set out in Schedule 1.

1. **Commencement**

The Poisons Standard 2013 commences on the day after registration.

**Schedule 1-Standard for the Uniform Scheduling of Medicines and Poisons No. 4**

**STANDARD FOR THE UNIFORM SCHEDULING OF**

**MEDICINES AND POISONS**

**No. 4**

**July 2013**

© Commonwealth of Australia 2013

Online ISBN: 978-1-74241-895-7

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice*,* all other rights are reserved andyou are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or via e-mail to copyright@health.gov.au.

Published by the Australian Government under the *Therapeutic Goods Act 1989*.

Publication approval number: 10329

This publication consolidates the previous Standard for the Uniform Scheduling of Medicines and Poisons and the subsequent amendments to that document. It records decisions made by the Secretary to the Department of Health and Ageing, or the Secretary's delegate, with implementation dates up to and including June 2013. The basis of these decisions can be found in the ‘Reasons for scheduling delegates' final decisions', which can be accessed from the TGA website:

*http://www.tga.gov.au/industry/scheduling-decisions-final.htm*

Further inquiries should be directed to:

The Secretary

Medicines and Poisons Scheduling Secretariat

GPO Box 9848

CANBERRA ACT 2601

Or by email: [*smp@health.gov.au*](mailto:smp@health.gov.au)

Media Liaison Unit

Australian Government Department of Health and Ageing

**Contents**

[INTRODUCTION iii](#_Toc359452330)

[CLASSIFICATION iv](#_Toc359452331)

[PRINCIPLES OF SCHEDULING iv](#_Toc359452332)

[READING THE SCHEDULES v](#_Toc359452333)

[Availability of poisons vi](#_Toc359452334)

[Preparations containing poisons listed in two or more Schedules vi](#_Toc359452335)

[PART 1](#_Toc359452336) - [INTERPRETATION 2](#_Toc359452337)

[PART 2](#_Toc359452338) - [LABELS AND CONTAINERS 10](#_Toc359452339)

[LABELS 10](#_Toc359452340)

[General requirements 10](#_Toc359452341)

[Immediate wrapper 10](#_Toc359452342)

[Primary packs and immediate containers 10](#_Toc359452343)

[Statements of quantity, proportion or strength 16](#_Toc359452344)

[Exemptions 17](#_Toc359452345)

[Selected containers and measure packs 17](#_Toc359452346)

[Ampoules, pre-filled syringes and injection vials 18](#_Toc359452347)

[Transport containers and wrappings 18](#_Toc359452348)

[Dispensary, industrial, laboratory and manufacturing poisons 18](#_Toc359452349)

[Exemptions from label requirements in certain circumstances 19](#_Toc359452350)

[Dispensed medicines 19](#_Toc359452351)

[Gas cylinders 19](#_Toc359452352)

[Paints 19](#_Toc359452353)

[Camphor and naphthalene 20](#_Toc359452354)

[Prohibitions 20](#_Toc359452355)

[CONTAINERS 20](#_Toc359452356)

[Containers for poisons other than Schedule 5 poisons 21](#_Toc359452357)

[Containers for Schedule 5 poisons 21](#_Toc359452358)

[Approved containers 22](#_Toc359452359)

[Child-resistant closures 22](#_Toc359452360)

[Schedule 8 poisons 24](#_Toc359452361)

[Exemptions 24](#_Toc359452362)

[Camphor and naphthalene 25](#_Toc359452363)

[Prohibitions 25](#_Toc359452364)

[PART 3](#_Toc359452365) - [MISCELLANEOUS REGULATIONS 26](#_Toc359452366)

[ADVERTISING 26](#_Toc359452367)

[SALE OR SUPPLY 26](#_Toc359452368)

[Schedule 2 poisons 26](#_Toc359452369)

[Schedule 3 poisons 26](#_Toc359452370)

[Schedule 4 poisons 27](#_Toc359452371)

[Schedule 7 poisons 27](#_Toc359452372)

[PROHIBITIONS ON SALE, PRESCRIBING AND POSSESSION 27](#_Toc359452373)

[STORAGE 28](#_Toc359452374)

[PART 4 -](#_Toc359452375) [THE SCHEDULES 30](#_Toc359452376)

[SCHEDULE 1 31](#_Toc359452377)

[SCHEDULE 2 32](#_Toc359452378)

[SCHEDULE 3 48](#_Toc359452379)

[SCHEDULE 4 54](#_Toc359452380)

[SCHEDULE 5 133](#_Toc359452381)

[SCHEDULE 6 161](#_Toc359452382)

[SCHEDULE 7 199](#_Toc359452383)

[SCHEDULE 8 209](#_Toc359452384)

[SCHEDULE 9 212](#_Toc359452385)

[PART 5 -](#_Toc359452386) [THE APPENDICES 218](#_Toc359452387)

[APPENDIX A](#_Toc359452388) - [General exemptions 219](#_Toc359452389)

[APPENDIX B](#_Toc359452390) - [Substances considered not to require control by scheduling](#_Toc359452391)  [222](#_Toc359452392)

[APPENDIX C](#_Toc359452393) - [Substances, other than those included in Schedule 9,](#_Toc359452394) [of such danger to health as to warrant](#_Toc359452395) [prohibition of sale, supply and use 231](#_Toc359452396)

[APPENDIX D](#_Toc359452397) - [Additional controls on possession or supply of poisons included in Schedule 4 or 8 235](#_Toc359452398)

[APPENDIX E](#_Toc359452399) - [First aid instructions for poisons 237](#_Toc359452400)

[APPENDIX F](#_Toc359452401) - [Warning statements and general safety directions for poisons 253](#_Toc359452402)

[APPENDIX G](#_Toc359452403) - [Dilute preparations 277](#_Toc359452404)

[APPENDIX H](#_Toc359452405) - [Schedule 3 poisons permitted to be advertised 278](#_Toc359452406)

[APPENDIX I](#_Toc359452407) - [Uniform Paint Standard 279](#_Toc359452408)

[APPENDIX J](#_Toc359452409) - [Conditions for availability and use of Schedule 7 poisons 280](#_Toc359452410)

[APPENDIX K](#_Toc359452411) - [Drugs required to be labelled](#_Toc359452412) [with a sedation warning 283](#_Toc359452413)

[APPENDIX L](#_Toc359452414) - [Requirements for dispensing labels for](#_Toc359452415) [human and veterinary medicines 286](#_Toc359452416)

[INDEX 289](#_Toc359452418)

# **INTRODUCTION**

The Poisons Standard 2013, which, under section 2 above consists of the *Standard for the Uniform Scheduling of Medicines and Poisons* (the Standard, or the SUSMP), is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989*, and is a compilation of the decisions made under section 52D of the same Act. The SUSMP should be read in conjunction with the *Scheduling Policy Framework* (SPF) of the National Coordinating Committee on Therapeutic Goods. Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).

The SUSMP serves two key purposes.

Firstly, the SUSMP contains the decisions of the delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, the SUSMP includes model provisions for labelling, containers, storage and possession of poisons in general, which are intended to be adopted for use in each jurisdiction of Australia, according to local requirements and local law. Appropriate labelling and container requirements for products, other than therapeutic goods and agricultural and veterinary chemicals, are imposed through adoption of Parts 1, 2 and 3 of the SUSMP into State or Territory legislation. Other government agencies may also impose controls on certain products, for example cosmetics.

The requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].Note, however that this exemption does not extend to controls on supply of these poisons.

The SUSMP is presented with a view to promoting uniform:

* scheduling of poisons throughout Australia;
* signal headings on labels for poisons throughout Australia;
* labelling and packaging requirements for poisons throughout Australia;
* additional controls on the availability and use of poisons in Australia.

The various Commonwealth Acts, legislative instruments and other documents which integrate with the SUSMP include:

* the *Agricultural and Veterinary Chemicals Code Act 1994*
* the *Agricultural and Veterinary Chemicals Code Regulations 1995*
* the *Therapeutic Goods Act 1989*
* Therapeutic Goods Order 69 – *General requirements for labels for medicines*
* Therapeutic Goods Order 80 – *Child-Resistant Packaging Requirements for Medicines*
* the *Required Advisory Statements for Medicine Labels* (RASML).

## CLASSIFICATION

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

**Schedule 1.** This Schedule is intentionally blank.

**Schedule 2. Pharmacy Medicine** – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

**Schedule 3. Pharmacist Only Medicine** – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

**Schedule 4. Prescription Only Medicine,** or **Prescription Animal Remedy** – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

**Schedule 5. Caution** – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

**Schedule 6. Poison** – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

**Schedule 7. Dangerous Poison** – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

**Schedule 8. Controlled Drug** – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

**Schedule 9. Prohibited Substance** – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

## PRINCIPLES OF SCHEDULING

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This Standard lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this Standard, the method by which it is implemented in the States and Territories may vary.

Substances in products which have been considered for scheduling, but have been exempted from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Appendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties. It is recommended that the provisions of this Appendix be put into effect through inclusion of the substances in appropriate State and Territory legislation.

## READING THE SCHEDULES

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Part 1, Interpretation, subparagraph 1(2).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this Standard to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:

**Group Example**

the parent acid of salts “oxalic acid” to find sodium oxalate

the radical of a salt “chromates” to find potassium

chromate

the element “arsenic” to find arsenic trioxide

a chemical group with similar “hydrocarbons, liquid” to find

toxicological or pharmacological kerosene

activity

a pharmacological group “anabolic steroidal agents” to find

“androsterone”

### **Availability of poisons**

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:

* that the poison is available; nor
* that is has been approved or is efficacious for any use that may be specified in a Schedule; nor
* does it negate any obligation for registration of a therapeutic good, or agricultural or veterinary chemical product containing that poison.

### **Preparations containing poisons listed in two or more Schedules**

If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.

Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.

The Schedules listed in order of greatest to least restriction on access and availability are 9, 8, 4, 7, 3, 2, 6, 5.

Schedule 1 is not currently in use.

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this Standard. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

| **Appendix** | **Title** | **Purpose/ controls imposed** |
| --- | --- | --- |
| Appendix A | General exemptions | List of classes of products or uses exempted from this Standard. |
| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
| Appendix C | Substances, other than those included in Schedule 9, of such danger to health as to warrant prohibition of sale, supply and use | List of poisons prohibited from sale, supply or use because of their known potential for harm to human and/or animal health. |
| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix G | Dilute preparations | Concentration cut-offs for specified poisons, below which the requirements of the Standard do not apply |
| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
| Appendix I | Uniform Paint Standard | Requirements applying to poisons included in paints or tinters. |
| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
| Appendix K | Human medicines required to be labelled with a sedation warning | List of human medicines required to be labelled with a warning regarding their sedation potential. |
| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |

This page is intentionally blank.

# **PART 1**

# **INTERPRETATION**

**1.** (1) In this Standard, unless the contrary intention appears —

“**Agricultural chemical**” means a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:

(a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing;

(b) destroying a plant;

(c) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity;

(d) modifying an effect of another agricultural chemical;

(e) attracting a pest for the purpose of destroying it; or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an agricultural chemical product;

but does not include:

(g) a veterinary chemical.

“**Agricultural chemical product**” has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

“**Animal**” means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

**“Animal feed premix”** means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

“**Appropriate authority**” means:

(a) in the Australian Capital Territory, ACT Government Health Directorate;

(b) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines Authority, the Chief Executive Officer or their delegate;

(c) in New South Wales, the Director-General of the NSW Ministry of Health;

(d) in the Northern Territory, the Chief Health Officer of the Department of Health;

(e) in Queensland, the Chief Executive of Queensland Health;

(f) in South Australia, the Chief Executive of the Department for Health and Ageing;

(g) in Tasmania, the Secretary of the Department of Health and Human Services;

(h) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 of this Standard

by the Therapeutic Goods Administration, the National Manager or their delegate;

(i) in Victoria, the Secretary to the Department of Health;

(j) in Western Australia, the Chief Executive Officer of the Department of Health.

**“Approved name”** means:

(a) in relation to a poison that is for human therapeutic use, the name approved for use by the Therapeutic Goods Administration;

(b) in relation to a poison that is for animal or agricultural use, the name approved for use by the Australian Pesticides and Veterinary Medicines Authority;

(c) in relation to all other poisons:

(i) the name used in an entry in these Schedules; or, if no such name is given,

(ii) the English name recommended by Standards Australia as the common name for the poison; or, if no such name is given,

(iii) the English name given to the poison by the International Organization for Standardization; or, if no such name is given,

(iv) the English name given to the poison by the British Standards Institution; or, if no such name is given,

(v) the name that would comply with the requirements of part (a) or (b) of this definition, or, if no such name is given,

(vi) the English name given to the poison by the European Committee for Standardization (CEN); or, if no such name is given,

(vii) the international non-proprietary name recommended for the poison by the World Health Organization; or, if no such name is given,

(viii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the *International Cosmetic Ingredient Dictionary & Handbook* published by the Personal Care Products Council of America; or, if no such name is given,

(ix) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

**“Australian Code for the Transport of Dangerous Goods by Road and Rail”** means the seventh edition of the document of that name.

“**Authorised prescriber**” means a registered medical, dental or veterinary practitioner or such other person authorised by the appropriate authority.

**“Blood”** means whole blood extracted from human donors.

“**Blood components**” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

**“Child-resistant closure”** means:

(a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) a closure approved by an order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989;* or

(c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.

See also "Non-access packaging**”**.

**“Child-resistant packaging”** means packaging that:

(a) complies with the requirements of the Australian Standard AS 1928-2007 entitled

*Child resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) is reclosable and complies with the requirements of at least one of the following Standards:

(i) the International Organization for Standardization Standard ISO 8317:2003 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages*;

(ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled

*Child-resistant packaging. Requirements and testing procedures for reclosable packages*;

(iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled *Reclosable Child-Resistant Packages;*

(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled *Poison prevention packaging standards* and Section 1700.20, entitled *Testing procedure for special packaging*;

(c) is approved as child-resistant by any order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled *Child-resistant packages.*

See also "Non-access packaging".

**“Compounded**” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

“**Debitterised neem seed oil**” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

**“Dermal use”** means application to the skin primarily for localised effect.

**“Designated solvent”** means the following:

acetone

dimethylformamide

N-(N-dodecyl)-2-pyrrolidone

hydrocarbons, liquid

methanol when included in Schedule 5

methyl ethyl ketone

methyl isoamyl ketone

methyl isobutyl ketone

N-methyl-2-pyrrolidone

N-(N-octyl)-2- pyrrolidone

phenyl methyl ketone

styrene

tetrachloroethylene

1,1,1-trichloroethane

**“Dispensing label”** means the label attached to the immediate container of a substance for therapeutic use at the time of dispensing.

**“Distributor”** means a person who imports, sells or otherwise supplies a poison.

**“Divided preparation”** means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

**“Dosage unit”** means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

**“Drug”** means a poison intended for human or animal therapeutic use.

**“Essential oils”** means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:

(a) oils of equivalent composition derived through synthetic means; or

(b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.

**“External”** in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

**“First Schedule Paint”** means a paint containing the specified proportion of any substance in the First Schedule to Appendix I of this Standard.

**“Free formaldehyde”** includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol.

**“Graphic material”** means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

**“Height”** in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

**“Hemp seed oil”** means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

**“Immediate container**” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

**“Immediate wrapper”** means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

**“Internal use”** means administration:

(a) orally, except for topical effect in the mouth; or

(b) for absorption and the production of a systemic effect;

(i) by way of a body orifice other than the mouth; or

(ii) parenterally, other than by application to unbroken skin.

**“Label”** means:

(a) a written statement on a container of a poison; and

(b) in relation to a therapeutic good, includes a display of printed information about the product:

(i) on, or attached to, the good;

(ii) on, or attached to, a container or primary pack in which the good is supplied; or

(iii) supplied with such a container or pack.

**“Main label”** means, where there are two or more labels on a container or a label is divided into two or more portions:

(a) the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and

(b) where there are two or more labels or two or more portions of a single label – that label or portion of the label where the product name is more or most conspicuously shown; or

(c) where the product name is equally conspicuous on two or more labels or portions of a label – each such label or portion.

**“Manufacturer”** means a person who manufactures, produces, or packs a poison.

**“Measure pack”** means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

**“Medicine”** means any poison for therapeutic use**.**

*Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to human or animal use is intended.*

**“Name and address”** means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.

**“Non-access packaging**” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled *Packages for chemicals not intended for access or contact with their contents by humans*, in relation to products that are not intended for human therapeutic use.

See also "Child-resistant closure" and "Child-resistant packaging”.”.

**“Non-volatile content”** in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005entitled *Paints and related materials – Methods of test – Non-volatile content by mass*.

“**Oromucosal use**” means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

**“Paint”**, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

**“Pesticide”** means any substance or mixture of substances used or intended to be used:

(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

**“Poison”** means any substance or preparation included in a Schedule to this Standard.

**“Primary pack”** means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.

**“Required Advisory Statements for Medicine Labels”** means the document made under subsection 3(5A) of the *Therapeutic Goods Act 1989* by the Therapeutic Goods Administration.

**“Restricted flow insert”** means a restriction fitted, or moulded, in the neck of a container which:

(a) cannot readily be removed from the container by manual force; and

(b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.

**“Second Schedule Paint”** means a paint containing the specified proportion of any substance in the Second Schedule to Appendix I of this Standard.

**“Selected container”** means:

(a) an injection vial having a nominal capacity of ten millilitres or less;

(b) a single use syringe; or

(c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.

**“Solid”** is considered to include “powder” for the purposes of scheduling.

**“Therapeutic good”** has the meaning defined in theCommonwealth*Therapeutic Goods Act 1989.*

**“Therapeutic use”** means use in or in connection with:

(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;

(b) influencing, inhibiting or modifying a physiological process in human beings or animals;

(c) testing the susceptibility of human beings or animals to a disease or ailment;

(d) influencing, controlling or preventing conception in persons or animals;

(e) testing for pregnancy in persons or animals; or

(f) the replacement or modification of parts of the anatomy in persons or animals.

**“Third Schedule Paint”** means a paint containing the specified proportion of any substance in the Third Schedule to Appendix I of this Standard.

**“Tinter”** means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

**“Topical use”** means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

**“Toy”** means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.

**“Transdermal use”** means application to the skin primarily for systemic effect.

**“Veterinary chemical”** means a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:

(a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest;

(b) curing or alleviating an injury suffered by the animal;

(c) modifying the physiology of the animal:

(i) so as to alter its natural development, productivity, quality or reproductive capacity; or

(ii) so as to make it more manageable;

(d) modifying the effect of another veterinary chemical

(e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an veterinary chemical product;

but does not include:

(g) an agricultural chemical.

**“Veterinary chemical product”** has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

**“Writing”** includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.

(2) Unless the contrary intention appears a reference to a substance in a Schedule or an Appendix to this Standard includes:

(a) that substance prepared from natural sources or artificially; and

(b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and

(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and

(d) every alkaloid of the substance and every salt of such an alkaloid; and

(e) every stereoisomer of the substance and every salt of such a stereoisomer; and

(f) every recombinant form of the substance; and

(g) a preparation or admixture containing any proportion of the substance,

but does not include:

(h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or

(i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or

(j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or

(k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Standards for Active Constituents*, as published by the Australian Pesticides and Veterinary Medicines Authority.

(3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a Schedule or an Appendix to this Standard in respect of a substance:

(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and

(b) the expression “one per cent” means:

(i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or

(ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and

(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

(4) A reference to a boiling or distillation temperature in the Schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

# **PART 2**

# **LABELS AND CONTAINERS**

## LABELS

**2**. A person must not sell or supply a poison unless it is labelled in accordance with paragraphs 3 to 19 of this Standard.

## General requirements

**3.** Any word, expression or statement required by this Standard to be written on a label or container must be written:

(1) on the outside face of the label or container; and

(2) in the English language; and

(3) in durable characters; and

(4) in a colour or colours to provide a distinct contrast to the background colour; and

(5) in letters at least 1.5 millimetres in height.

**4.** Subparagraph 3(5) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:

(1) an appropriate authority approves the use of smaller letters; and

(2) the letters are at least 1 millimetre in height.

**5.** The label must be printed on, or securely attached to:

(1) the outside of the immediate container; and

(2) if the immediate container is enclosed in a primary pack, the outside of that primary pack.

## Immediate wrapper

**6.** (1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with paragraph 7 of this Standard; and

(2) the immediate wrapper must be conspicuously labelled with:

(a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

(b) the approved name of the poison; and

(c) a statement of the quantity or strength of the poison in accordance with   
paragraph 8 of this Standard.

## Primary packs and immediate containers

**7.** (1) The primary pack and immediate container of a poison must be labelled as follows:

(a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:

Schedule Purpose Signal words required

2 for any purpose **PHARMACY MEDICINE**

3 for any purpose **PHARMACIST ONLY MEDICINE**

4 for human use **PRESCRIPTION ONLY MEDICINE**

4 for animal use **PRESCRIPTION ANIMAL REMEDY**

5 for any purpose **CAUTION**

6 for any purpose **POISON**

7 for any purpose **DANGEROUS POISON**

8 for any purpose **CONTROLLED DRUG**

written:

(i) on the first line or lines of the main label; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:

(A) 6 millimetres on labels for packages having a nominal capacity of   
2 litres or less; or

(B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and

(iv) if the poison:

(A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail* or a statement of the principal hazard of the poison, written on that line; or

(B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on that line;

(b) if the poison is a Schedule 8 poison, with the cautionary statement –

**POSSESSION WITHOUT AUTHORITY ILLEGAL**

written:

(i) on a separate line or lines immediately below the signal words required by subparagraph 7(1)(a); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with no other statement written on the same line;

(c) with the cautionary statement –

**KEEP OUT OF REACH OF CHILDREN**

written:

(i) on a separate line or lines:

(A) immediately below the signal word or words required by subparagraph 7(1)(a); or

(B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by subparagraph 7(1)(b), on the line immediately below that statement; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, **except** for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FIRE AND EXPLOSION HAZARD**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –

**BURNS SKIN AND THROAT**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line of the main label;

(f) if the poison is an aqueous solution of paraquat, with the cautionary statements –

**CAN KILL IF SWALLOWED**

**DO NOT PUT IN DRINK BOTTLES**

**KEEP LOCKED UP**

written:

(i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same lines of the main label;

(g) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if safety directions are required on the label by subparagraph 7(1)(n), with the cautionary statement –

**READ SAFETY DIRECTIONS BEFORE OPENING**

**OR USING**

or with the cautionary statement –

**READ SAFETY DIRECTIONS**

written:

(i) on a separate line or lines;

(A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); or

(B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(h) if the poison meets the criteria for a ‘flammable liquid’ in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FLAMMABLE**

written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the *Australian Code for the Transport of Dangerous Goods by Road and Rail*;

(i) if the poison is for the treatment of animals, with the cautionary statement –

**FOR ANIMAL TREATMENT ONLY**

written on the main label in bold-face sans serif capital letters of uniform thickness;

(j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –

DO NOT SWALLOW

written in sans serif capital letters on the main label or as part of the directions for use;

(k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with paragraph 8:

(i) if the poison is for human therapeutic use, written in accordance with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act, 1989*; or

(ii) if the poison is not for human therapeutic use, written in bold-face sans serif capital letters on the main label, unless:

(A) a list of approved names is required; and

(B) it is impractical to include the list on the main label; and

(C) an appropriate authority has authorised its inclusion on another part of the label; or

(iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:

**TABLE**

**Column 1 Column 2**

Alkaline salts Alkaline salts

Amines for use as curing Aliphatic amines or

agents for epoxy resins aromatic amines

(unless separately specified

in the Schedules)

Epoxy resins, liquid Liquid epoxy resins

Hydrocarbons, liquid Liquid hydrocarbons

Quaternary ammonium Quaternary ammonium

compounds compound(s)

(iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:

(A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or

(B) where the designated solvent is a ketone as “ketones”; or

(C) in any other case as “solvents” or “other solvents”;

(l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –

**AN ANTICHOLINESTERASE COMPOUND**

(i) the requirements of subparagraph 7(1)(l) do not apply to:

(A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or

(B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

(C) an organophosphorus compound or carbamate contained in a

pressurised spray pack for household use;

(m) for any poison other than a poison for human therapeutic use labelled in accordance with Therapeutic Goods Order 69 *General requirements for labels for medicines* or in an agricultural or veterinary chemical product labelled in compliance with the *Agricultural and Veterinary Chemicals Code Act 1994*, if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:

(i) the poison is included in Schedule 4 or Schedule 8; or

(ii) it is impractical to include such directions on the label and:

(A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and

(B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and

(C) the insert is enclosed in the primary pack;

(n) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –

**SAFETY DIRECTIONS**

written in bold-face capital letters;

(o) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:

(i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or

(ii) if there are no safety directions, immediately preceding the directions for use;

(p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):

(i) grouped together and prefaced by the words –

**FIRST AID**

written in bold-face capital letters; or

(ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(A) written on each immediate container as specified in subparagraph 7(1)(p)(i); and

(B) replaced on the primary pack with the statement –

FIRST AID: See inner packs;

(q) with the name and address of the manufacturer or distributor.

(2) For the purposes of subparagraph 7(1)(a)(iii) the term “largest letter or numeral” does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name; or

(c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

## Statements of quantity, proportion or strength

**8.** The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(1) if the poison is for human therapeutic use, in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*;

(2) if the poison is for a purpose or purposes other than human therapeutic use and:

(a) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;

(b) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;

(c) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;

(d) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(e) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(f) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(g) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(h) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;

(3) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;

(4) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

contains not more than 10 per cent of (*insert* *name of the metal*); or

contains not more than 30 per cent of (*insert name of the metal*); or

contains more than 30 per cent of (*insert name of the metal*);

(5) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;

(6) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

(7) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

(8) For the purposes of subparagraph 8(7) “derivative” includes alkaloid.

## Exemptions

### **Selected containers and measure packs**

**9.** The requirements of paragraph 7 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which paragraph 10 or 11 apply) when:

(1) the immediate container is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the immediate container is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) labelled with:

(i) the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to subparagraph 7(1)(a); and

(ii) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

(iii) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(iv) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

### **Ampoules, pre-filled syringes and injection vials**

**10.** The requirements of paragraph 7 do not apply to a selected container, or an ampoule (other than an ampoule to which paragraph 11 applies) when:

(1) the selected container or ampoule is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the selected container or ampoule is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) labelled with:

(i) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

(ii) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(iii) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

**11.** The requirements of paragraph 7 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(1) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) the strip is labelled in accordance with paragraph 10; and

(c) the ampoule is labelled with:

(i) the approved name of the poison or the trade name of the product; and

(ii) the quantity, proportion or strength of the poison in accordance with paragraph 8.

### **Transport containers and wrappings**

**12.** The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

### **Dispensary, industrial, laboratory and manufacturing poisons**

**13.** The labelling requirements of this Standard do not apply to a poison that:

(1) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

(2) is labelled in accordance with Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].

### **Exemptions from label requirements in certain circumstances**

**13A.** (1) The labelling requirements of paragraphs 7 to 12 do not apply to a poison where an appropriate authority has granted a labelling exemption in whole or in part for these sections for a specified product; and

(2) the labelling exemption from an appropriate authority referred to in subparagraph (1) is limited to no more than 12 months from the effective date of the decision for retail supply of the product; and

(3) for the avoidance of doubt this paragraph does not apply to exemptions issued under subparagraph 7(1)(m)(ii)(B) of this Standard.

### **Dispensed medicines**

**14.** Unless otherwise specified by regulation:

(1) The labelling requirements of this Standard do not apply to a medicine that:

(a) is supplied by an authorised prescriber or other person authorised to supply and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(b) is supplied on and in accordance with a prescription written by an authorised prescriber and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(c) is prepared and supplied by a pharmacist for an individual patient and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard.

(2) A person must not supply a dispensed medicine for human use containing:

(a) a poison listed in column 1 of the table at Appendix L Part 2 of this Standard unless it is clearly labelled with the warning statement(s) specified in column 2 of that table; or

(b) a poison listed in Appendix K unless it is clearly labelled with a sedation warning (being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).

### **Gas cylinders**

**15.** The requirements of subparagraphs 7(1)(a)(iv), 7(1)(c)(iv), and 7(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.

### **Paints**

**16.** The requirements of paragraph 7 do not apply to:

(1) paint (other than a paint for therapeutic or cosmetic use) which:

(a) contains only Schedule 5 poisons; or

(b) is a First Schedule or Second Schedule paint that is labelled with:

(i) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

(ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

(iii) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

(iv) the name and proportion of the First Schedule or Second Schedule poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or

(2) a tinter which contains:

(a) only Schedule 5 poisons; or

(b) a poison included in the First Schedule or Second Schedule to Appendix I, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.

### **Camphor and naphthalene**

**17.** The labelling requirements of subparagraph 3(4) and paragraph 7 do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

(1) complies with paragraph 28; and

(2) is sold or supplied in a primary pack labelled in accordance with paragraphs 3 and 7.

### **Prohibitions**

**18**. A label used in connection with any poison must not include:

(1) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or

(2) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or

(3) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

(4) any trade name or description that:

(a) represents any single constituent of a compound preparation; or

(b) misrepresents the composition or any property or quality of the poison; or

(c) gives any false or misleading indication of origin or place of manufacture of the poison.

**19.** A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:

(1) any expression required by this Standard to be written or embossed on the container or pack; or

(2) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.

## CONTAINERS

**20.** A person must not sell or supply a poison unless the immediate container complies with the requirements of paragraphs 21 to 28 of this Standard.

## Containers for poisons other than Schedule 5 poisons

**21.** If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances*.

**21a.** Notwithstanding subparagraph 21, a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances,* if:

(1) the other safety factors are not diminished; and

(2) the container has a restricted flow insert and a child-resistant closure.

**22**. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:

(1) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*; and

(2) have the word “POISON”:

(a) in sans serif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:

(i) embossed; or

(ii) indelibly written in a colour in distinct contrast to the background colour;

(b) on the side or shoulder of the container.

## Containers for Schedule 5 poisons

**23.** (1) The container in which any Schedule 5 poison is sold or supplied must:

(a) comply with the container requirements of paragraph 21 or paragraph 22; or

(b) be readily distinguishable from a container in which food, wine or other beverage is sold; and

(i) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*, excluding paragraph 1.4.3;

(ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and

(iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

(2) Notwithstanding subparagraph 23(1), the following Schedule 5 poisons namely:

(a) methylated spirit(s);

(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

(c) petrol;

(d) toluene; or

(e) xylene,

must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in paragraph 21.

## Approved containers

**24.** Notwithstanding subparagraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of Australian Standard AS2216-1997 entitled *Packaging for poisonous substances* or the requirements of subparagraphs 22(2) or 23(1)(iii) if:

(1) the other safety factors are not diminished;

(2) the container is for a specific purpose; and

(3) an appropriate authority has approved the use of the container for that purpose.

## Child-resistant closures

**25.** (1) If a poison, other than a poison included in a therapeutic good packaged in a manner compliant with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*, listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2, it must be closed with a child-resistant closure.

**TABLE**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Name of the poison Nominal capacity**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Alkaline salts included in Schedule 5, All sizes  
when packed and labelled as dishwashing

machine tablets.

Alkaline salts included in Schedule 5, 5 litres /kilograms or less  
when packed and labelled as dishwashing

machine liquids, solids or gels.

Alkaline salts included in Schedule 5, when 2.5 litres or less

packed and labelled as a food additive.

Anise oil when included in Schedule 5. 200 millilitres or less

Basil oil when included in Schedule 5. 200 millilitres or less

Bay oil when included in Schedule 6. 200 millilitres or less

Cajuput oil when included in Schedule 6. 200 millilitres or less

Cassia oil when included in Schedule 5. 200 millilitres or less

Cineole when included in Schedule 6. 2 litres or less

Cinnamon bark oil when included 200 millilitres or less

in Schedule 5.

Cinnamon leaf oil when included in Schedule 6. 200 millilitres or less

Clove oil when included in Schedule 6. 200 millilitres or less

Essential oils when included in Schedule 6 200 millilitres or less

because of their natural camphor component.

Ethylene glycol when included in Schedule 6. 5 litres or less

Ethylene glycol when included in 5 litres or less

Schedule 5 in preparations containing

more than 50 per cent of ethylene glycol.

Eucalyptus oil when included in Schedule 6. 2 litres or less

Eugenol when included in Schedule 6. 200 millilitres or less

Hydrocarbons, liquid, when packed 5 litres or less

as kerosene, lamp oil, mineral turpentine,

thinners, reducers, white petroleum spirit

or dry cleaning fluid.

Hydrochloric acid when included in Schedule 6. 5 litres or less

*Leptospermum scoparium* oil (manuka oil) 200 millilitres or less

when included in Schedule 6

Marjoram oil when included in Schedule 5. 200 millilitres or less

Melaleuca oil (tea-tree oil) when included 200 millilitres or less

in Schedule 6.

Methylated spirit excluding preparations or 5 litres or less

admixtures.

Methyl salicylate and preparations containing 200 millilitres or less

more than 50 per cent of methyl salicylate.

Nutmeg oil when included in Schedule 5. 200 millilitres or less

Oil of turpentine. 5 litres or less

Pennyroyal oil when included in Schedule 6. 200 millilitres or less

Potassium hydroxide as such. 2.5 litres or less

Potassium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

d-Pulegone when included in Schedule 6. 200 millilitres or less

Sage oil (Dalmatian) when included 200 millilitres or less

in Schedule 6.

Sodium hydroxide as such. 2.5 litres or less

Sodium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

Thujone when included in Schedule 6. 200 millilitres or less

Thyme oil when included in Schedule 5. 200 millilitres or less

(2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.

## Schedule 8 poisons

**25A.** (1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

(2) This paragraph does not apply to the supply of a Schedule 8 poison by an:

(a) authorised prescriber or other authorised supplier;

(b) pharmacist on the prescription of an authorised prescriber;

(c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse or midwife in charge of the ward in which the Schedule 8 poison is to be used or stored; or

(d) nurse or midwife on the direction in writing of an authorised prescriber.

## Exemptions

**26.** (1) Paragraphs 21, 22 and 23 do not apply to the immediate container of a poison prepared, packed and sold:

(a) for human internal or animal internal use; or

(b) as a solid or semi-solid preparation for human external or animal external use; or

(c) as a paint, other than a paint for therapeutic or cosmetic use; or

(d) in containers having a nominal capacity of 15 millilitres or less; or

(e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or

(f) solely for dispensary, industrial, laboratory or manufacturing purposes.

(2) Paragraph 25 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

**27**. The tactile identification or embossing required by paragraphs 21, 22 or 23 of this Standard or Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances* do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

## Camphor and naphthalene

**28**. The container requirements of paragraph 21 do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

(1) in normal use, prevents removal or ingestion of its contents; and

(2) is incapable of reacting with the poison; and

(3) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

(4) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

## Prohibitions

**29.** A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

**30**. A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.

**31**. A person must not sell any poison which is for internal use or any food, drink or condiment in a container prescribed by paragraph 21, 22 or 23 of this Standard.

**31A.** A person must not sell any poison in a container used expressly for any food, drink or condiment.

# **PART 3**

# **MISCELLANEOUS REGULATIONS**

(It is recommended that the States and Territories implement regulations which   
provide controls similar to those included in this Part of the Standard.)

## ADVERTISING

**32.** A person must not include any reference to a poison included in:

(a) Schedule 3 unless included in Appendix H; or

(b) Schedule 4 or Schedule 8,

of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

**33.** A person must not include any reference to a poison included in Schedule 9 or Appendix C of this Standard in any advertisement.

## SALE OR SUPPLY

## Schedule 2 poisons

**34**. A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.

**35**. A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:

(1) he or she is carrying on the business of selling goods by retail; and

(2) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and

(3) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.

## Schedule 3 poisons

**36**. A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

**37.** The person who sells or supplies a Schedule 3 poison must:

(1) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and

(2) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and

(3) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.

## Schedule 4 poisons

**38**. A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.

**39.** Paragraph 38 does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:

(1) the patient is under medical treatment with the poison and continuation of medication is essential; and

(2) the quantity sold or supplied does not exceed 3 days' medication; and

(3) the pharmacist is satisfied that an emergency exists.

**40.** Paragraphs 34, 36, 37 and 38 do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.

## Schedule 7 poisons

**41.** (1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.

(2) A person must not sell or supply:

(a) a Schedule 7 poison for domestic or domestic garden purposes; or

(b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or

(c) a Schedule 7 poison for which an authorisation to possess or use is required by subparagraph (3) unless the purchaser produces his or her authorisation.

(3) A person must not possess or use any of the following Schedule 7 poisons unless he or she is authorised to do so by the appropriate authority:

Arsenic

Cyanides

Fluoroacetic acid

Fluoroacetamide

Hydrocyanic acid

Strychnine

Thallium.

(4) The appropriate authority may exempt a person or a class of persons from the requirement to hold an authorisation under subparagraph (3) and may vary or revoke the exemption by notice in writing.

## Prohibitions on sale, prescribing and possession

**42.** A person must not:

(1) knowingly have in his or her possession or sell, supply or use a poison listed in Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Appendix C; or

(2) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or

(3) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.

## STORAGE

**43.** A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.

**44**. A person who sells or supplies Schedule 3, Schedule 4 or Schedule 7 poisons must keep those poisons in a part of the premises to which the public does not have access.

This page is intentionally blank.

# **PART 4**

# **THE SCHEDULES**

## SCHEDULE 1

This Schedule is intentionally blank.

## 

## SCHEDULE 2

(Substances marked † are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMOROLFINE in preparations for topical use **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except**:

(a) when included in Schedule 4, 5 or 6;

(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:

(i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and

(ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant closure;

(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325  mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant

closure;

(ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ATROPA BELLADONNA (belladonna):

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE:

(a) in preparations for nasal use ; or

(b) in topical eye preparations containing 0.05 per cent or less of azelastine.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

CICLOPIROX:

1. in preparations for dermal use containing 2 per cent or less of ciclopirox **except** in preparations for the treatment of tinea pedis; or
2. in preparations for application to the nails containing 8 per cent or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CODEINE in preparations for the treatment of coughs and colds when:

(a) not combined with any other opiate substance;

(b) compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:

(i) in divided preparations containing 10 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 60 mg of codeine; and

(d) in packs containing not more than 6 days' supply at the maximum dose recommended on the label.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DATURA TATULA (stramonium) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of *Delphinium staphisagria*.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

1. in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;
2. in preparations for dermal use containing 4 per cent or less of diclofenac **except** in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or
3. in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:

(a) containing 5 mg or less of dihydrocodeine per dosage unit;

(b) packed in blister or strip packaging or in a container with a child-resistant closure;

(c) enclosed in primary packs containing 25 or less dosage units; and

(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ETAFEDRINE.

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 10 per cent or less of ether.

ETHYLMORPHINE when:

(a) compounded with one or more other therapeutically active substances:

(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;

(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FLUORIDES for human use:

(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:

(i) for therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels* **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of *Required Advisory Statements for Medicine Labels;* or

(ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or

(b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.

FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

† FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

GELSEMIUM SEMPERVIRENS.

GLUTARALDEHYDE for human therapeutic use.

HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:

(a) in preparations containing 0.75 per cent or less of hexachlorophane; or

(b) in preparations for use on infants, as specified in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except** in hair preparations containing 0.3 per cent or less of hydroquinone.

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.

HYOSCINE (excluding hyoscine butylbromide):

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2  mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:

(a) in liquid preparations when sold in the manufacturer’s original pack containing 8 grams or less of ibuprofen; or

(b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:

(i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);

(ii) packed in blister or strip packaging or in a container with a child-resistant closure;

(iii) in a primary pack containing not more than 25 dosage units;

(iv) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(v) not labelled for the treatment of children 6 years of age or less; and

(vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

INDANAZOLINE.

INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

IODINE:

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),

**except** in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:

(a) when included in Schedule 4; or

(b) when labelled with a recommended daily dose of 24 mg or less of iron:

(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

(ii) in divided preparations:

(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

(B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the

scalp; or

(b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.

LEVOCABASTINE in topical eye or nasal preparations.

LIGNOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.

LITHIUM in preparations for dermal use containing 1 per cent or less of lithium **except**:

(a) when present as an excipient at 0.25 per cent or less of lithium; or

(b) in preparations containing 0.01 per cent or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less **except** in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing 5 dosage units or less; and

(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome **except** when included in Schedule 6.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

METHOXAMINE in preparations for external use **except** in preparationscontaining 1 per cent or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

PAPAVERINE **except** when included in Schedule 4.

PARACETAMOL for therapeutic use **except**:

(a) when included in Schedule 4;

(b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesinor when combined with effervescent agents) when:

(i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;

(ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iii) not labelled for the treatment of children 6 years of age or less; and

(iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or

(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:

(i) packed in blister or strip packaging or in a container with a child-resistant closure;

(ii) in a primary pack containing not more than 25 tablets or capsules;

(iii) compliant with the requirements of the *Required Advisory Statements for*

*Medicine Labels*;

(iv) not labelled for the treatment of children 6 years of age or less; and

(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.

† PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

PENCICLOVIR for external use for the treatment of herpes labialis.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 3 per cent or less of such substances.

PHENYLEPHRINE **except**:

(a) when included in Schedule 4;

(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

(a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply **except** in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

(a) for topical use containing 3.5 per cent or less of selenium sulfide;

(b) when included in Schedule 4; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

(a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in other preparations containing 1 per cent or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1 per cent or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses

are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night

doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

## SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AZATADINE in oral preparations.

BROMPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTOL in preparations for human use **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days' supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when:

(a) not combined with any other opiate substance;

(b) compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:

(i) in divided preparations containing 12 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and

(d) in packs containing not more than 5 days' of supply at the maximum dose recommended on the label,

**except** when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,

**except** when included in Schedule 2.

DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ERYTHRITYL TETRANITRATE for therapeutic use.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:

(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

(a) in preparations for oral use; or

(b) in preparations for rectal use.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

(i) in undivided preparations, in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories,

**except** when included in Schedule 2.

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units when labelled:

(a) with a recommended daily dose of 1200 mg or less of ibuprofen; and

(b) not for the treatment of children under 12 years of age,

**except** when included in or expressly excluded from Schedule 2.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

LEVONORGESTREL for emergency post-coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations **except** when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

Malathion in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.

PHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

SALBUTAMOL as the only therapeutically active substance:

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40 per cent or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.

TERBUTALINE as the only therapeutically active substance:

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

TRIMEPRAZINE:

(a) in solid oral preparations **except** when included in Schedule 2; or

(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

## SCHEDULE 4

(Substances marked † are listed in Appendix C)

(Substances marked # are listed in Appendix D)

ABACAVIR.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

# ACITRETIN.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

(a) when included in Schedule 2;

(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE. **except**:

(a) when included in Schedule 3; or

(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AFAMELANOTIDE.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALATROFLOXACIN MESYLATE.

ALBENDAZOLE **except**:

(a) when included in Schedule 5 or 6; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

# ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALISKIREN.

ALLERGENS.

ALLOPURINOL.

ALLYLOESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPHA1-PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALPHAXALONE.

ALPRAZOLAM.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

# AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMETHOCAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5-AMINOLEVULINIC ACID.

AMINOMETRADINE.

† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMODIAQUINE.

AMOROLFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXYCILLIN.

AMPHOMYCIN.

AMPHOTERICIN.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE.

AMYLOBARBITONE when packed and labelled for injection.

AMYLOCAINE.

# ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANECORTAVE.

# ANDROGENIC STEROIDAL AGENTS.

# ANDROISOXAZOLE.

# ANDROSTANOLONE.

# ANDROSTENEDIOL.

# ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

(a) when separately specified in these Schedules; or

(b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTIHISTAMINES **except**:

(a) when included in Schedule 2 or 3; or

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIPRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASENAPINE.

ASPIRIN:

(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or

(b) for injection.

ASTEMIZOLE.

# ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

(a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or

(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 1 per cent or less of azelaic acid for non-human use.

AZELASTINE **except** when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

(a) when included in Schedule 6; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE **except** when included in Schedule 2.

BELATACEPT.

BELIMUMAB.

BEMEGRIDE.

BENACTYZINE.

BENAZEPRIL.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZHEXOL.

BENZILONIUM.

BENZOCAINE **except**:

(a) when included in Schedule 2;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZTROPINE (benzatropine).

BENZYDAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACIN HYDROCHLORIDE.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

# BEXAROTENE.

BEZAFIBRATE.

BICALUTAMIDE.

BIFONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

BIMATOPROST.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or

(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BOCEPREVIR.

# BOLANDIOL.

# BOLASTERONE.

# BOLAZINE.

# BOLDENONE (dehydrotestosterone).

# BOLENOL.

# BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;

(b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

BORTEZOMIB.

# BOSENTAN.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use **except** when separately specified in

these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC **except**:

(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or

(b) in suppositories.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

CABERGOLINE.

CADMIUM COMPOUNDS for human therapeutic use.

CALCIPOTRIOL.

CALCITONIN.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

# CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALORIDINE.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

CERIVASTATIN.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE **except**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL **except** when included in Schedule 3.

# CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

# 4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

# CHLOROXYDIENONE.

CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORTHALIDONE.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except**:

1. when included in Schedule 2 or 3; or
2. in preparations for the treatment of tinea pedis.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILOSTAZOL.

CIMETIDINE **except** when included in Schedule 3.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESYLATE.

CISPLATIN.

CITALOPRAM.

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

# CLOMIPHENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

# CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

# CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1 per cent or less of codeine,

**except** when included in Schedule 2 or 3.

CO-DERGOCRINE.

COLASPASE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5 per cent or less of copper compounds.

# CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CROFELEMER.

CRYSTAL VIOLET for human use **except** when used as a dermal marker.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

# CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOSPORIN.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

CYSTEAMINE for human therapeutic use.

CYTARABINE.

DABIGATRAN.

DACARBAZINE.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

# DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

# DARBEPOETIN.

DARIFENACIN.

DARUNAVIR.

DATURA spp. **except**:

(a) when included in Schedule 2; or

(b) when separately specified in this Schedule.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DATURA TATULA (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DAUNORUBICIN.

DEANOL.

DEBRISOQUINE.

DECAMETHONIUM.

DEFERASIROX.

DEFERIPRONE.

DEFLAZACORT.

DEGARELIX.

# DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE (includes delavirdine mesylate).

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENOSUMAB.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DERACOXIB.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEXAMETHASONE.

DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

# DEXTROPROPOXYPHENE:

(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except:**

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or

(ii) containing more than 4 per cent of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,

**except** when included in Schedule 2 or 3.

DIHYDROERGOTOXINE.

# DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

† DI-IODOHYDROXYQUINOLINE (iodoquinol) **except**:

(a) when included in Schedule 3; or

(b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

# DIMETHANDROSTANOLONE.

# DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use **except**:

(a) when included in Schedule 6; or

(b) in *in vitro* test kits.

DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

# DINOPROST.

# DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

# DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULOXETINE.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDETIC ACID for human therapeutic use **except**:

(a) in preparations containing 0.25 per cent or less of edetic acid;

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

EFORMOTEROL.

ELETRIPTAN.

ELTENAC.

ELTROMBOPAG.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2 per cent or less of emetine.

EMTRICITABINE.

ENALAPRIL.

# ENESTEBOL.

ENFLURANE for therapeutic use.

ENFUVIRTIDE.

# ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.

# EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

# EPITIOSTANOL.

EPLERENONE.

# EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESYLATE.

ERLOTINIB.

ERTAPENEM.

ERYSIMUM spp.

ERYTHROMYCIN.

# ERYTHROPOIETIN.

# ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESMOLOL.

ESOMEPRAZOLE.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETANERCEPT.

ETHACRYNIC ACID.

ETHAMBUTOL.

ETHAMIVAN.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLOESTRADIOL.

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

# ETHYLDIENOLONE.

† ETHYLHEXANEDIOL for animal use.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;

**except** when included in Schedule 2.

# ETHYLOESTRENOL.

ETHYNODIOL.

ETIDOCAINE.

ETIDRONIC ACID (includes disodium etidronate):

(a) for internal use; or

(b) in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRAVIRINE.

# ETRETINATE.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR **except** when included in Schedule 3.

FAMOTIDINE **except** when included in Schedule 2.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FEXOFENADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FIBRINOLYSIN **except** for external use.

FIDAXOMICIN.

FILGRASTIM.

FINASTERIDE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

# FLUOXYMESTERONE.

FLUPENTHIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURANDRENOLONE.

FLURAZEPAM.

FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE **except** when separately specified in this Schedule.

# FOLLISTATIN.

# FOLLITROPIN ALPHA.

# FOLLITROPIN BETA.

FOMIVIRSEN.

FONDAPARINUX.

# FORMEBOLONE.

FORMESTANE.

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

FOSPHENYTOIN.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

# FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GITALIN.

GLATIRAMER ACETATE.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUTATHIONE for parenteral use.

# GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GREPAFLOXACIN.

GRISEOFULVIN.

GUAIPHENESIN for human therapeutic use **except**:

(a) when included in Schedule 2;

(b) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or

(c) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANIDINE for therapeutic use.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (*Hemerocallis flava*).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHANE:

(a) in preparations for use on infants; or

(b) in other preparations **except**:

(i) when included in Schedule 2 or 6; or

(ii) in preparations containing 0.75 per cent or less of hexachlorophane.

HEXAMETHONIUM.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.

HMG-CoA REDUCTASE INHIBITORS (including "statins") **except** when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:

(a) for tissue augmentation;

(b) for cosmetic use; or

(c) for the treatment of animals.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

(a) for human use **except** when included in Schedule 2 or 3; or

(b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

(a) when included in Schedule 2; or

(b) in hair preparations containing 0.3 per cent or less of hydroquinone.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

# HYDROXYSTENOZOL.

HYDROXYUREA.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCYAMUS NIGER **except**:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBUFENAC.

IBUPROFEN **except**:

(a) when included in or expressly excluded from Schedule 2 or 3; or

(b) in preparations for dermal use.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENIM.

IMIPRAMINE.

IMIQUIMOD.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETHACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN**.**

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INGENOL MEBUTATE.

# INSULIN-LIKE GROWTH FACTOR I.

# INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

IPILIMUMAB.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

# ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

(a) for human use; or

(b) for the treatment of mange in dogs.

IXABEPILONE.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.

KETAZOLAM.

KETOCONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN **except**:

(a) in preparations for dermal use; or

(b) when included in Schedule 3.

KETOROLAC (includes ketoralac trometamol).

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN **except**:

(a) when included in Schedule 5 ; or

(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE **except** when included in Schedule 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

† LEAD for human therapeutic use.

LEFETAMINE.

LEFLUNOMIDE.

# LENALIDOMIDE.

LENOGRASTIM.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

(a) for human therapeutic use; or

(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVODOPA.

LEVOMEPROMAZINE.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOFLAZINE.

LIGNOCAINE **except**:

(a) when included in Schedule 2;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIRAGLUTIDE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

(a) when included in Schedule 2;

(b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or

(c) in preparations containing 0.01 per cent or less of lithium.

LIXISENATIDE.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except:**

(a)when included in Schedule 2 ; or

(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

LOPRAZOLAM.

LORACARBEF.

LORATADINE **except**:

1. when included in Schedule 2; or
2. in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
3. in a primary pack containing 5 dosage units or less; and
4. labelled with a recommended daily dose not exceeding 10 mg of loratadine.

LORAZEPAM.

LORMETAZEPAM.

LOSARTAN.

LOXAPINE.

LUMEFANTRINE.

LUMIRACOXIB.

# LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MAROPITANT.

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

# MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELATONIN for human use.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

# MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME **except** when included in Schedule 2 or 6.

MERCURY for cosmetic or therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

# MESABOLONE.

MESALAZINE.

MESNA.

# MESTANOLONE (androstalone).

# MESTEROLONE.

MESTRANOL.

# METANDIENONE.

METARAMINOL.

# METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENOESTRIL.

# METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

# METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 1 per cent or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

# METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYL MERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITONE.

METHYLPREDNISOLONE.

METHYL SALICYLATE in preparations for internal therapeutic use.

# METHYLTESTOSTERONE.

METHYLTHIOURACIL.

# METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

# METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

# MIBOLERONE.

MICAFUNGIN.

MICONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.

MIDODRINE.

MIFEPRISTONE.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOMETASONE **except** when included in Schedule 2.

MONENSIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use.

MONOCLONAL ANTIBODIES for therapeutic use **except**:

(a) in diagnostic test kits; or

(b) when separately specified in these Schedules.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALORPHINE.

NALOXONE.

NALTREXONE.

# NANDROLONE.

NAPROXEN **except** when included in Schedule 2.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN **except** for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEDOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.

NICOTINIC ACID for human therapeutic use **except**:

(a) when separately specified in these Schedules;

(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISOLDIPINE.

NITISINONE.

NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIZATIDINE **except** when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

# 19-NORANDROSTENEDIOL.

# 19-NORANDROSTENEDIONE.

# NORANDROSTENOLONE.

# NORBOLETHONE.

# NORCLOSTEBOL.

NORELGESTROMIN.

# NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

# NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NYSTATIN **except** when included in Schedule 2 or 3.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.

OESTROGENS **except** when separately specified in these Schedules.

OESTRONE.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLEANDOMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLMESARTAN.

OLODATEROL.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE **except** when included in Schedule 3.

ONDANSETRON.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:

(a) when separately specified in these Schedules; or

(b) in preparations containing 2 per cent or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OUABAIN.

# OVANDROTONE.

# OXABOLONE.

OXACILLIN.

OXALIPLATIN.

# OXANDROLONE.

OXAPROZIN.

OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPENTIFYLLINE (pentoxifylline).

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

# OXYMESTERONE.

# OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

PACLITAXEL.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes disodium pamidronate).

PANCREATIC ENZYMES **except**:

(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

(b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANTOPRAZOLE **except** when included in Schedule 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

(a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;

(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;

(c) in slow release tablets or capsules containing more than 665 mg of paracetamol;

(d) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;

(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or

(f) for injection.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PASIREOTIDE DIASPARTATE .

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVISOMANT.

PEMETREXED.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** when included in Schedule 2.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isethionate).

PENTHIENATE.

PENTOBARBITONE when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PERGOLIDE.

PERHEXILINE.

PERICYAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITONE.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

# PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

(a) in preparations for injection; or

(b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHOLCODINE:

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5 per cent or less of pholcodine,

**except** when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS **except**:

(a) when separately specified in these Schedules; or

(b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Australian Register of Therapeutic Goods in preparations:

(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet

or capsule; or

(ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or

(c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLERIXAFOR.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

(a) when containing less than 550 mg of potassium chloride per dosage unit;

(b) in preparations for oral rehydration therapy;

(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

(d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMOCAINE.

PRAMPINE.

# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE PENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use except when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

# PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

# QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE **except** when included in Schedule 3.

RABIES VACCINE.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RANIBIZUMAB.

RANITIDINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

RETAPAMULIN.

RETEPLASE.

RETIGABINE.

RIBAVIRIN.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

RIVASTIGMINE.

RIZATRIPTAN.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

ROMIFIDINE.

ROMIPLOSTIM.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

# ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUPATADINE.

SALBUTAMOL **except** when included in Schedule 3.

SALCATONIN.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.

SCOPOLIA CARNIOLICA for therapeutic use.

# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

(a) for human oral use with a recommended daily dose of more than 300 micrograms; or

(b) for the treatment of animals **except**:

(i) when included in Schedule 6 or 7;

(ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;

(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;

(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

(v) in feeds containing 1 g/tonne or less of selenium.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

# SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

SILVER SULFADIAZINE.

SIMVASTATIN.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

# SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for injection for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SOLASODINE.

SOLIFENACIN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

# SOMATROPIN (human growth hormone).

SONTOQUINE.

SORAFENIB.

SOTALOL.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

# STANOLONE.

# STANOZOLOL.

STAVUDINE.

# STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBOESTROL (diethylstilboestrol).

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 3, 5 or 6; or

(c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal and alkyl sulfonals).

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFLUPROST.

TALIGLUCERASE ALFA.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

T-CELL RECEPTOR ANTIBODY.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

# TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

# TESTOLACTONE.

# TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACOSACTRIN.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

# THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOGUANINE.

# THIOMESTERONE (tiomesterone).

THIOPENTONE.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less of thiourea.

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TIOTROPIUM.

TIPEPIDINE.

TIPRANAVIR.

TIRILAZAD.

TIROFIBAN.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRAMADOL.

TRANDOLAPRIL.

TRANEXAMIC ACID **except** in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

TRAVOPROST.

TRAZODONE.

# TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

# TRESTOLONE.

TRETAMINE.

# TRETINOIN.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRILOSTANE.

TRIMEPRAZINE **except** when included in Schedule 2 or 3.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROMETAMOL in preparations for injection **except** in preparations containing 3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN **except**:

(a) when included in Schedule 5;

(b) in animal feeds containing 50 mg/kg or less of antibiotic substances:

(i) for growth promotion;

(ii) for the prevention of liver abscesses in cattle; or

(iii) for the prevention of ileitis in pigs; or

(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYPHOID VACCINE.

UNOPROSTONE.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

# UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES, veterinary live virus **except**:

(a) poultry vaccines;

(b) pigeon pox vaccine; or

(c) scabby mouth vaccine.

VACCINIA VIRUS VACCINE.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VELAGLUCERASE ALFA.

VEMURAFENIB.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILANTEROL.

VILANTEROL TRIFENATATE.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISNADINE.

VITAMIN A for human th**e**rapeutic or cosmetic use except:

(a) in preparations for topical use containing 1 per cent or less of Vitamin A;

(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

(c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except:**

1. in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or
2. when included in Schedule 3.

VORICONAZOLE.

VORINOSTAT.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR .

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

## SCHEDULE 5

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ABSCISIC ACID.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH3COOH) **except**:

(a) when included in Schedule 2 or 6; or

(b) for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;

(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:

(i) in food additive preparations for domestic use; or

(ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,

**except** when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

(a) in insecticidal mats; or

(b) in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMITROLE.

AMINOCYCLOPYRACHLOR.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:

(a) in preparations for human internal therapeutic use;

(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of anise oil.

ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ATRAZINE.

† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS delta endotoxin encapsulated in killed *Pseudomonas fluorescens*.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5 per cent or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.

BENALAXYL.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 5 per cent or less of benzoyl peroxide.

BERGAMOT OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.4 per cent or less of bergamot oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or

(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3 per cent or less of total bifluorides.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

BISPYRIBAC **except** in preparations containing 10 per cent or less of bispyribac.

BORIC ACID (excluding its salts) and BORAX **except**:

(a) when included in Schedule 4;

(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or

(c) in hand cleaning preparations.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF3).

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:

(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5 per cent or less of camphor.

† CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

CARBARYL:

(a) in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or

(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CASSIA OIL **except**:

(a) in food additives;

(b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or

(c) in other preparations containing 2 per cent or less of cassia oil.

CHLORFENAC.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except**:

(a) in preparations containing 1 per cent or less of chlorhexidine; or

(b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except**:

(a) when separately specified in these Schedules;

(b) sodium hypochlorite preparations with a pH of less than 11.5;

(c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(d) liquid preparations containing less than 2 per cent of available chlorine; or

(e) other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;

(b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or

(c) in other preparations containing 5 per cent or less of chlorpyrifos,

**except** in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a) in food additives; or

(b) in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate **except** in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide **except** in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides **except**:

(a) in preparations for internal use;

(b) in marine paints; or

(c) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride **except** in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5 per cent or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

4-CPA.

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives **except**:

(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

(i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

(ii) enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANURIC ACID (excluding its salts and derivatives).

CYANTRANILIPROLE.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUTHRIN:

(a) in wettable powders containing 10 per cent or less of cyfluthrin;

(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or

(c) in emulsions containing 5 per cent or less of cyfluthrin.

cyhalofop-butyl.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole.

CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or

(b) in undivided preparations containing 5 per cent or less of cythioate.

2,4-D in preparations containing 20 per cent or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DELTAMETHRIN:

(a) when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;

(b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;

(c) in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;

(d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or

(e) in other preparations containing 0.5 per cent or less of deltamethrin,

**except** in preparations containing 0.1 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

(a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(b) liquid preparations containing less than 2 per cent of available chlorine; or

(c) other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;

(b) in other preparations in pressurised spray packs; or

(c) in paints and tinters containing 5 per cent or less of dichloromethane.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;

(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or

(c) in pressurised spray packs containing 10 grams or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing 5 per cent or less of diethanolamine.

† DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except:**

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

(a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:

**WARNING**: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

(c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.

DIPHENAMID.

DITHIOPYR.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

EMAMECTIN in preparations containing 2 per cent or less of emamectin.

EMODEPSIDE in preparations:

(a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or

(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.

ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.

1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.

ETHOXYSULFURON.

† ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*) , **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENSON.

FENTHION:

(a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or

(b) in preparations containing 10 per cent or less of fenthion.

FIPRONIL in preparations containing 10 per cent or less of fipronil **except** in preparations containing 0.05 per cent or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-M-METHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10 per cent or less of fludioxonil.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3 per cent or less offlumethrin; or

(b) in oil based preparations containing 1 per cent or less of flumethrin.

flumiclorac pentyl.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) in preparations for human use; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.

HEXAZINONE in preparations containing 25 per cent or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

(a) toluene and xylene when included in Schedule 6;

(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;

(c) food grade and pharmaceutical grade white mineral oils;

(d) in solid or semi-solid preparations;

(e) in preparations containing 25 per cent or less of designated solvents;

(f) in preparations packed in pressurised spray packs;

(g) in adhesives packed in containers each containing 50 grams or less of adhesive;

(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

(i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:

(a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or

(b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

† HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or

(b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).

IMAZALIL.

IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.

IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.

IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.

IMIDACLOPRIDin preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1 per cent or less of

indoxacarb.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except** in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.

IRON COMPOUNDS:

(a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):

(i) in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or

(ii) in other preparations containing 4 per cent or less of iron **except**:

(A) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(B) in animal feeds or feed premixes; or

(b) in garden preparations **except** in preparations containing 4 per cent or less of iron.

ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

(a) in preparations for the prophylaxis of heartworm in cats and dogs;

(b) in intraruminal implants containing 160 mg or less of ivermectin;

(c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or

(d) in other preparations containing 2 per cent or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or

(b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.

† LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEMON OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.05 per cent or less of lemon oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except**:

(a) when included in Schedule 4; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIME OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.5 per cent or less of lime oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON **except**:

(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.

MALATHION in preparations containing 10 per cent or less of malathion except:

(a) for human therapeutic use; or

(b) in dust preparations containing 2 per cent or less of malathion.

MANCOZEB.

MANDIPROPAMID.

MARJORAM OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of marjoram oil.

MCPA:

(a) in preparations containing25 per cent or less of MCPA (acid); or

(b) in preparations containing 50 per cent or less of the salts and esters of MCPA.

MCPB.

MEBENDAZOLE for the treatment of animals:

(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

(b) in undivided preparations containing 25 per cent or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2 per cent or less of mecoprop.

MEFENPYR-DIETHYL.

MEPIQUAT.

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35 per cent or less of metalaxyl.

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a) when included in preparations or admixtures; or

(b) when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

(a) when packed in single use containers having a capacity of 2 mL or less; or

(b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:

(a) in preparations for therapeutic use; or

(b) in preparations containing 5 per cent or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

METIRAM.

METOLACHLOR.

METRAFENONE in preparations containing 50 per cent or less of metrafenone.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;

(b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or

(c) for internal use for the treatment of animals:

(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

(ii) in other preparations containing 2 per cent or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25 per cent or less of NAA.

NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NAPTALAM.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) **except** in preparations containing 0.5 per cent or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:

(a) when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(b) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of

N-octyl bicycloheptene dicarboximide.

N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of

N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or

N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL in implant preparations for growth promotion in animals.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

ORANGE OIL (BITTER) **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 1.4 per cent or less of orange oil (bitter);

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD **except** in preparations containing 20 per cent or less of penthiopyrad.

PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

(a) in preparations containing 25 per cent or less of permethrin; or

(b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,

**except** in preparations containing 2 per cent or less of permethrin.

PETROL **except** preparations containing 25 per cent or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.

PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less of o-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H3PO3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) **except**:

(a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(b) in solid or semi-solid preparations; or

(c) in professional dental kits.

ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.

PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.

PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.

POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.

POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts **except** in preparations containing 1 per cent or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 10 per cent or less of potassium chlorate.

† POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of potassium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b) liquid or semi-solid preparations, the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE:

(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

(b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:

(a) in preparations containing 30 per cent or less of propionic acid; or

(b) for therapeutic use.

PROPOXUR:

(a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;

(b) in dust preparations containing 3 per cent or less of propoxur;

(c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;

(d) in pressurised spray packs containing 10 g or less of propoxur; or

(e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PROPYZAMIDE.

PROTHIOCONAZOLE-DESCHLORO **except** in preparations containing 0.5 per cent or less of prothioconazole-deschloro.

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE **except** in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 10 per cent or less of such substances.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:

(a) when separately specified in these Schedules;

(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of

quizalofop-p-ethyl.

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.

RESMETHRIN in preparations containing 10 per cent or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SAFLUFENACIL in water dispersible granule preparations.

SALICYLANILIDE.

SEDAXANE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) barium silicofluoride when separately specified in this Schedule; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin **except** in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.

† SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of sodium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.

STAR ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H3NO3S).

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

† SYMPHYTUM spp. (Comfrey) for dermal use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.

TEMEPHOS:

(a) in liquid preparations containing 10 per cent or less of temephos;

(b) in powders containing 2 per cent or less of temephos; or

(c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:

(a) when included in Schedule 2;

(b) in preparations for the treatment of animals; or

(c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

THIABENDAZOLE:

(a) for the treatment of animals; or

(b) when packed and labelled for use as a fungicide **except** in preparations containing 50 per cent or less of thiabendazole.

THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.

THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.

THYME OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of thyme oil.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

† 1,1,1-TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs;

(b) in preparations containing 25 per cent or less of designated solvents;

(c) in preparations, other than writing correction fluids or thinners for writing correction fluidsin containers having a capacity of 50 mL or less; or

(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in

distinct contrast to the background; and

(ii) the expression:

**WARNING** − DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIETHANOLAMINE (excluding its salts and derivatives) **except** in preparations containing 5 per cent or less of triethanolamine.

TRIFLOXYSTROBIN.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

Avoid contact with eyes and skin; and

Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

(a) when packed in a sealed water-soluble measure pack; or

(b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of

3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:

(a) for growth promotion;

(b) for the prevention of liver abscesses in cattle; or

(c) for the prevention of ileitis in pigs.

VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.

ZINEB.

## SCHEDULE 6

(Substances marked † are listed in Appendix C)

ABAMECTIN:

(a) in preparations for pesticidal use containing 2 per cent or less of abamectin **except** when included in Schedule 5; or

(b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.

ALBENDAZOLE for the treatment of animals **except:**

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN **except**:

(a) when included in Schedule 5;

(b) in insecticidal mats containing 20 per cent or less of allethrin; or

(c) in other preparations containing 1 per cent or less of allethrin.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 10 per cent or less of alpha-cypermethrin,

**except** when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOPYRALID.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal therapeutic use;

(c) in preparations for inhalation when absorbed in an inert solid material; or

(d) in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

ANTIMONY COMPOUNDS **except**:

(a) when included in Schedule 4;

(b) antimony chloride in polishes;

(c) antimony titanate pigments in paint; or

(d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ARSENIC:

(a) in ant poisons containing 0.4 per cent or less of arsenic;

(b) in animal feed premixes containing 4 per cent or less of arsenic; or

(c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

**except** when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole.

† AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal use;

(c) debitterised neem seed oil;

(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

BARIUM SALTS **except**:

(a) when included in Schedule 5;

(b) barium sulfate; or

(c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

† BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except**:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

(b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

BAY OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;

(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;

(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or

(d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

**except** when included in Schedule 5.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of benzalkoniumchloride.

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of bioallethrin.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

† BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

2-BUTOXY-2’-THIOCYANODIETHYL ETHER.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

(a) in animal feed premixes containing 4 per cent or less of arsenic; or

(b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAJUPUT OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cajuput oil; or

(f) in oils containing 25 per cent or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

CAMBENDAZOLE.

CAMPHOR **except**:

(a) when included in Schedule 4 or 5;

(b) when enclosed in an inhaler device which prevents ingestion of its contents;

(c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;

(d) in liquid preparations containing 2.5 per cent or less of camphor;

(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBON DISULFIDE.

† CARBAMIDE PEROXIDE **except**:

(a) when included in Schedule 5; or

(b) in other preparations containing 9 per cent or less of carbamide peroxide.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:

(a) when included in Schedule 5;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) when in solid preparations.

CHLORINATING COMPOUNDS **except**:

(a) when included in Schedule 5;

(b) when separately specified in these Schedules;

(c) sodium hypochlorite preparations with a pH of less than 11.5;

(d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(e) in liquid preparations containing less than 2 per cent of available chlorine; or

(f) in other preparations containing 4 per cent or less of available chlorine.

CHLORMEQUAT.

CHLOROFORM **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of chloroform.

ALPHA-CHLOROHYDRIN.

CHLOROPHACINONE.

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL

(uniconazole-p) **except** in preparations containing 5 per cent or less of

(E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROTHALONIL **except** in water-based paint containing 0.5 per cent or less of chlorothalonil.

CHLORPYRIFOS **except**:

(a) when included in Schedule 5; or

(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES(including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CINEOLE **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cineole;

(f) in oils containing 25 per cent or less of cineole; or

(g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CLIMBAZOLE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except** when included in Schedule 5.

CLOTRIMAZOLE for external treatment of animals.

CLOVE OIL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.

COPPER ACETATE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

(c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;

(d) in feed additives containing 1 per cent or less of copper; or

(e) in other preparations containing 5 per cent or less of copper compounds.

COPPER HYDROXIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use;

(c) in marine paints; or

(d) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent of less of copper oxychloride.

COPPER SULFATE **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use; or

(c) in other preparations containing 5 per cent or less of copper sulfate.

COUMAPHOS:

(a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

(b) in other preparations containing 5 per cent or less of coumaphos.

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

(a) when included in Schedule 2;

(b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or

(c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-cyclohexyldiazeniumdioxy-potassium.

CYFLUTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYSTEAMINE for cosmetic use **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

(a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;

(b) in wettable granular preparations containing 25 per cent or less of deltamethrin;

(c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;

(d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or

(e) in other preparations containing 3 per cent or less of deltamethrin,

**except** when included in Schedule 5 or in preparations containing 0.1 per cent or less of deltamethrin.

DERQUANTEL.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5;

(b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(c) in liquid preparations containing less than 2 per cent of available chlorine; or

(d) in other preparations containing 4 per cent or less of available chlorine.

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

(a) when included in Schedules 4 or 5; or

(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of diethanolamine.

† DIETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

† 5,6-DIHYDROXYINDOLINE.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

DIMETHYLFORMAMIDE **except**:

(a) when included in Schedule 5; or

(b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYL SULFOXIDE(excluding dimethyl sulfone):

(a) when not for therapeutic use; or

(b) for the treatment of animals:

(i) when combined with no other therapeutic substance(s);

(ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or

(iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20 per cent or less of diquat.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N-(N-DODECYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

ECONAZOLE for external treatment of animals.

EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20 per cent or less of endothal.

EPTC.

ESBIOTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

ETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

(a) when included in Schedule 2, 4 or 5; or

(b) in preparations containing 10 per cent or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.

ETHYL BROMIDE.

Ethyl formate when packed and labelled for use as a fumigant.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

† ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 10 per cent or less of such substances.

ETRIMFOS.

EUCALYPTUS OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of eucalyptus oil.

EUGENOL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of eugenol.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FEBANTEL **except**:

(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

(b) in undivided preparations containing 10 per cent or less of febantel.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPYROXIMATE.

FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.05 per cent or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLONICAMID.

FLUAZIFOP-BUTYL.

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUMETHRIN **except** when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for human use; or

(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

† FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

GLUTARALDEHYDE **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

(a) in cosmetic preparations for salon use only, when labelled in accordance with Safe Work Australia’s *National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012(1994)];

(b) in preparations containing 5 per cent or less of glycolic acid; or

(c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.

GUANIDINE **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 1 per cent or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HEPTACHLOR.

HEXACHLOROPHANE in preparations for the treatment of animals.

HEXAZINONE **except** when included in Schedule 5.

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride **except** when included in Schedule 5.

† HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or

(c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) **except** when included in Schedule 5.

IMIDACLOPRID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of imidacloprid.

IMIDOCARB.

iminoctadine trialbesilate.

IMIPROTHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) **except** when included in Schedule 5.

IODINE (excluding its salts, derivatives and iodophors) **except**:

(a) when included in Schedule 2; or

(b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except:**

(a) when included in Schedule 5; or

(b) in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE **except** when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except**:

(a) when included in Schedule 5;

(b) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(c) in animal feeds or feed premixes.

ISOCONAZOLE for external treatment of animals.

ISOCYANATES, free organic, boiling below 300°C, **except** in:

(a) viscous polyurethane adhesives; or

(b) viscous polyurethane sealants;

containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

ISOEUGENOL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of isoeugenol.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or

(b) in other preparations containing 1 per cent or less of lambda-cyhalothrin,

**except** when included in Schedule 5.

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding its salts and derivatives) **except**:

(a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;

(b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

† LEAD COMPOUNDS **except**:

(a) when included in Schedule 4 or 5;

(b) in paints, tinters, inks or ink additives;

(c) in preparations for cosmetic use containing 100 mg/kg or less of lead;

(d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or

(e) in ceramic glazes when labelled with the warning statement:

CAUTION − Harmful if swallowed. Do not use on surfaces which contact food or drink.

written in letters not less than 1.5 mm in height.

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of *Leptospermum scoparium* oil.

LEVAMISOLE for the treatment of animals **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION except:

(a) when included in Schedule 5;

(b) for human therapeutic use; or

(c) in dust preparations containing 2 per cent or less of malathion.

MCPA **except** when included in Schedule 5.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-P.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MENAZON.

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60 per cent or less of methacrifos.

METHAM.

METHANOL (excluding its derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of methanol.

METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.

Methylcyclopentadienyl Manganese Tricarbonyl in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

† METHYLDIBROMO GLUTARONITRILE **except** in preparations intended to be in contact with the skin, including cosmetic use.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bisthiocyanate.

METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.

METHYL ISOTHIOCYANATE.

† METHYL METHACRYLATE (excluding its derivatives) **except**:

(a) for cosmetic use; or

(b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.

METHYLNORBORNYLPYRIDINE.

N-METHYL-2-PYRROLIDONE  **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 5 per cent or less of methyl salicylate.

METOFLUTHRIN.

METOSULAM.

METRAFENONE **except** when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MONENSIN:

(a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or

(b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.

MORANTEL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of morantel.

MOXIDECTIN for external use:

(a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

(b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,

**except** when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) **except** in liquid hydrocarbons as an impurity.

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).

NITROBENZENE **except**:

(a) in solid or semi-solid polishes;

(b) in soaps containing 1 per cent or less of nitrobenzene; or

(c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

(a) when included in Schedule 5;

(b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(c) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(d) in preparations for human use.

1-Octen-3-ol **except** in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.

N-(N-OCTYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquindox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except** its derivatives and insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS Strain 251.

† PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of d-pulegone.

PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.

PERMETHRIN **except**:

(a) when included in Schedule 4 or 5;

(b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or

(c) in preparations containing 2 per cent or less of permethrin.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5; or

(c) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.

† PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:

(a) in preparations packed and labelled for photographic purposes;

(b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;

(c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(c) in solid or semi-solid preparations; or

(d) in professional dental kits.

PHOXIM.

ortho-PHTHALALDEHYDE **except** when included in Schedule 5.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIXETONIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM CYANATE.

† POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of potassium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:

(a) when included in Schedule 5;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

(a) when included in Schedule 5;

(b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or

(c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or

(ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 1 per cent or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 30 per cent or less of propionic acid; or

(c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

d-PULEGONE **except** in preparations containing 4 per cent or less of d- pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

Pyridalyl.

PYRIDATE.

PYRIPROLE.

pyrithione copper.

PYRITHIONE ZINC **except**:

(a) when included in Schedule 2 or 5;

(b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in semi-solid hair preparations for animal use;

(d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”;

(e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or

(f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.

PYROXASULFONE in water dispersible granule preparations when for pre-emergence herbicide use.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5;

(c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUIZALOFOP ETHYL.

QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-P-TEFURYL.

RESMETHRIN **except** when included in Schedule 5.

ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.

† SAFROLE **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SAGE OIL (Dalmatian) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of thujone.

SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.

SASSAFRAS OIL **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SELENIUM:

(a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:

(i) for the blueing of gun barrels;

(ii) for photographic purposes; or

(iii) for the colouring of lead or lead alloys;

(b) in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or

(c) for the treatment of animals:

(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;

(ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;

(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

(iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

SILICOFLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE **except**:

(a) when included in or expressly excluded from Schedule 2; or

(b) in preparations containing 1 per cent or less of silver.

SINBIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

(a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b) in liquid preparations, the pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.

† SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of sodium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

SODIUM LAURYL SULFATE (excluding its salts and derivatives) **except:**

(a) in wash-off preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER;

(b) in leave-on preparations containing 1.5 per cent or less of sodium lauryl sulfate;

(c) in toothpaste and oral hygiene preparations containing 5 per cent or less of sodium lauryl sulfate;

(d) in other preparations for animal use containing 2 per cent or less of sodium lauryl sulfate; or

(e) in other preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM PERSULFATE:

(a) in hair preparations; or

(b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFURIC ACID (excluding its salts and derivatives) **except**:

(a) in fire extinguishers; or

(b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230-290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or

(c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOPHANATE-METHYL **except** when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS **except**:

(a) when separately specified in these Schedules; or

(b) for therapeutic use.

THIRAM **except** in paint containing 0.5 per cent or less of thiram.

THUJONE **except** in preparations containing 4 per cent or less of thujone.

THYMOL when packed and labelled for the control of *Varroa* mites in bee hives.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.

†TOLUENEDIAMINE not elsewhere specified in these Schedules:

(a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

(a) in preparations containing 1 per cent or less of transfluthrin; or

(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

(a) when included in Schedule 5; or

(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

(a) when included in Schedule 4 or 5; or

(b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 5 per cent or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

VAMIDOTHION.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 5 per cent or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.

ZINC SULFATE **except**:

(a) when included in or expressly excluded from Schedule 4; or

(b) in other preparations containing 5 per cent or less of zinc sulfate.

ZIRAM in granular preparations.

## SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-S-METHYL.

ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINACRINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 4 or 6;

(c) as selenium arsenide in photocopier drums;

(d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;

(e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other thanwhen included in articles:

(i) in contact with food stuffs, animal feeds or potable water;

(ii) of clothing and footwear in contact with the skin;

(iii) used as infant wear; or

(iv) intended for use as packaging materials;

(f) in animal feeds containing 75 g/tonne or less of arsenic; or

(g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5 per cent or less of benomyl.

BENZENE (excluding its derivatives) **except**:

(a) preparations containing 15 mL/L or less of benzene; or

(b) petrol containing 50 mL/L or less of benzene.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

(a) when included in Schedule 6; or

(b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant.

CACODYLIC ACID **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR  **except** when included in Schedule 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

4-CHLORO-o-TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

(a) ferricyanides;

(b) ferrocyanides; or

(c) when separately specified in these Schedules.

CYANOGEN.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except**:

(a) when included in Schedule 5 or 6; or

(b) when in preparations containing 0.1 per cent or less of deltamethrin.

DEMETON.

DEMETON-O-METHYL.

DEMETON-S-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4 or 6.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5.

ETACONAZOLE.

ETHION.

ETHOPROPHOS **except** when included in Schedule 6.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN **except** when included in Schedule 6.

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FOLPET.

FORMETANATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any

fraction of which boils above 350°C **except**:

(a) when in solid polymers;

(b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or

(c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

(a) when included in Schedule 4; or

(b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

MADURAMICIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 2, 4 or 6;

(c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;

(d) mercury (metallic) in scientific instruments;

(e) dental amalgams; or

(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

Methylcyclopentadienyl Manganese Tricarbonyl **except**:

(a) when included in Schedule 6;

(b) when used in laboratory analysis; or

(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

(a) when included in Schedule 6;

(b) in preparations for human therapeutic use; or

(c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

PYROXASULFONE **except** when included in Schedule 6.

QUININE for veterinary use **except** when included in Schedule 5.

SAFLUFENACIL **except** when included in Schedule 5.

SCHRADAN.

SELENIUM **except**:

(a) when included in Schedule 6;

(b) as selenium arsenide in photocopier drums;

(c) in preparations for therapeutic use other than:

(i) drench concentrates containing 2.5 per cent or less of selenium; or

(ii) pour-on preparations containing 0.5 per cent or less of selenium;

(d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or

(e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

(a) when included in Schedule 2, 5 or 6;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule;

(b) in plastics;

(c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or

(d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.

ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (s,s,s-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

## SCHEDULE 8

(Substances marked # are listed in Appendix D.)

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

AMPHETAMINE.

AMYLOBARBITONE **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITONE.

BUTORPHANOL.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 2, 3 or 4.

CODEINE-N-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITONE.

DEXAMPHETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.

DIHYDROMORPHINE.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

# DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ETHYLAMPHETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMPHETAMINE.

LEVOMETHAMPHETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

METHADONE.

METHYLAMPHETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

# NABIXIMOLS (botanical extract of *Cannabis sativa* which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

QUINALBARBITONE.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITONE.

SUFENTANIL.

TAPENTADOL.

THEBACON.

THEBAINE.

TILIDINE.

## SCHEDULE 9

(Trivial or unofficial names are marked \*)

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these schedules.

BENZETHIDINE.

BENZOYLINDOLES **except** when separately specified in these Schedules.

BENZYLPIPERAZINE \*(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE \*(Bromo-Dragonfly).

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA).

BUFOTENINE.

CANNABIS **except**:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CATHINONE.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS **except** when separately specified in these Schedules.

DESOMORPHINE.

DIAMPROMIDE.

DIBENZOPYRANS **except** when separately specified in these Schedules.

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE \*(DET).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMPHETAMINE \*(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB).

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE or PSILOTSIN).

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA).

N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,N-DIMETHYLTRYPTAMINE \*(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE \*(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE \*(PCE).

ETONITAZENE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4-FLUORO-N-METHYLAMPHETAMINE.

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE \*(AM-694).

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

(a) containing 0.1 per cent or less of harmala alkaloids; or

(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL).

4-HYDROXYBUTANOIC ACID and its salts. \*(GAMMA HYDROXYBUTYRATE (GHB) ).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(Cannabicyclohexanol or CP 47,497 C8 homologue).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497).

HYDROXYPETHIDINE.

ISOMETHADONE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5-METHOXY- α -METHYLTRYPTAMINE \*(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA).

4-METHOXY- α -METHYLPHENYLETHYLAMINE \*(PMA).

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250).

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE \*(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA).

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV).

3-METHYLFENTANYL.

4-METHYLMETHCATHINONE \*(MEPHEDRONE).

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(N-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE \*(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP).

4-METHYLTHIOAMPHETAMINE.

3-METHYLTHIOFENTANYL.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES **except** when separately specified in these Schedules.

NAPHTHOYLPYRROLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES **except** when separately specified in these Schedules.

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE \*(JWH-073).

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. \*(JWH-122).

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE \*(PCP).

N-PHENETHYL-4-PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES **except** when separately specified in these Schedules.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PSILOCYBINE.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE \*(PHP or PCPY).

SALVIA DIVINORUM.

TENOCYCLIDINE \*(TCP).

SYNTHETIC CANNABINOMIMETICS **except** when separately specified in these Schedules.

TETRAHYDROCANNABINOLS and their alkyl homologues **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 8;

(c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:

Not for internal use; or

Not to be taken; or

(d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE \*(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine **except**:

(a) methoxyphenamine; or

(b) when separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

# **PART 5**

# **THE APPENDICES**

## APPENDIX A

## GENERAL EXEMPTIONS

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 *Safety of toys* entitled *Part 4: Experimental sets for chemistry and related activities*.

COPPER COMPOUNDS in paints.

DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes−/blood volume expanders−.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

(a) food additives before incorporation into food; or

(b) when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

HUMAN BLOOD PRODUCTS including:

(a) whole blood;

(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and

(c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives:

(i) albumin;

(ii) anticoagulation complex;

(iii) C1 esterase inhibitors;

(iv) clotting factors;

(v) fibrinogen;

(vi) protein C;

(vii) prothrombin complex concentrate (PCC) ; and

(viii) thrombin.

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

INTRAOCULAR VISCOELASTIC PRODUCTS.

LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.

MATCHES.

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS −−−.

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, **except**:

(a) injectable tissue reconstructive, augmentation and restoration materials−, including collagen;

(b) medical devices which include anticoagulants;

(c) artificial tears;

(d) urinary catheters; or

(e) intra-articular fluids.

MOTOR, HEATING or FURNACE FUELS− **except**:

(a) when the contrary intention appears in any Schedule;

(b) when containing methanol;

(c) toy or hobby fuels; or

(d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.

PAPER **except**:

(a) when prepared for pesticidal use; or

(b) when containing a poison included in Schedule 8 or 9.

PHOTOGRAPHIC PAPER or FILM.

PIGMENTS when immobilised in a polymer.

PORCELAIN.

PRINTING INKS or INK ADDITIVES **except**:

(a) when containing a pesticide; or

(b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.

RADIOISOTOPES for therapeutic use.

SEEDS treated with seed protectants.

SINGLE-USE TUBES for the estimation of alcohol content of breath.

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.

VITREOUS ENAMELS.

WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

## APPENDIX B

## SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

(This Appendix should be read in conjunction with Appendix A.)

## INTRODUCTION

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

• the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;

• the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or

• the public access was limited such that scheduling was inappropriate or unnecessary.

The list was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

**APPENDIX B**

**PART 1**

**REASONS FOR ENTRY**

a Low Toxicity.

b Use pattern restricts hazard.

c Presentation/packaging restricts hazard.

d Industrial use only.

**PART 2**

**AREAS OF USE**

1. Agricultural

1.1 Herbicide

1.2 Insecticide

1.2.1 Insecticide for codling moth

1.2.2 Termiticide

1.3 Fungicide

1.3.1 On seed fungicide

1.4 Bird Repellent

1.5 Fertiliser

1.6 Plant Growth Regulator

1.7 Insect Pheromone

1.8 Mushroom Bactericide

1.9 Acaricide

1.10 Biological control agent

2. Veterinary

2.1 For animal use

2.2 Treatment of mastitis in cows

2.3 Coccidiostat

2.4 Feed additive

2.5 Antiseptic

2.6 Scabicide

2.7 Anthelmintic

2.8 Vitamin/Mineral

2.9 Growth Promotant

2.10 Ectoparasiticide

3. Domestic

3.1 Aromatherapy

3.2 Food additive

3.3 Cosmetic

3.4 Human use

3.5 Miticide

4. Industrial

4.1 Water treatment

4.2 Biological control agent

5. Environmental

5.1 Mosquito control

6. Human therapeutic use

6.1 Diagnostic agent

6.2 Medical device

6.3 Antiseptic

6.4 Sunscreen

6.5 External use

6.6 Laxative

6.7 Antiseborrheic

6.8 Cytoprotective

6.9 Vitamin/Mineral

6.10 Eye Drops

7. General

7.1 Any use

7.2 Excipient

7.3 Synergist

7.4 Flux

7.5 Pesticide

7.6 Insect repellent

7.7 Solvent

7.8 Disinfectant

7.9 Preservative

7.10 Antioxidant

7.11 Resin activator/accelerant

7.12 Sweetener artificial

7.13 Food additive

**APPENDIX B**

**PART 3**

**SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL   
BY SCHEDULING**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**REASON AREA  
 DATE OF FOR OF  
SUBSTANCE ENTRY LISTING USE**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4-[4-(ACETYLOXY)PHENYL]-2-

BUTANONE Feb 2005 b 1.7

*AGROBACTERIUM RADIOBACTER* Nov 1989 a 1

ALCOHOL, DEHYDRATED Aug 2000 b 6

ALUM May 1997 a 7.1

ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1

ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1

ALUMINIUM SILICATE Nov 1974 a 7.1

ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1

AMETOCTRADIN May 2012 a 1.3

AMMONIUM PHOSPHATE Nov 1974 a 7.1

AMMONIUM THIOSULPHATE Nov 1974 a 7.1

AMPROLIUM Jun 1969 a 2.3

AMYL ACETATE Nov 1974 a 7.1

α -AMYLASE derived from *Aspergillus niger* Feb 2005 a 2.4

ANDROSTENEDIONE ALBUMEN

 CONJUGATE WITH DEA DEXTRAN

 ADJUNCT Jun 2004 a 2.1

ASPARTIC ACID - a 6

ASULAM May 1986 a 1

AZIMSULFURON Jun 2003 a 1.1

*BACILLUS SPHAERICUS* STRAIN 2362 Feb 2003 a 5.1

*BACILLUS THURINGIENSIS* May 1992 a 5.1  
 (excluding endotoxin) Jun 2003 a 2.10

*BACILLUS TOYOI* Aug 1980 a 2.9

BACULOVIRUS *CYDIA POMONELLA* Jun 2006 a 1.2

BENFLURALIN - a 1.1

BENSULFURON-METHYL Aug 1987 a 1

BENTONITE Jun 2002 a 7.1

BENZYL BENZOATE Aug 1989 a 1.3.4

BETAINE HYDROCHLORIDE Nov 1974 a 7.1

BIFENAZATE Oct 2002 a 1.9

BISMUTH SUBNITRATE Nov 1999 b, c 2.1

BISTRIFLURON Sep 2012 a 1.1.2

BIURET Nov 1974 a 2.4

BOSCALID June 2003 a 1.3

BOVINE SOMATOTROPHIN May 1992 a 2

BROMACIL Aug 1987 a 1

BROMOPROPYLATE Nov 1994 a 1

BUPIRIMATE Nov 1990 a 1

BUTAFENACIL May 2000 a 1

BUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7

n-BUTYL BUTYRATE - a 7.1

n-BUTYL LACTATE - a 7.1

CARBETAMIDE Aug 1991 a 1

CARBOXIN Aug 1987 a 1

CARFENTRAZONE-ETHYL Aug 1998 a 1

CELLULASE derived from  
 *Aspergillus niger*  
 Feb 2005 a 2.4

CETYL ALCOHOL Nov 1974 a 7.1

CHAMOMILE OIL Feb 2000 a 3.1

CHINA CLAY Nov 1974 a 7.1

CHLORANTRANILIPROLE Sep 2008 a 1.2

CHLORFLUAZURON Oct 2005 a 1.2.2

CHLORFLURENOL Feb 1974 a 1.6

CHLORIDAZON May 1988 a 1

CHLOROXYLENOLS Feb 1975 a 7.8

CITRONELLA OIL Feb 2000 a 7.1

CLARY SAGE OIL Feb 2000 a 7.1

CLOPIDOL Nov 1974 d 2.3

COBALT NAPHTHENATE - d 7.1

COLOPHONY Feb 1997 b 7.4

CROSPOVIDONE Aug 1996 a 2

*CULICINOMYCES CLAVOSPORUS* Nov 1982 a 5.1

CYCLAMIC ACID Nov 1971 a 7.1

CYCLOHEXANE Nov 1974 a 7.7

CYCLOHEXANOL ACETATE - a 7.7

CYROMAZINE Nov 1980 a 2

DICLAZURIL Nov 2001 a 2.3

DIETHYL CARBONATE - a 7.1

DIFLUFENICAN Feb 1987 a 1

DIKEGULAC-SODIUM Mar 1980 a 1.6

DIMETHICONE a 7.1

DIMETHYL ETHER Nov 1988 d 4

DIPHENYLAMINE Feb 1988 a 1

DIPROPYLENE GLYCOL   
 MONOMETHYL ETHER Nov 1987 a 4

DIURON Nov 1987 a 1

DOCUSATE SODIUM   
 (DIOCTYL SODIUM SULFOSUCCINATE) Feb 1970 a 7.1

2,2-DPA Nov 1989 a 1

drometrizole trisiloxane Oct 2003 a 6.4

EPSIPRANTEL Nov 1991 a 2

ETHAMETSULFURON-METHYL Nov 2000 a 1.1

ETHOPABATE Jun 1969 d 2.3

ETHYL ACETATE Nov 1974 a 7.1

ETHYL ALCOHOL Nov 1974 a 7.1

ETHYLBUTYLACETYL-  
 AMINOPROPRIONATE Aug 2000 a 3.4

ETHYL BUTYRATE - a 7.1

ETHYL LACTATE - a 7.1

ETOXAZOLE Oct 2003 a 1.2

FENFURAM May 1977 a 1.3.1

FENHEXAMID Feb 1999 a 1

FENOXYCARB Feb 1988 a 1

FLUFENOXURON Feb 1997 a 1

FLUMETSULAM Feb 1992 a 1

FLUOMETURON Aug 1989 a 1

FLUTOLANIL Nov 2001 a 1.3

FLUROXYPYR May 1986 a, c 1

FORCHLORFENURON Feb 2005 a 1.6

FULLERS EARTH Nov 1974 a 7.1

FUNGAL PROTEASE derived from

*Aspergillus niger* Feb 2005 a 2.4

GERANIUM OIL Feb 2000 a 7.1

GIBBERELLIC ACID Nov 1974 a 1.6

-GLUCANASE derived from *Aspergillus niger* Feb 2005 a 2.4

HEXAFLURON Nov 1988 a 1

HEXYL ACETATE - a 7.7

HEXYTHIAZOX Feb 1988 a 1

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2

HYDROPRENE Feb 1988 a 1

HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1

ICODEXTRIN Nov 2000 b 6

INDOLE-3-ACETIC ACID Feb 1985 b 1.6

ISOPRENE ALCOHOL - a 7.1

IPRODIONE Feb 1997 a 1

ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1

KAOLIN Nov 1974 a 7.1

KRESOXIM-METHYL Aug 1999 a 1

KUNZEA OIL Feb 2000 a 7.1

LAURIC ACID Oct 2005 a 7.1

LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1

LAVANDIN OIL Feb 2000 a 7.1

LAVENDER OIL Feb 2000 a 7.1

LEAD METALLIC - a 7.1

LEMONGRASS OIL Feb 2000 a 7.1

LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1

LIMONENE (DIPENTENE) Jun 2002 a 7.1

LINOLEIC ACID Oct 2005 a 7.1

LINSEED FATTY ACIDS Aug 1990 a 2.1

LINURON Feb 1990 a 1

LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1

MALEIC HYDRAZIDE Nov 1992 a 1

MANGANESE DIOXIDE May 1999 b 1

MESOLSULFURON-METHYL Feb 2002 a 1.1

*METARHIZIUM ANISOPLIAE* Feb 2000 b 4.2

*METARHIZIUM ANISOPLIAE* Jun 2003 a 1.10

METHOPRENE Aug 1987 a 1

METHOXYFENOZIDE Nov 2000 a 1

METHYL ACETATE - a 7.7

METHYL BENZOQUATE Nov 1974 d 2.3

1-METHYLCYCLOPROPENE Jun 2003 a 1.6

METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9

METSULFURONMETHYL Nov 1985 a 1.1

MYRISTIC ACID Oct 2005 a 7.1

NAPROPAMIDE Aug 1987 a 1

NAPTHYL ACETAMIDE Nov 1974 a 1.6

NEROLI OIL Feb 2000 a 7.1

NICARBAZIN Jun 1969 d 2.3

NISIN Jun 2003 a 3.2

NORFLURAZON Nov 1983 a 1.1

NOVALURON Nov 2000 a 1

Nuclear Polyhedrosis Virus of   
 *Helicoverpa armigera* occlusion bodies Feb 2004 a 1.2

OCTYL ALCOHOLS Nov 1974 a 7.1

OLEIC ACID Oct 2005 a 7.1

ORANGE OIL, SWEET Aug 2000 a 7.1

OXABETRINIL Feb 1987 a 1

OXYFLUORFEN May 2001 a 1

PALMAROSA OIL Feb 2000 a 7.1

PALMITIC ACID Oct 2005 a 7.1

PATCHOULI OIL Feb 2000 a 7.1

PECTINASE derived from *Aspergillus niger* Feb 2005 a 2.4

PENCYCURON Aug 1994 a 1

PENTADECANOIC ACID Oct 2005 a 7.1

PEPPERMINT OIL Feb 2000 a 7.1

PHENMEDIPHAM May 1989 a 1.1

d-PHENOTHRIN Feb 1982 a 7.5, 1.2

PHYTASE Feb 1996 a 2.4

PICLORAM Aug 1987 a 1

PICOLINAFEN May 2000 a 1

PIMELIC ACID Oct 2005 a 7.1

PIPERONYL BUTOXIDE Aug 1991 a 7.5

POLOXALENE Nov 1974 a 7.1

POLY DIALLYL DIMETHYL AMMONIUM   
 CHLORIDE (PolyDADMAC) Nov 1997 a 4.1

POLYHEDROSIS VIRUS of   
  *Helico zea* occlusion bodies Nov 1996 a 1

POLY (GNRF) OVALBUMIN Feb 1990 a 2

POLYSORBATE 20 May 2001 a 1

PORCINE SOMATOTROPHIN Nov 1991 c 2

potassium sorbate Oct 2004 a 1.3

POTASSIUM BICARBONATE Jun 2004 a 1

PROPYL ACETATES - a 7.1

PROPYLENE GLYCOL Nov 1974 a 7.1

2-PROPYLENE GLYCOL 1-MONOMETHYL   
 ETHER Nov 1987 a 4

PROTHIOCONAZOLE June 2005 a 1.3.1

*PSEUDOMONAS FLUORESCENS* May 1985 a 1.8

PYRIMETHANIL Feb 1996 a 1

PYRIPROXYFEN Aug 1994 a 1

QUASSIA Nov 1974 d 6, 2.1

QUINOXYFEN Nov 2001 a 1.3

ROSEMARY OIL Feb 2000 a 7.1

SAGE OIL (Spanish) Feb 2000 a 7.1

SANDALWOOD OIL Feb 2000 a 7.1

SEAWEED & UNFRACTIONED   
  SEAWEED EXTRACTS Feb 1985 d 1.5

SIMAZINE Nov 1987 a 1.1

SODIUM BICARBONATE Jun 2004 a 1

sodium propionate Oct 2004 a 1.3

STERIC ACID Oct 2005 a 7.1

SUCRALFATE Aug 1982 a 6.8

SULESOMAB Jun 2002 b 6.1

SULFOSULFURON Feb 1998 a 1

SULPHATED POLYSACCHARIDES - a 7.1

TANNIC ACID Dec 1965 a 7.1

TANNIC ACID/BENZYL ALCOHOL   
 PRODUCT Nov 1993 a 7.1

TERBACIL Aug 1987 a 1

THAUMATIN Nov 1990 a 3.2

THIDIAZURON Nov 1989 a 1

TRIASULFURON Feb 1988 a 1

TRICHODERMA HARZIANUM May 1996 a 1

(Z)-9-TRICOSENE Aug 1991 a 1

TRIETHYLENE GLYCOL Nov 1974 a 7.1

TRIFLOXYSULFURON Feb 2002 a 1.1

TRIFLURALIN Aug 1990 a 1

TRIFORINE Aug 1987 a 1

Ulocladium oudemansii Oct 2003 a 1.10

UREA Nov 1974 a 7.1

13C-UREA May 2001 a 6.1

VETIVER OIL Feb 2000 a 7.1

VINYL ETHER Nov 1987 b 6

VITAMIN K Jul 1963 a 6.9, 2.8

XANTHOPHYLL (lutein) Nov 1974 a 7.1

XYLANASE derived from *Aspergillus niger* Feb 2005 a 2.4

YLANG YLANG OIL Feb 2000 a 7.1

ZINC NAPHTHENATE - a 1.3

## APPENDIX C

## SUBSTANCES, OTHER THAN THOSE INCLUDED IN SCHEDULE 9,

## OF SUCH DANGER TO HEALTH AS TO WARRANT

## PROHIBITION OF SALE, SUPPLY AND USE

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALLYLISOPROPYLACETYLUREA for therapeutic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** ‘debitterised neem seed oil’*.*

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use **except** when being used solely for experimental purposes in humans and where such use:

(a) is in accordance with:

(i) an approval granted under paragraph 19(1)(b) of the *Therapeutic Goods Act 1989*, including any conditions specified in the notice of approval; and

(ii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(1A) of the *Therapeutic Goods Act 1989*; and

(iii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(4A) of the *Therapeutic Goods Act 1989*; or

(b) is in accordance with the requirements of item 3 of Schedule 5A to the *Therapeutic Goods Regulations 1990*.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25 per cent or less of diethylene glycol.

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of diethylphthalate.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.

1,3-DIMETHYLAMYLAMINE (DMAA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of dimethylphthalate.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25 per cent or less of ethylene glycol.

ETHYLHEXANEDIOL for human use.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

LEAD COMPOUNDS in paints, tinters, inks or ink additives **except** in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1 per cent or less of safrole.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use **except** when included in Schedule 5.

TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

## APPENDIX D

## ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8

(The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)

**1. Poisons available only from or on the prescription or order of an authorised medical practitioner.**

CLOMIPHENE for human use.

CLOZAPINE for human use.

CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.

CYCLOFENIL for human use.

DINOPROST for human use.

DINOPROSTONE for human use.

FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.

FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.

LUTEINISING HORMONE for human use.

TERIPARATIDE for human use.

UROFOLLITROPIN (human follicle-stimulating hormone) for human use.

**2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:**

(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(2) if the drug is -

(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or

(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

ACITRETIN for human use.

BEXAROTENE for human use.

ETRETINATE for human use.

ISOTRETINOIN for human oral use.

THALIDOMIDE for human use.

**3. Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the *Therapeutic Goods Act 1989*.**

DRONABINOL (delta-9-tetrahydrocannabinol).

NABIXIMOLS.

**4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

LENALIDOMIDE.

TRETINOIN for human oral use.

**5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).**

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

DARBEPOETIN.

DEXTROPROPOXYPHENE.

EPHEDRINE.

EPOETINS.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in this Appendix.

FOLLISTATIN.

GLUTETHIMIDE.

INSULIN-LIKE GROWTH FACTORS.

PHENTERMINE.

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.

SOMATROPIN (human growth hormone).

**6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

AMBRISENTAN for human use.

BOSENTAN for human use.

SITAXENTAN for human use.

**7. Poisons available only from or on the prescription or order of a dermatologist.**

ALEFACEPT for human use.

## APPENDIX E

## FIRST AID INSTRUCTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the

Australian Pesticides and Veterinary Medicines Authority and medicines for human use

when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Directions for First Aid Attention**

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this Appendix may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.

**Modified First Aid Instruction on Primary Pack**

Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(a) each immediate container must be labelled with first aid instructions appropriate for its contents; and

(b) the primary pack must be labelled with the statement:

FIRST AID: See inner packs.

**Exempt Preparations**

This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX E**

**PART 1**

**STANDARD STATEMENTS**

To be grouped together and prefaced with the words “FIRST AID” (see subparagraph 7(p) of this Standard).

*Basic*

A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).

Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

*General*

G1 Urgent hospital treatment is likely to be needed.   
(Note − the words ‘at once’ to be added to instruction A).

G2 If swallowed, give activated charcoal if instructed.   
(Note − the words ‘at once’ to be added to instruction A).

G3 If swallowed, do NOT induce vomiting.

G4 Immediately give a glass of water.

G5 Avoid giving milk or oils.

G6 If sprayed in mouth, rinse mouth with water.

*Eyes*

E1 If in eyes wash out immediately with water.

E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.

*Respiratory system*

R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.

*Skin*

S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).

*Special Purpose*

SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

**APPENDIX E**

**PART 2**

**FIRST AID INSTRUCTIONS**

Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).

**POISON** **STANDARD** **STATEMENT**S

Acetic acid A,G3,E2,S1

Acetic anhydride A,G3,E2,S1

Acetone A,G3

Acrolein A,G1,G2,G3,E2,R2,S2

Alkaline salts A,G3,E2,S1

Amines for use as curing agents A,G3,E1,S1

4-Aminopyridine A,G1,G2,E1,S1

Ammonia

• 5 per cent or less A

• above 5 per cent A,G3,E1,R1,S1

Ammonium persulfate A,G3,E2

Ammonium thiocyanate A

Anhydrides, organic acid, for use as   
curing agents for epoxy resins A,G3,E1,S1

Aniline A,E2,R1,S1

Anise oil A,G3

Antimony chloride A,E2,S2

Antimony compounds, **except** antimony chloride A

Azadirachta indica (neem) including its extracts   
and derivatives when included in Schedule 6. A,E1

Barium salts, **except** barium sulfate A

Basil oil A,G3

Bay oil A,G3

Benzalkonium chloride

• when included in Schedule 5 A,G3,E2

• when included in Schedule 6 A,G3,E2,S1

Benzene A,G3,E1,R1,S1

Benzoyl peroxide

• above 20 per cent A,E2,S1

• above 10 per cent up to 20 per cent A,E1

• 10 per cent or less A

Bergamot oil A,G3

Bifluorides   
(including ammonium, potassium and sodium salts)

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Borax A

Boric acid A

Boron trifluoride

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Bromoform A,G3,E2,R1,S2

Brucine A,G1,G2,G3,R2

2-Butoxyethanol and its acetates A,E2,S1

Cadmium compounds A

Cajuput oil A,G3

Camphor A,G1,G3,G5

Carbamide peroxide

• more than 9 per cent up to 60 per cent A,G3,E2,S1

• more than 60 per cent A,G1,G3,G4,E2,S1

Carbon disulfide A,G3,E2,R1,S2

Carbon tetrachloride A,G3,E1,R1,S1

Cassia oil A,G3

Chlorinating compounds, **except** when   
separately specified, containing

• above 4 per cent and below 10 per cent   
 of available chlorine A,G3,E1,S1

• 10 per cent or more of available chlorine A,G3,E2,S1

Chlorine (gas) A,E1,R1

Chlorocresol A,G3,E2,S2

Chloroform A,G3,E1,R1,S1

Chromates A,G3,E2,S1

Chromium trioxide A,G3,E2,S1

Cineole A,G1,G3

Cinnamon bark oil A,G3

Cinnamon leaf oil A,G3

Climbazole A

Clove oil A,G1,G3,E2

Copper sulfate A,G3,E2,S1

Creosote A,G3,E2,S1

Cresols A,G3,E2,S3

Cresols in pressurised spray packs A,G6,E1,S1

Cyanides A,G1,E1,R2

Cyanoacrylic acid esters A

Cyanuric acid A

Cyclohexanone peroxide A,G3,E2,S1

Cysteamine E1

ortho-Dichlorobenzene A,G3,E1,S1

para-Dichlorobenzene (PDB) A

Dichloroethyl ether A,G3,E1,R1,S1

Dichloroisocyanurates A,G3,E1,S1

Dichloromethane (methylene chloride) A,G3,G5,E1,R1,S1

• in pressurised spray packs A,G6,S1

Dichromates A,G1,G3,E2,S1

Didecyldimethylammonium salts A,G3

Diesel (distillate) A,G3

Diethanolamine

• when included in Schedule 5 A,G3

• when included in Schedule 6 A,G3,E2,S1

5,6-Dihydroxyindoline E1

Dimethylformamide

• less than 75 per cent A

• 75 per cent or more A,E1,R1,S1

Dimethyl sulfoxide A,G3,E1,S1

Dinitrocresols A,G1,E1,S1

Dinitrophenols A,G1,E1,S1

Dioxane A,G3,E1,R1,S1

Distillate A,G3

N-(N-Dodecyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Epoxy resins liquid A,G3,E2,S1

Essential oils containing camphor as natural   
component unless otherwise specified. A,G3

Ethanolamine

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Ether A,G3,E1,R1

Ethyl bromide A,E2,S1,R1

Ethylene glycol A

Ethylene glycol monoalkyl ethers and their   
acetates, **except** when separately specified A,G3,E2,S1

Ethylene oxide A,E2,R1

Eucalyptus oil A,G1,G3

Eugenol A,G1,G3,E2

Fluorides **except** when separately specified

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

Formaldehyde (see also paraformaldehyde) A,G3,E2,R1,S1

Formic acid A,G3,E2,S1

Glutaraldehyde

• below 5 per cent A,G3,E1

• 5 per cent or more A,G3,E2,S1

Glycolic acid A,G3,E2

Guanidine when included in Schedule 6 A,G3,E2,S1

Hexachlorophane when included in Schedule 6 A

Hydrazine A,G1,G3,E2,R1,S1

Hydrocarbons, liquid A,G3

Hydrochloric acid A,G3,E2,S1

• when included in Schedule 5 A,G3

Hydrofluoric acid and admixtures that   
generate hydrofluoric acid

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Hydrogen peroxide

• more than 3 per cent up to 20 per cent A,G3,E2,S1

• more than 20 per cent A,G1,G3,G4,E2,S1

Hydroquinone

• when included in Schedule 2 A

• when included in Schedule 4 or 6 A,G2,G3,E2,R2,S1

Hydrosilicofluoric acid

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Iodine (excluding salts, derivatives and iodophors)

• 2.5 per cent or more for human external use A,E2

• 2.5 per cent or more for other uses A,E2,S1

• below 2.5 per cent A

Iodophors A

Isocyanates, free organic A,E2,S1

Isophorone A,G3,E2,S1

Kerosene A,G3

Laureth carboxylic acids

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

Lauryl isoquinolinium bromide A,E1

Lead compounds

• in hair cosmetics A

• in other preparations A,S1

Lemon oil A,G3

*Leptospermum scoparium* oil (manuka oil) A,G1,G3

Lime oil A,G3

Magnesium chlorate A

Malathion at 20 per cent or less A

Marjoram oil A,G3

Melaleuca oil A,G1,G3

Mercuric chloride

• for external therapeutic use A

• for other uses A,G1,G3,E2,R2,S1

Mercuric iodide A,G1,G3,E2,R2,S1

Mercuric nitrate A,G1,G3,E2,R2,S1

Mercuric oxide A,G1,G3

Mercuric potassium iodide A,G1,G3,E2,R2,S1

Mercuric thiocyanate A,G1,G3,E2,R2,S1

Mercurochrome A

Mercurous chloride A

Mercury metallic A

Mercury, organic compounds A,S1

• in preparations for human external use A

Metaldehyde A,E1,S1

Methanol

• above 10 per cent A,G3

• 10 per cent or less A

Methylated spirit A,G3

Methyl ethyl ketone A,G3

Methyl ethyl ketone peroxide A,G3,E2,S1

Methyleugenol A

Methyl isoamyl ketone A,G3

Methyl isobutyl ketone A,G3

N-Methyl-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

Methyl salicylate liquid when included   
in Schedule 5 or 6 A,G3,E1

Naphthalene A,G1,G3

Nitric acid A,G3,E2,S1

Nitrobenzene A,G3,E1,S1

Nitrophenol A,G3,E2,S1

Nitroprussides

• in aerosols A,G6,R1

• in other preparations A,G3

Nonoxinol 9 A,E2

Nutmeg oil A,G3

2-Octyl-4-isothiazolin-3-one (Ocithilinone) A,G3,E2,S1

N-(N-Octyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

Orange oil (bitter) A,G3

Oxalic acid A,G3,E2,S1

Paraformaldehyde A,G3,E2,R1,S1

Pennyroyal oil A,G3

Peracetic acid

• when included in Schedule 5 A,G3,E1,S1

• when included in Schedule 6 A,G3,E2,S1

Petrol A,G3,R1

Phenols

• 25 per cent and less A,G3,E2,S3

• above 25 per cent A,G3,E2,S4

Phenols in pressurised spray packs A,E1

Phenylenediamines and   
alkylated phenylenediamines

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

Phenyl methyl ketone

• as such, or in preparations of similar viscosity A,G3,E1

N,N-bis(phenylmethylene)-bicyclo  
-(2.2.1)heptane-2,5-dimethanamine A,E2,S1

N,N-bis(phenylmethylene)-bicyclo-  
(2.2.1)heptane-2,6-dimethanamine A,E2,S1

ortho-Phenylphenol A,G3,E2,S1

• in pressurised spray packs A,G6,E2,S1

Phosphonic acid A,G3,E2,S1

• neutralised to pH 6 (approx) A

• in spray packs A,E2,S1

Phosphoric acid A,G3,E2,S1

Phosphorus, yellow A,G1,G3,E2,R2,S2

ortho-Phthalaldehyde

• when included in Schedule 5 A,E1

• when included in Schedule 6 A,G3,E2,S1

Picric acid A,G1,G3,E2,R1,S1

Polyethanoxy (15) tallow amine A,E2,S1

Poly(oxy-1,2-ethanediyl), α -  
[2-[(2-hydroxyethyl)amino]-2-  
oxoethyl]- α -hydroxy-,mono-C13-15-alkyl ethers A,E1

Potassium bromate A

Potassium chlorate A

Potassium cyanate A,E1,S1

Potassium hydroxide A,G3,E2,S1

Potassium metabisulphite A

Potassium nitrite

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

Potassium peroxomonosulfate triple salt

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Potassium persulfate A,G3,E2

Potassium sulfide A,G3,E2,S1

Propionic acid A,G3,E1,S1

d-Pulegone A,G3

Pyrithione zinc A,E1

Quaternary ammonium compounds **except**

when separately specified

• above 20 per cent A,G3,E2

• 20 per cent and below A,E2

• in pressurised spray packs A,E2,G6

Safrole A,G1,G3

Sage oil (Dalmatian) A,G3

Sassafras oil A,G1,G3

Selenium compounds A,G1,E1,S1

Silicofluorides

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

Silver salts A,E2

Sodium aluminate A,G3,E2,S1

Sodium bromate A,G1

Sodium chlorate A

Sodium diacetate A,G3,E2,S1

Sodium dichloroisocyanurate A,G3,E1,S1

Sodium dodecylbenzene sulfonate A,G3,E2,S1

Sodium hydrogen sulfate A,G3,E1,S1

Sodium hydrosulfite A,G3,E2,S1

Sodium hydroxide A,G3,E2,S1

Sodium laureth-6 carboxylate A

Sodium lauryl sulfate

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

Sodium metabisulphite A, G3

Sodium nitrite

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

Sodium percarbonate

• when included in Schedule 5 A,G3,S1

• when included in Schedule 6 A,G3,E2,S1

Sodium persulfate A,G3,E2

Sodium stannate A,E1

Sodium sulfide A,G3,E2,S1

Sodium trichloroacetate A

Strychnine A,G1,G2,G3,R2

Styrene A,G3,S1,E1

Sulcofuron A

Sulfamic acid A,G3,E2,S1

Sulfuric acid A,G3,E2,S1

Terpenes, chlorinated A,G3

Tetrachloroethane A,G3,E1,R1,S1

Tetrachloroethylene A,G3,E2,R1,S1

Thiourea A

Thujone A,G3

Thyme oil A,G3

ortho-Tolidine A

Toluene

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A

Toluenediamine

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

Trichloroacetic acid A,G3,E2,S1

Trichloroacetic acid alkali salts A

1,1,1-Trichloroethane A,G3,E1,R1,S1

Trichloroethylene A,G3,E1,R1,S1

Trichloroisocyanuric acid A,G3,E1,S1

Triethanolamine A,G3,E1,S1

Triethyl phosphate A,E1

Trifluoromethanesulfonic acid A,G3,E2

Triisopropanolamine lauryl ether sulfate A,E1,S1

Turpentine (mineral) A,G3

Turpentine oil (vegetable) A,G3,E2

White spirit A,G3

Xylene

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A,G6,E1,S1

Xylenols A,G3,E2,S3

• in pressurised spray packs A,E1

Zinc chloride A,G3,E2,S1

Zinc sulfate A,G3,E2,S1

## APPENDIX F

## WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the

Australian Pesticides and Veterinary Medicines Authority and medicines for human use

when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Warning Statements and Safety Directions**

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX F**

**PART 1**

**WARNING STATEMENTS**

1. Highly corrosive.

2. Corrosive.

3. Corrosive liquid.

4. Strongly alkaline.

5. Irritant.

6. May cause cancer.

7. WARNING − Causes birth defects.

8. WARNING − May be fatal to children.

9. Can be fatal to children if sucked or swallowed.

10. May produce severe burns.

11. WARNING − Vapour may be harmful.

12. Vapour is harmful to health on prolonged exposure.

13. May be fatal if inhaled, swallowed or absorbed through skin.

14. Dust will irritate and burn eyes, nose and skin.

15. Liquid will cause burns.

16. Forms dangerous gas near radiators or naked flames.

17. Contact with eyes even for short periods can cause blindness.

18. Product will irritate the eyes, nose, throat and skin.

19. WARNING − Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.

20. May give off dangerous gas if mixed with other products.

21. WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

22. Highly reactive oxidising chlorine compound.

23. May cause fire or explosion.

24. For external washing only. Rinse skin thoroughly after use.

25. Do not use on broken skin. Wash hands thoroughly after use.

26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.

27. Not for therapeutic use.

28. (Over) (Repeated) exposure may cause sensitisation.

29. If congestion persists, consult your doctor or pharmacist.

30. WARNING − Do not use on face or on anal or genital areas.

31. WARNING − Do not use on face or on anal or genital areas except on doctor’s advice.

32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.

33. Do not take for periods longer than four weeks except on medical advice.

34. WARNING − This medication may be dangerous when used in large amounts or for a long time (period).

35. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.

36. For use under medical supervision only.

37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.

38. CAUTION − Do not use for children under 2 years old unless a doctor has told you to.

39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.

40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.

41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.

42. WARNING − Overuse may stain the skin or mouth.

43. Use of this product is not necessary in areas supplied with fluoridated water.

44. WARNING − May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.

45. WARNING − If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.

46. WARNING − Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).

47. WARNING − This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

48. WARNING − This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

49. WARNING − Do not mix with other medication except on veterinarian’s advice.

50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.

52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.

53. CAUTION − (Name of substance) should not be used by pregnant women.

54. Seek medical advice before first course of treatment.

55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.

56. WARNING − Can cause elevated blood pressure and interact adversely with other medication.

57. Not to be applied to infants under 12 months of age unless on doctor’s advice.

58. Highly reactive oxidising bromine and chlorine compound.

59. May cause allergy.

60. Do not mix with detergents or other chemicals.

61. WARNING − Can react with other medicines. Ask your doctor or pharmacist before taking.

62. Do not use if pregnant.

63. See a doctor if you are pregnant or diabetic.

64. See a doctor (or) *(dentist)* if no better after (Insert number of days as per approved Product Information) days.

65. If getting better, keep using for (Insert number of days as per approved Product Information ) days.

66. See a doctor if problem returns.

67. Do not use if pregnant or likely to become pregnant.

68. If symptoms persist beyond 5 days consult a doctor (or) *(dentist)*.

69. If symptoms recur within two weeks of completing the course, consult a doctor.

70. Use only under medical supervision if you are taking other medicines.

71. Do not use during the last three months of pregnancy.

72. Do not use in the eyes.

73. Do not use for acne.

74. Do not use under waterproof bandages unless a doctor has told you to.

75. Do not use for more than 7 days unless a doctor has told you to.

76. Do not become pregnant during use or within (*Insert number of months as per approved Product Information*) month(s) of stopping treatment.

77. WARNING − May cause birth defects.

78. Attacks skin and eyes.

79. Will irritate eyes.

80. (Intentionally blank)

81. (Intentionally blank)

82. (Intentionally blank)

83. This paint is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use on, in or around the home.

84. Breathing the vapour is dangerous.

Provide adequate ventilation during application.

Do not use in the presence of a naked flame.

Do not smoke.

85. This paint contains lead and is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use for painting any building or fixed structure.

Do not use where contact with food or drinking water is possible.

86. This tinter contains lead.

Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.

87. (*Insert brand name*) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.

89. Application to skin may increase sensitivity to sunlight.

90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.

91. CAUTION − Total iodine intake may exceed recommended level when taking this preparation.

92. WARNING − Contains iodine - do not take when pregnant **except** on physician’s advice.

93. Causes severe burns, which are not likely to be immediately painful or visible.

94. WARNING − Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.

95.CAUTION − Do not use for children under 12 years old unless a doctor has told you to.

96. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.

97*. Adults:* Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.

98. *Children and adolescents:* Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New  Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.

101. Don’t use [this product/name of the product]:  
If you have a stomach ulcer

In the last 3 months of pregnancy *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]*

If you are allergic to (name of substance) or anti-inflammatory medicines.

102. Unless a doctor has told you to, don’t use [*this prouct/name of the product*]:

For more than a few days at a time

With other medicines containing aspirin or other anti-inflammatory medicines

If you have asthma

In children under 12 years of age

In children 12-16 years of age with or recovering from chicken pox, influenza or fever

If you are pregnant.

103. See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [*This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients*.]

104. Unless a doctor has told you to, don’t use [this product/name of the product]:

For more than a few days at a time

With other medicines containing (name of substance) or other anti-inflammatory medicines

If you have asthma

If you are pregnant *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea]*.

105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.

106. Contains formaldehyde.

**APPENDIX F**

**PART 2**

**SAFETY DIRECTIONS - GENERAL**

To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Labels and Containers, subparagraph 7(n) to this Standard).

1. Avoid contact with eyes.

2. Attacks eyes − protect eyes when using.

3. Wear eye protection when mixing or using.

4. Avoid contact with skin.

5. Wear protective gloves when mixing or using.

6. Wash hands after use.

7. Wash hands thoroughly after use.

8. Avoid breathing dust (or) vapour (or) spray mist.

9. Use only in well ventilated area.

10. Ensure adequate ventilation when using.

11. No smoking.

12. Do not allow product to come into contact with other chemicals, especially acids.

13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.

14. Do not allow to get damp.

15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.

16. Store and transport in an upright container.

17. Do not mix with other chemicals.

18. Do not mix with different types of chlorinating chemicals.

19. Use clean containers for dispensing.

20. Mix with water only.

21. Do not add water to product − add product to water, but in case of fire drench with water.

22. In case of spillage flush with large quantities of water.

23. Keep away from heat, sparks and naked flames.

24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.

25. Avoid contact with food.

26. Avoid contact with clothing.

27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.

28. Do not mix with hot water.

29. Obtain a supply of calcium gluconate gel.

30. (Intentionally blank.)

31. Do not use on broken skin.

32. Do not use under occlusive dressing.

33. Mix strictly according to instructions.

34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.

35. Wash gloves thoroughly, immediately after use.

36. Protect cuticles with grease or oil.

**APPENDIX F**

**PART 3**

**POISONS (other than agricultural and veterinary chemicals)   
TO BE LABELLED WITH WARNING STATEMENTS**

**OR SAFETY DIRECTIONS**

(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**WARNING SAFETY**

**POISON** **STATEMENTS DIRECTION**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Acetic acid in concentrations of 80 per cent 2 1,4,8

or more **except** when in Schedule 2.

Acetic anhydride 2 1,4,8

Acetone in concentrations greater than 75 per cent. 1,4,8

Acitretin 7,62,76

Adapalene for topical use. 62,77

Alclometasone when included in Schedule 3. 38,72,73,74,75

Alkaline salts 4 1,4

Ambrisentan 7,62,76

Amines used as curing agentsfor epoxy resins. 1,3,4,5,8

Ammonia/ammonium hydroxide in concentrations 4 1,4,8

greater than 20 per cent ammonia **except**

in smelling salts.

Ammonium persulfate 5,21,25 1,5,23,33,34

Anhydrides, organic acid, for use as curing agents 1,3,4,5,8

for epoxy resins.

Aniline 13 1,4,8

Antihistamines not separately specified 39 or 40

in this Appendix **except**:

(a) dermal, ocular, parenteral and   
paediatric preparations;

(b) oral preparations of astemizole,

desloratadine, fexofenadine,

loratadine or terfenadine;

(c) nasal preparations of azelastine; or

(d) preparations for the treatment of animals.

Aromatic extract oils 1,3,4,5,6

Aspirin

(a) for inhibition of platelet aggregation. 36

(b) in sustained release preparations 36  
containing 650 mg or more of aspirin.

(c) in other preparations. 101,102,103

Astemizole 61

Azadirachta indica (neem) including its extracts  
and derivatives when included in Schedule 6. 67

Azocyclotin 48

Benomyl 46

Benzene 12 1,4,9

Benzoyl peroxide when included in Schedule 2. 55

Benzoyl peroxide when included in Schedule 5. 1,4,8

Bergamot oil 89

Beryllium 1,4,8

Bexarotene

(a) for human use. 7,62,76

(b) for topical use. 62,77

Bifluorides (including ammonium, potassium and sodium salts)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Bithionol for the treatment of animals. 1,4,8

Boron trifluoride (including mixtures that

generate boron trifluoride)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Bosentan 7,62,76

Bromoform 1,4,8

2-Butoxy-2’-thiocyanodiethyl ether 1,4,8

2-Butoxyethanol and its acetates 1,4,8

Camphor

(a) in block, ball, disc, pellet or flake form, 9

enclosed in a device which, in normal use,

prevents removal or ingestion of its contents.

(b) in other forms. 9 1

Carbamide peroxide

(a) more than 9 per cent up to 30 per cent. 5 1

(b) more than 30 per cent up to 60 per cent. 5 2

(c) more than 60 per cent. 2 2,4

Carbon disulphide 12 1,4,8,9,23

Carbon tetrachloride 12 1,4,8,9

Cassia oil 4

Chlorinating compounds

(a) in household cleaning or bleaching 20

preparations.

(b) in preparations containing less than 11 1,4,10

10 per cent of available chlorine.

(c) in liquid preparations containing 3,18 1,4,6,8,10, 15,16,

10 per cent or more of available chlorine. 17,18, 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,

or more of available chlorine. 14,15,16,17, 18,

19,20,21, 22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,  
 or more of available chlorine certified by a 14,15,16,17,  
 relevant State or Territory authority as not 18,19,20,21,  
 being a Dangerous Good of Class 5, 22,26  
 Division 5.1:Oxidising substances, as

specified inthe *Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in compressed block or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine 17,18,19,21  
 **except** in preparations for use in toilet   
 cisterns only, containing 15 g or less of

trichloroisocyanuric acid.

(g) in other compressed blocks or tablets 10,22 12,13,14,15,

containing 10 per cent or more of available 17,18,19,21

chlorine certified by a relevant State or

Territory authority as not being a Dangerous

Good of Class 5, Division 5.1: Oxidising

substances, as specified inthe *Australian*

*Code for the Transport of Dangerous Goods*

*by Road and Rail* **except** in preparations for

use in toilet cisterns only, containing 15 g or

less of trichloroisocyanuric acid.

Chloroform when included in Schedule 6 1,4,8

alpha-Chlorohydrin 13,51 1,4,8,9

Chromates (including dichromates) of alkali metals or ammonia 1,4,8

Chromium trioxide 2,14,15,23 1,4,8,13

Cimetidine when included in Schedule 3 70,96

Cinnamon bark oil 4

Clobetasone when included in Schedule 3. 72,73,74,75,95

Clotrimazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Clove oil 1

Cyanides when included in Schedule 7. 13 4,8

Cyanuric acid 1,4,8

Cyclohexanone peroxide 1,4,8

Cysteamine 1

4,4-Diaminodiphenylmethane (methylene dianiline) 1,4,8

ortho-Dichlorobenzene 1,4,8

para-Dichlorobenzene 1,4

Dichloroethylene 1,4,8

Dichloroethyl ether 1,4,8

Dichloroisocyanurates

(a) in household cleaning or bleaching 20  
 preparations.

(b) in preparations containing less than 11 1,4,10  
 10 per cent of available chlorine. .

(c) in liquid preparations containing 10 per cent 3,18 1,4,6,8,10,  
 or more of available chlorine. 15,16,17,18,  
 . 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,14,  
 or more of available chlorine. 15,16,17,18,19,  
 . 20,21,22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,14,

or more of available chlorine certified by a 15,16,17,18,19,

relevant State or Territory authority as not 20,21,22,26

being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as

specified in*the Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in anti-bacterial tablets containing 2.5 g or 60  
 less of sodium dichloroisocyanurate..

(g) in other compressed blocks or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine **except** 17,18,19,21  
 in preparations containing 21 g or less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(h) in other compressed blocks or tablets containing 10,22 12,13,14,15,17,

10 per cent or more of available chlorine 18,19,21

certified by a relevant State or Territory authority

as not being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as specified

in*the Australian Code for the Transport of*

*Dangerous Goods by Road and Rail* **except** in

preparations containing 21 g less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(i) in other compressed blocks or tablets containing

10 per cent or more of available chlorine in

preparations containing 5 g or less of sodium

dichloroisocyanurate for use in toilet bowls only:

(i) during storage 10,22,23 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

(j) in other compressed blocks or tablets containing

10 per cent or more of available chlorine certified

by a relevant State or Territory authority as not

being a Dangerous Good of Class 5, Division 5.1:

Oxidising substances, as specified inthe

*Australian Code for the Transport of Dangerous*

*Goods by Road and Rail* in preparations

containing 5 g or less of sodium dichloroisocyanurate

for use in toilet bowls only.

(i) during storage 10,22 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

Dichloromethane (methylene chloride)

(a) in paint or lacquer removers. 12,16 1,4,8,11

(b) other than in paint or lacquer removers 1,4,8,25

.

Diclofenac 101,104

Dienestrol 67

Diethanolamine when included in Schedule 5. 5 1,4

Diethanolamine when included in Schedule 6. 2,11,18 1,4,8

Diethyltoluamide for human use. 44

5,6-Dihydroxyindoline 21,28

Dimethylformamide 1,4,8

Dimethyl sulfate 2 1,4,8

Dimethyl sulfoxide

(a) when not packed and labelled for therapeutic use. 27 1,4,5,8

(b) when packed and labelled for treatment of animals. 49 1,4,5,8

Dinitrocresols (and their homologues) **except** when for 1,4,8

therapeutic use.

Dinitrophenols (and their homologues) **except** when 1,4,8

for therapeutic use.

Dinocap 47

Dioxane 1,4,8

Diphenoxylate when included in Schedule 3. 39 or 40,41

Econazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Ephedrine in nasal preparations for topical use. 29

Epichlorohydrin 2 1,4,8

Epoxy resins, liquid. 1,3,4,5,8

Ethanolamine when included in Schedule 5. 5 1,4

Ethanolamine when included in Schedule 6. 2,11,18 1,4,8

Ether when included in Schedule 5 or 6. 1,4,8

Ethoxyethylmercuric chloride 1,4

Ethyl bromide 1,4,8

Ethylene chlorohydrin 1,4,8

Ethylene glycol monoalkyl ethers and their acetates 1,4,8

except when separately specified.

Ethylene oxide 1,4,8

Ethylmercuric chloride 1,4

Ethyl methacrylate 28 4,9,23

Etretinate 7,62,76

Eugenol 1

Famotidine when included in Schedule 2. 96

Fenoterol in metered aerosols. 32

Fluconazole in oral preparations when included in 64   
Schedule 3.

Fluorides (including silicofluorides) when included in 1,4

Schedule 5 or 6 **except** when separately specified.

Formaldehyde

(a) in nail hardener cosmetics. 106 1,4,8,36

(b) in other preparations. 106 1,4,8

Formic acid 1,4,8

Glazing preparations containing lead compounds.. 50

Glutaraldehyde **except** when in Schedule 2

(a) 25 per cent or less. 5,59 1,4,5

(b) more than 25 per cent. 3,59 1,4,5,8

Glycolic acid 79 1,5,6,31

Hexachlorophane in preparations for skin cleansing 24

purposes containing 3 per cent or less of

hexachlorophane.

Hydrazine 1,4,8

Hydrochloric acid

(a) 30 per cent or less of HCl. 1,4

(b) more than 30 per cent of HCl. 1,4,8

Hydrocortisone

(a) for dermal use when included in 38,72,73,74,75

Schedule 2 or 3.

(b) for topical rectal use when includeed 38,75

in Schedule 2 or 3.

Hydrocyanic acid when included in Schedule 7. 13 4,8

Hydrofluoric acid (including mixtures that generate

hydrofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Hydrogen peroxide

(a) more than 3 per cent up to 10 per cent. 5 1

(b) more than 10 per cent up to 20 per cent. 5 2

(c) more than 20 per cent. 2 2,4

Hydroquinone

(a) when in Schedule 2. 45

(b) **except** when in Schedule 2 or 4. 1,4

Hydrosilicofluoric acid (including mixtures

that generate hydrosilicofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

8-Hydroxyquinoline (including salts and 33

derivatives) when prepared for

internal use.

Ibuprofen 101,104

Iodine

(a) more than 20 per cent. 1,4,8

(b) in preparations for human internal therapeutic 91,92   
 use containing 300 micrograms or more of

iodine per recommended daily dose.

Ipratropium bromide in metered aerosols. 32

Isocyanates (free organic)

(a) when in paint. 28,52 1,5,8,10,27

(b) other than in paint. 28,52 1,4,8

Isoprenaline in metered aerosols 32

Isotretinoin

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

Lead compounds

(a) in hair cosmetics. 25

(b) when in Schedule 6. 1,4,8

Leflunomide 7,62,87

Lemon oil 89

Lenalidomide 7,62,76

Levocabastine

(a) in eye or nasal preparations containing 62

0.5 mg/mL or less of levocabastine.

(b) in other preparations. 62 and

either 39 or 40

Lime oil 89

Loperamide when in Schedule 2. 41

Magnesium chlorate 1,4

Mefenamic acid 101,104

Mercuric thiocyanate 1,4

Metacresolsulphonic acid and formaldehyde 1,4

condensation product for the treatment of animals.

Methanol **except** in methylated spirit. 1,4,8

Methoxamine in nasal preparations for topical use. 29

Methyl chloride 1,4,8

Methyl ethyl ketone 5 1,4,8

Methyl ethyl ketone peroxide 2 2,3,4,6

Methyl iso-amyl ketone 1,4,8

Methyl iso-butyl ketone 1,4,8

Methyl iso-thiocyanate 5,12 1,4,8

Methyl methacrylate 28 4,9,23

Methyldibromo glutaronitrile 28 1,4,7

Methylene bisthiocyanate 1,4

Methyleugenol 1,6

Methylnorbornylpyridine 59

1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-

N,N-diethylaminobenzene 1,4,8

Miconazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Misoprostol 53

Naphazoline in nasal preparations for topical use. 29

Naphthalene

(a) in block, ball, disc, pellet or flake form, 9,105

enclosed in a device which, in normal

use, prevents removal or ingestion of its

contents.

(b) in other forms. 9,105 1

Naproxen 101,104

Nicotine **except** when in tobacco or when included 1,4  
in Schedule 2.

Nitric acid

(a) 75 per cent or less HNO3. 2 1,4

(b) more than 75 per cent HNO3. 2 1,4,8

Nitrobenzene 1,4,8

Nitrophenols 1,4

Nitroprussides in aerosols. 84 8

Nizatidine when included in Schedule 2. 96

Noradrenaline in metered aerosols. 32

Nystatin in vaginal preparations when included 54,63,64,65,66

in Schedule 3.

Orange oil (bitter) 89

Orciprenaline in metered aerosols. 32

Oxalates, metallic 4,8

Oxalic acid 2 4,8

Oxymetazoline in nasal preparations for topical use. 29

Paint

(a) First Schedule paints. 83

(b) Second Schedule paints. 84

Paracetamol 97 and/or 98,99,100

Pentachlorophenol 1,4,8

Peracetic acid 2 1,4,8

Permanganates 2 24

Phenol and any other homologue of phenol. 1,4

Phenols 5

Phenylenediamines and alkylated   
phenylenediamines

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

Phenylephrine in nasal preparations 29

for topical use.

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,5-dimethanamine 5,28 1,4,5,10

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,6-dimethanamine 5,28 1,4,5,10

ortho-Phenylphenol **except** when in 1,4

antiseptics.

Phenylpropanolamine 56

Phenytoin in pastes for the treatment of horses. 9

Phosphonic acid 1,4

Phosphoric acid 1,4

Phosphorus (yellow) 2 1,4

ortho-Phthalaldehyde

(a) when included in Schedule 5. 51,52,59 1,4,5,8,10

(b) when included in Schedule 6. 51,52,59 2,4,5,8,10

Picric acid (more than 20 per cent). 1,4

Podophyllin

(a) in preparations specifically for use on 36

anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

Podophyllotoxin

(a) in preparations specifically for 36

use on anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

Polihexanide 1,4,8

Polyethanoxy (15) tallow amine 1,4

Poly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino] 5,88 1,5

-2-oxoethyl]- α -hydroxy-,mono-C13-15 -alkyl ethers

Potassium hydroxide

(a) in preparations containing 5 1,4,6  
 0.5 per cent or less of potassium

hydroxide.

(b) in solid preparations containing 2,10,78 3,5,28

more than 0.5 per cent of potassium   
 hydroxide.

(c) in liquid preparations containing 2,10,78 3,5  
 more than 0.5 per cent of potassium   
 hydroxide.

Potassium metabisulphite 5,26 1,4

Potassium nitrite in pickling or curing salts. 94

Potassium persulfate 5,21,25 1,5,23,33,34

Potassium sulfide 2 1,4

Propionic acid when in Schedule 6. 2 1,4

Ranitidine when included in Schedule 2. 96

Safrole

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

Salbutamol in metered aerosols or in dry 32  
powder formulations.

Salicylamide 34 or 35

Sassafras oil

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

Selenium compounds **except** when for 1,4,8

therapeutic use (human or animal).

Silver in smoking deterrents. 42

Sitaxentan 7, 62, 76

Sodium aluminate 2 1,4

Sodium chlorate 1,4

Sodium dodecylbenzene sulfonate 79 1

Sodium fluoride in preparations for 43

human ingestion when in Schedule 2.

Sodium hydrogen sulfate 1,4,8

Sodium hydrosulfite 5,26 1,4,8

(more than 50 per cent)

Sodium hydroxide

(a) in preparations containing 0.5 per cent 5 1,4,6  
 or less of sodium hydroxide.

(b) in solid preparations containing more than 2,10,78 3,5,28  
 0.5 per cent of sodium hydroxide.

(c) in liquid preparations containing more than 2,10,78 3,5  
 0.5 per cent of sodium hydroxide.

Sodium laureth-6 carboxylate 79 1

Sodium metabisulphite 5,26 1,4

(more than 50 per cent)

Sodium nitrite in pickling or curing salts 94

Sodium persulfate 5,21,25 1,5,23,33,34

Sodium sulfide 2 1,4

Styrene 1,4,8

Sulfamic acid 2 1,4

Sulfuric acid 2 1,4

Symphytum spp. (Comfrey) when included in Schedule 5. 31,32

Tazarotene for topical use. 77,62

Terbutaline in metered aerosols or in dry powder formulations. 32

Terfenadine 61

Teriflunomide. 7,62,87

Terpenes, chlorinated 1,4,8

Tetrachloroethane 12 8

Tetrachloroethylene when in Schedule 5 or 6. 12,16 1,4,8,11

Tetrahydrozoline in nasal preparations for topical use. 29

Thalidomide 7,62,76

Thiourea 1,4

Toluene 1,4,8

Toluenediamine

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

Tramazoline in nasal preparations for topical use. 29

Tretinoin

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

Triamcinolone when in topical preparations 64 or 68

for the treatment of mouth ulcers.

Trichloroacetic acid **except** when for 2 1,4

therapeutic use.

1,1,1-trichloroethane 8,9

Trichloroethylene **except** when for 12 1,4,5,8,9  
therapeutic use.

Trichlorophenol 1,4,8

Triethanolamine 5 1,4

Triethyl phosphate 1,4,8

Trifluoromethanesulfonic acid

(a) more than 10 per cent. 1,17 1,4,8

(b) 10 per cent or less. 1,4,8

Triisopropanolamine lauryl ether sulfate 1,4,6

3,6,9-Trioxaundecanedioic acid 5 1

Tymazoline in nasal preparations for topical use. 29

Vinclozolin 46

Xylene 1,4,8

Xylometazoline in nasal preparations for topical use. 29

Zinc chloride 1,4

Zinc sulfate when in Schedule 6. 1,4

## APPENDIX G

## DILUTE PREPARATIONS

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.

**Column 1 Column 2**

**Poison Concentration**

**(quantity per litre**

**or kilogram**)

ACETYLCHOLINE 1 mg

ALDOSTERONE 10 micrograms

ANTIMONY COMPOUNDS 1 mg

APOMORPHINE 1 mg

ARSENIC 1 mg

ATROPA BELLADONNA (belladonna) 300 micrograms

ATROPINE 300 micrograms

CANTHARIDIN 10 micrograms

CHLORINE 5 mg

CROTON TIGLIUM (croton oil) 1 mg

DIOXANE 100 mg

ERYSIMUM spp. 1 mg

FOLLICLE-STIMULATING HORMONE 100 micrograms

GELSEMIUM SEMPERVIRENS 1 mg

GLUCAGON 100 micrograms

GLYCERYL TRINITRATE 100 micrograms

GROWTH HORMONE 10 micrograms

HALOPERIDOL 1 mg

HYDROCYANIC ACID 1 microgram

HYOSCINE 300 micrograms

HYOSCYAMINE 300 micrograms

HYOSCYAMUS NIGER 300 micrograms

HYPOTHALAMIC RELEASING FACTORS 10 micrograms

INDOMETHACIN 1 mg

MERCURY 1 mg

METHYLMERCURY 300 micrograms

NAPHTHALENE 1 mg

NERIUM OLEANDER 1 mg

OESTRADIOL 10 micrograms

OESTRONE 100 micrograms

OXYTOCIN 1 microgram

PHOSPHORUS 1 mg

PODOPHYLLUM RESIN (podophyllin) 1 mg

PROGESTERONE 1 mg

PROPRANOLOL 1 mg

SELENIUM 100 micrograms

STROPHANTHUS spp. 1 mg

STRYCHNINE 1 mg

TESTOSTERONE 1 mg

THYROXINE 10 micrograms

## APPENDIX H

## SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED

.

Butoconazole.

Clotrimazole.

Diclofenac.

Dimenhydrinate for the prevention and relief of motion sickness.

Diphenoxylate.

Econazole.

Fluconazole.

Hydrocortisone.

Miconazole.

Nystatin.

## APPENDIX I

## UNIFORM PAINT STANDARD

This Appendix provides regulations for adoption by the States and Territories.

1. A person must not manufacture, sell, supply or use a First Schedule Paint for application to:

(1) a roof or any surface to be used for the collection or storage of potable water; or

(2) furniture; or

(3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or

(4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

2. A person must not manufacture, sell, supply or use a Third Schedule paint.

3. A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012 entitled *Safety of toys Part 3: Migration of certain elements* (ISO 8124-03:2010, MOD).

4. A person must not manufacture, sell, supply, or use a paint containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.

**The First Schedule**

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

**Substance Proportion**

ANTIMONY or antimony compounds other than more than 5 per cent

antimony titanate pigments

BARIUM salts **except** barium sulfate or barium metaborate more than 5 per cent

CADMIUM or cadmium compounds more than 0.1 per cent

CHROMIUM as chromates of ammonia, barium, potassium, more than 5 per cent

sodium, strontium or zinc

SELENIUM or selenium compounds more than 0.1 per cent

**The Second Schedule**

**Substance Proportion**

DICHLOROMETHANE (methylene chloride) more than 5 per cent by wt

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates more than 10 per cent by vol

TOLUENE more than 50 per cent by vol

XYLENE more than 50 per cent by vol

**The Third Schedule**

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

**Substance Proportion**

LEAD or lead compounds more than 0.1 per cent

## APPENDIX J

## CONDITIONS FOR AVAILABILITY AND USE OF SCHEDULE 7 POISONS

**PART 1**

**CONDITIONS FOR AVAILABILITY AND USE**

The following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.

1. Not to be available except to authorised or licensed persons.

2. Not to be used in printing inks.

3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.

4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.

**APPENDIX J**

PART 2

A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**POISONS CONDITIONS**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Abamectin 1

Acibenzolar-s-methyl 1

Acrolein 1

Acrylonitrile 1

Alachlor 1

Allyl alcohol 1

4-Aminopyridine 1

Arprinocid 1

Arsenic 1

Azocyclotin 1

Benzene 1

Bifluorides (including ammonium, potassium and sodium salts) 1

Boron trifluoride 1

Brodifacoum 1

Bromadiolone 1

Bromine 1

Brucine 1

Calciferol 1

Captafol 1

Carbadox 1

Carbon tetrachloride 1

Chlordecone 1

Chlordimeform 1

Chlorine 1

Chloromethiuron 1

Chloropicrin 1

4-Chloro-o-toluidine 1

Colecalciferol 1

Coumatetralyl 1

Cyanogen 1

Cyhexatin 1

4,4-Diaminodiphenylmethane (methylene dianiline) 1

1,2-Dibromo-3-chloropropane 1

1,3-Dichloropropene 1

Difenacoum 1

4-Dimethylaminoazobenzene 1

Dinitrocresols 1

Dinitrophenols 1

Dinoseb 1

Epichlorohydrin 1

Epidermal growth factor 1

Etaconazole 1

Ethylene dibromide 1

Ethylene oxide 1

Fluoracetamide 3

Fluoroacetic acid 3

Folpet 1

Halofuginone 1

Halogenated dibenzodioxins and dibenzofurans 1

HCB 1

Hydrocyanic acid and cyanides 1

Hydrofluoric acid 1

Hydrosilicofluoric acid 1

Iodomethane 1

Maduramicin 1

Mercury 1

Methacrifos 1

Methoxyethylmercuric acetate 1

Methoxyethylmercuric chloride 1

Methyl bromide 1

4,4’-Methylenebis[2-chloroaniline] 1

Mirex 1

Molinate 1

Nicotine 1

Nitrofen 1

Phenylmercuric acetate 1

Phosphides, metallic 1

Phosphine 1

Propylene oxide 1

Pyrinuron 1

Strychnine 1

Sulcofuron 1

Tetrachloroethane 1

2,2’,6,6’-Tetraisopropyl-diphenyl-carbodiimide 1

Thallium 3

ortho-Tolidine 1

Trichloroisocyanuric acid 1

Vinyl chloride 1

## APPENDIX K

## DRUGS REQUIRED TO BE LABELLED

## WITH A SEDATION WARNING

(see Part 2, Labels and Containers, subparagraph 14(2))

Alprazolam

Amisulpride

Amitriptyline

Amylobarbitone

Aripiprazole

ASENAPINE

Azatadine

Baclofen

Benztropine

Bromazepam

Brompheniramine

Buclizine

Buprenorphine

Butobarbitone

Cetirizine

Chloral hydrate

Chlordiazepoxide

Chlormethiazole

Chlorpheniramine

Chlorpromazine

Clemastine

Clomipramine

Clonazepam

Clonidine

Clorazepate

Clozapine

Codeine **except** when included in Schedule 2 or 3.

Cyclizine

Cyclobarbitone

Cycloserine

Cyproheptadine

Cysteamine

Dantrolene

Desipramine

Dexchlorpheniramine

Dextromoramide

Dextropropoxyphene

Diazepam

Difenoxin

Dihydrocodeine

Dimenhydrinate

Dimethindene

Diphenhydramine

Diphenoxylate

Diphenylpyraline

Dothiepin

Doxepin

Doxylamine

Dronabinol (*delta*-9-tetrahydrocannabinol)

Droperidol

Duloxetine

Ethylmorphine

Fenfluramine

Flunitrazepam

Flupenthixol

Fluphenazine

Flurazepam

Gabapentin

Gemcitabine

Glutethimide

Haloperidol

Hydrocodone

Hydromorphone

Hydroxyzine

Imipramine

Lamotrigine

Levetiracetam

Levocabastine

Lorazepam

Mazindol

Mebhydrolin

Meclozine

Medazepam

Meprobamate

Mepyramine

Methadone

Methdilazine

Methocarbamol

Methylphenobarbitone

Mianserin

Mirtazapine

Morphine

Nabiximols

Nalbuphine

Nitrazepam

Normethadone

Nortriptyline

Olanzapine

Opium in any form **except** the alkaloids noscapine and papaverine.

Oxazepam

Oxycodone

Paliperidone

Papaveretum

Pentazocine

Pentobarbitone

Pericyazine

Perphenazine

Pethidine

Phenelzine

Pheniramine

Phenobarbitone

Phenoperidine

Phenyltoloxamine

Pholcodine

Pimozide

Pizotifen

Prazepam

Pregabalin

Prochlorperazine

Promazine

Promethazine

Protriptyline

Quetiapine

Quinalbarbitone

RETIGABINE

Risperidone

Rotigotine

RUPATADINE

Secbutobarbitone

TAPENTADOL

Temazepam

Thenyldiamine

Thiethylperazine

Thiopropazate

Thioridazine

Thiothixene

Tramadol

Tranylcypromine

Trifluoperazine

Trimeprazine

Trimipramine

Triprolidine

Ziprasidone

Zolpidem

Zonisamide

Zopiclone

## APPENDIX L

## REQUIREMENTS FOR DISPENSING LABELS FOR

## HUMAN AND VETERINARY MEDICINES

**PART 1**

**GENERAL REQUIREMENTS FOR DISPENSING LABELS**

(see Part 2, Labels and Containers, subparagraph 14(1))

(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.

(2) All symbols, numbers and words on a label must be in durable characters.

(3) The label on a container of a substance for therapeutic use must contain the following details:

(a) the name, address and telephone number of the dispenser supplying the substance;

(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);

(c) adequate directions for use;

(d) the strength and form of the substance;

(e) the total quantity of the goods in the container;

(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;

(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;

(h) if the substance is a medicine, the name of the person for whom it was dispensed; and

(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.

(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:

(a) the prescription reference number;

(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

(c) the directions for use set out in the prescription.

**APPENDIX L**

**PART 2**

**ADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN MEDICINES**

(see Part 2, Labels and Containers, subparagraph 14(2))

Medicines required to be labelled with certain warning statements A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as specified opposite in Column 2.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Substance Warning statement**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Acitretin:

1. for oral use. 7,62 and 76
2. for topical use. 62 and 77

Adapalene:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Ambrisentan. 7, 62 and 76

Bexarotene:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Bosentan. 7, 62 and 76

Dienestrol. 67

Etretinate:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Fingolimod. 76

Isotretinoin:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Leflunomide. 7, 62 and 76

Lenalidomide:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Levocabastine. 62

Misoprostol. 53

Sitaxentan. 7, 62 and 76

Teriflunomide. 7, 62 and 87

Thalidomide:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Tretinoin:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

# **INDEX**

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200) 215

(1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE) \*(AM-694) 214

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) 169

(Z)-9-TRICOSENE 230

1

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE 217

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP) 217

1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHYLAMINOBENZENE 271

1,1,1-TRICHLOROETHANE 159, 234, 251, 276

*See also* DESIGNATED SOLVENT 5

1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE

*See* TDE 158, 196

1,2-DIBROMO-3-CHLOROPROPANE 202, 281

1,2-DICHLOROPROPANE 174

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and N-METHYLMETHANAMINE 143

1,3-DICHLOROPROPENE 202, 281

1,3-DIMETHYLAMYLAMINE 232

1,4-BUTANEDIOL 231

13C-UREA 230

19-NORANDROSTENEDIOL 105

19-NORANDROSTENEDIONE. 105

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE 162

1-DODECANOL

*See* LAURYL ALCOHOL 228

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP) 215

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (PETHIDINE INTERMEDIATE C) 210

1-METHYLCYCLOPROPENE 228

1-OCTEN-3-OL 187

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018) 216

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE \*(JWH-122) 216

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP) 216

2

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250) 215

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE 69

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE 196, 208, 282

2,2-DPA 227

2,3,6-TBA 158

2,4,5-T 195

2,4-D 140, 173

2,4-DB 140

2,4-DES 140

2,4-DICHLORPROP 174

2,4-DINITROCHLOROBENZENE 78

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7) 213

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB) 213

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET) 213

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2) 213

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I) 213

2,5-DIMETHOXYAMPHETAMINE \*(DMA) 213

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(CANNABICYCLOHEXANOL OR CP 47,497 C8 HOMOLOGUE) 214

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497) 214

2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE

*See* BASIC ORANGE 31 163, 231

2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

*See* TCMTB 195

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM) 212

2-BUTOXY-2’-THIOCYANODIETHYL ETHER 166, 263

2-BUTOXYETHANOL AND ITS ACETATES 241, 263

2C-I

*See* 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE 213

2C-T-2

*See* 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE 213

2C-T-7

*See* 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE 213

2-MERCAPTOETHANOL 184

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (MORAMIDE INTERMEDIATE) 215

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE 150

2-OCTYL-4-ISOTHIAZOLIN-3-ONE (OCITHILINONE) 247

2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER 229

3

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(DMHP) 213

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE OR PSILOTSIN) 213

3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) 217

3,4,5-TRIMETHOXY--METHYLPHENYLETHYLAMINE \*(TMA) 217

3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE

*See* N,A-DIMETHYL-3,4-(METHYLENEDIOXYL)PHENYLETHYLAMINE

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA) 215

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV) 215

3,6,9-TRIOXAUNDECANEDIOIC ACID 160, 276

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL) 214

3-IODO-2-PROPYNYL BUTYL CARBAMATE (iodocarb) 146, 181

3-METHYLFENTANYL 215

3-METHYLTHIOFENTANYL 215

4

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA) 205, 282

4,4-DIAMINODIPHENYLMETHANE (METHYLENE DIANILINE) 202, 264, 281

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE (Bromo-Dragonfly) 212

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE 174

4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE 225

4-AMINOPYRIDINE 57, 199, 240, 281

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA) 212

4-CHLOROMETHANDIENONE 69

4-CHLORO-o-TOLUIDINE 201, 281

4-CHLOROTESTOSTERONE

*See* CLOSTEBOL 71

4-CPA 139

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (PETHIDINE INTERMEDIATE A) 209

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE 213

4-DIMETHYLAMINOAZOBENZENE 202, 281

4-FLUORO-N-METHAMPHETAMINE

*See* 4-FLUORO-N-METHYLAMPHETAMINE

4-FLUORO-N-METHYLAMPHETAMINE 214

4-HYDROXYBUTANOIC ACID (GAMMA HYDROXYBUTYRATE (GHB)) 214

4-METHOXY--METHYLPHENYLETHYLAMINE \*(PMA) 215

4-METHYLAMINOREX 215

4-METHYLHEXANE-2-AMINE

*See* 1,3-DIMETHYLAMYLAMINE

4-METHYLMETHCATHINONE \*(MEPHEDRONE) 215

4-METHYLTHIOAMPHETAMINE 215

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (PETHIDINE INTERMEDIATE B) 211

5

5-(2-AMINOPROPYL)INDAN 212

5,6-DIHYDROXYINDOLINE 174, 232, 243, 266

5-AMINOLEVULINIC ACID 57

5-CHLORO-3-METHYL-4-NITROPYRAZOLE 201

5-MeO-AMT

*See* 5-METHOXY--METHYLTRYPTAMINE 215

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA) 215

5-METHOXY--METHYLTRYPTAMINE \*(5-MeO-AMT) 215

6

6-BENZYLADENINE 164

8

8-HYDROXYQUINOLINE 40, 269

*See also* CLIOQUINOL 70, 232

A

ABACAVIR 54

Abamectin 133, 161, 199, 281

ABATACEPT 54

ABCISIC ACID 133

ABCIXIMAB 54

ABIRATERONE ACETATE 54

ABRUS PRECATORIUS (Jequirity) 231

ACAMPROSATE CALCIUM 54

ACARBOSE 54

ACEBUTOLOL 54

ACEPHATE 161

ACEPROMAZINE 54

ACETAMIPRID 161

ACETANILIDE 54

ACETARSOL 54

ACETAZOLAMIDE 54

ACETIC ACID 32, 133, 161, 240, 261

ACETIC ANHYDRIDE 161, 240, 261

ACETOHEXAMIDE 54

Acetone 133, 240, 261

*See also* DESIGNATED SOLVENT 4

ACETORPHINE 212

ACETYL ISOVALERYLTYLOSIN 54

ACETYL-ALPHA-METHYLFENTANYL 212

ACETYLCARBROMAL 54

ACETYLCHOLINE 54, 277

ACETYLCYSTEINE 32, 54

ACETYLDIGITOXIN 54

ACETYLDIHYDROCODEINE 209

ACETYLMETHADOL 209

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE 54

ACETYLMORPHINES 209

4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE 225

ACETYLSTROPHANTHIDIN 54

ACIBENZOLAR-S-METHYL 199, 281

ACICLOVIR 54

ACIFLUORFEN 161

ACINITRAZOLE 161

ACIPIMOX 54

Acitretin 54, 235, 261, 287

ACOKANTHERA OUABAIO 54

ACOKANTHERA SCHIMPERI 54

ACONITUM 32, 55

ACORUS CALAMUS (Calamus) 231

ACRIFLAVINE 133, 199

ACRIVASTINE 55

Acrolein 199, 240, 281

ACRYLONITRILE 199, 281

ADALIMUMAB 55

Adapalene 55, 261, 287

ADEFOVIR 55

ADENOSINE 55

ADHESIVES, GLUES AND CEMENTS − MEDICAL AND VETERINARY 220

ADIPHENINE 55

ADONIS VERNALIS 55

ADRAFINIL 55

ADRENALINE 48, 55

ADRENOCORTICAL HORMONES 55

ADVERTISING 26

AFAMELANOTIDE 55

AFLIBERCEPT 55

AGALSIDASE 55

AGLEPRISTONE 55

AGOMELATINE 55

AGRICULTURAL CHEMICAL 2

AGRICULTURAL CHEMICAL PRODUCT 2

AGROBACTERIUM RADIOBACTER 225

AKLOMIDE 133

ALACHLOR 199, 281

ALATROFLOXACIN MESYLATE 55

ALBENDAZOLE 55, 133, 161

ALBUMIN

*See* HUMAN BLOOD PRODUCTS 219

ALCLOFENAC 55

ALCLOMETASONE 48, 55, 261

ALCOHOL, DEHYDRATED 225

ALCURONIUM 56

ALDESLEUKIN 56

ALDICARB 199

ALDOSTERONE 56, 277

ALDOXYCARB 199

ALDRIN 161

ALEFACEPT 56, 236

ALEMTUZUMAB 56

ALENDRONIC ACID 56

ALFACALCIDOL 56

ALFENTANIL 209

ALFUZOSIN 56

ALGICIDES 219

ALGLUCERASE 56

ALGLUCOSIDASE 56

ALISKIREN 56

Alkaline salts 14, 22, 133, 161, 231, 240, 261

ALKOXYAMPHETAMINES 212

ALKOXYLATED FATTY ALKYLAMINE POLYMER 133, 161

ALKOXYPHENYLETHYLAMINES 212

ALKYL ACETANILIDES

*See* ACETANILIDE 54

ALKYL SULFONALS

*See* SULFONMETHANE 123

ALKYL THIOUREAS

*See* THIOUREA AND ALKYL THIOUREAS 196

ALKYLATED PHENYLENEDIAMINES

*See* PHENYLENEDIAMINES 189, 248

ALKYLTHIOAMPHETAMINES 212

ALLERGENS 56

ALLETHRIN 133, 161

ALLOPURINOL 56

ALLOXYDIM 133

ALUMINIUM PHOSPHIDE

*See* PHOSPHIDES, METALLIC

ALLYL ALCOHOL 199, 281

ALLYLISOPROPYLACETYLUREA 231

ALLYLOESTRENOL 56

ALLYLPRODINE 212

ALOGLIPTIN 56

ALOSETRON 56

ALOXIPRIN 32

ALPHA1-PROTEINASE INHIBITOR (HUMAN) 56

ALPHACETYLMETHADOL 209

ALPHA-CHLORALOSE

*See* CHLORALOSE 168

ALPHA-CHLOROHYDRIN 169, 264

ALPHA -CYPERMETHRIN 134, 162, 199

ALPHADOLONE 56

ALPHAMEPRODINE 212

ALPHAMETHADOL 212

ALPHA -METHYLFENTANYL 212

ALPHA -METHYLTHIOFENTANYL 212

ALPHAPRODINE 209

ALPHAXALONE 56

ALPRAZOLAM 56, 283

ALPRENOLOL 56

ALPROSTADIL 56

ALSEROXYLON 56

ALTEPLASE 56

ALTRENOGEST 56

ALTRETAMINE (hexamethylmelamine) 56

ALUM 225

ALUMINIUM AMMONIUM SULFATE 225

ALUMINIUM POTASSIUM SULFATE 225

ALUMINIUM SILICATE 225

ALUMINIUM tris (ETHYLPHOSPHONATE) 225

AM-694

*See* 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE 214

AMANTADINE 56

AMBENONIUM CHLORIDE 56

AMBRISENTAN 57, 236, 261, 287

AMBUCETAMIDE 57

AMBUTONIUM BROMIDE 57

AMCINONIDE 57

AMETHOCAINE 32, 57

AMETOCTRADIN 225

AMETRYN 134

AMFEBUTAMONE

*See* BUPROPION

AMICARBAZONE 162

AMIDITHION 162

AMIDOPYRINE

*See* AMINOPHENAZONE 57, 231

AMIFOSTINE 57

AMIKACIN 57

AMILORIDE 57

AMINACRINE 134, 199

AMINES FOR USE AS CURING AGENTS FOR EPOXY RESINS 14, 134, 240, 261

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM) 212

AMINOCAPROIC ACID 57

AMINOCARB 162, 199

AMINOCYCLOPYRACHLOR 134

AMINOETHOXYVINYLGLYCINE 162

AMINOGLUTETHIMIDE 57

5-AMINOLEVULINIC ACID 57

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE 162

AMINOMETRADINE 57

AMINOPHENAZONE (amidopyrine) 57, 231

2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE

*See* BASIC ORANGE 31 163, 231

AMINOPHYLLINE 48, 57

5-(2-AMINOPROPYL)INDAN 212

AMINOPTERIN 57

4-AMINOPYRIDINE 57, 199, 240, 281

AMINOPYRALID 162

AMINOREX 57

AMINOSALICYLIC ACID 57

AMIODARONE 57

AMIPHENAZOLE 57

AMISOMETRADINE 57

AMISULPRIDE 57, 283

AMITON 199

AMITRAZ 162

AMITRIPTYLINE 57, 283

AMITROLE 134

AMLODIPINE 57

AMMI VISNAGA 57

Ammonia 134, 162, 240, 261

*See also* CHROMATES 264

AMMONIUM BIFLUORIDE

*See* BIFLUORIDES

AMMONIUM BROMIDE 57

AMMONIUM CHROMATE

*See* CHROMATES 169

*See* CHROMIUM 279

AMMONIUM hydroxide

*See* AMMONIA 134, 162

S*ee* AMMONIA/AMMONIUM HYDROXIDE 261

AMMONIUM PERSULFATE 162, 240, 261

AMMONIUM PHOSPHATE 225

AMMONIUM SALTS

*See* BIFLUORIDES 136, 165, 200, 241, 262, 281

AMMONIUM THIOCYANATE 134, 240

AMMONIUM THIOSULPHATE 225

AMODIAQUINE 57

AMOROLFINE 32, 58

AMOXAPINE 58

AMOXYCILLIN 58

AMPHETAMINE 209

AMPHOMYCIN 58

AMPHOTERICIN 58

AMPICILLIN 58

AMPRENAVIR 58

AMPROLIUM 225

AMRINONE 58

AMSACRINE 58

AMYGDALIN 231

AMYL ACETATE 225

AMYL NITRITE 58

AMYLASE 225

AMYLOBARBITONE 58, 209, 283

AMYLOCAINE 58

ANABOLIC STEROIDAL AGENTS iv, 58, 236

ANAGRELIDE 58

ANAKINRA 58

ANALYTICAL PREPARATIONS

*See* IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS 220

ANASTROZOLE 58

ANCESTIM 58

ANCHUSA OFFICINALIS 231

ANCROD 58

ANDROGENIC STEROIDAL AGENTS 58, 236

ANDROISOXAZOLE 58

ANDROSTALONE

*See* MESTANOLONE 99

ANDROSTANOLONE 58

ANDROSTENEDIOL 58

ANDROSTENEDIONE 58

ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEXTRAN ANDJUNCT 225

ANDROSTERONE iv

*See* ANABOLIC STEROIDAL AGENTS

ANECORTAVE 58

ANGIOTENSIN AMIDE 58

Anhydrides, organic acid FOR USE AS CURING AGENTS FOR EPOXY RESINS 134, 240, 261

ANIDULAFUNGIN 58

ANILERIDINE 209

Aniline 162, 240, 261

ANIMAL 2

ANIMAL FEED PREMIX 2

ANISE OIL 22, 134, 240

ANISTREPLASE 59

ANTAZOLINE 32, 59

ANTIBIOTIC SUBSTANCES 59

*See also* BACTERIAL CULTURE MEDIA 219

ANTICOAGULANT MEDICAL DEVICES

*See* MEDICAL DEVICES 220

ANTICOAGULATION COMPLEX

*See* HUMAN BLOOD PRODUCTS 219

ANTIGENS 59

ANTIHISTAMINES 59, 261

ANTIMONY 59, 279

*See also* ANTIMONY COMPOUNDS 162

ANTIMONY CHLORIDE 240

*See also* ANTIMONY COMPOUNDS 162, 240

ANTIMONY COMPOUNDS 162, 240, 277

*See also* ANTIMONY 279

ANTIMONY TITANATE

*See* ANTIMONY COMPOUNDS 162

*See* ANTIMONY 279

ANTISERA (immunosera) 59

APIXABAN 59

APOCYNUM spp 59

APOMORPHINE 59, 277

APPROPRIATE AUTHORITY 2

APPROVED NAME 3

APRACLONIDINE 59

APRAMYCIN 59

APREPITANT 59

APRONAL 59

APROTININ 59

ARBUTIN

*See* HYDROQUINONE

ARECOLINE 59

ARIPIPRAZOLE 59, 283

ARISTOLOCHIA spp 231

ARISTOLOCHIC ACID 231

*See also* bragantia 231

*See also* ASARUM spp 231

AROMATIC EXTRACT OILS 262

*See also* HYDROCARBONS LIQUID AROMATIC 204

ARPRINOCID 199, 281

ARSENIC iv, 27, 59, 162, 199, 277, 281

*See also* CACODYLIC ACID 166, 200

*See also* TERMITE BARRIERS 221

ARSENIC TRIOXIDE iv

*See* ARSENIC

ARTEMETHER 59

ARTICAINE 59

ARTIFICIAL TEARS

*See* MEDICAL DEVICES 220

ASARUM spp. 231

ASENAPINE 283

ASPARTIC ACID 225

ASPERGILLUS NIGER

*See* -AMYLASE 225

*See* CELLULASE 226

*See* FUNGAL PROTEASE 227

*See* -GLUCANASE 227

*See* PECTINASE 228

*See* XYLANASE 230

ASPIDOSPERMA QUEBRACHO

*See* YOHIMBINE

ASPIRIN 32, 59, 134, 163, 262

*See* *also* DIHYDROCODEINE (+ aspirin) 37

*See also* PARACETAMOL(*+* aspirin) 108

*See also* SALICYLAMIDE (+ aspirin) 119

ASTEMIZOLE 59, 262

*See also* Antihistamines 261

ASULAM 225

ATAMESTANE 60

ATAZANAVIR 60

ATENOLOL 60

ATIPAMEZOLE 60

ATOMOXETINE 60

ATORVASTATIN 60

ATOSIBAN 60

ATOVAQUONE 60

ATRACURIUM BESYLATE 60

ATRAZINE 134

ATROPA BELLADONNA (belladonna) 33, 60, 277

ATROPINE 33, 60, 239, 277

ATROPINE METHONITRATE 60

*See also* ATROPINE 33

ATROPINE SULFATE

*See* DIFENOXIN (+ atropine sulfate) 76

*See* DIPHENOXYLATE (+ atropine sulfate) 49, 78

AURANOFIN 60

AUROTHIOMALATE SODIUM 60

AUSTRALIAN CODE FOR THE TRANSPORT OF DANGEROUS GOODS BY ROAD AND RAIL 3

AUTHORISED PRESCRIBER 3

AVILAMYCIN 60

AVIPTADIL 60

AVOPARCIN 60

AXITINIB 60

AZACITIDINE 60

AZACONAZOLE 163

AZACYCLONOL 60

AZADIRACHTA INDICA (Neem) 134, 163, 231, 240, 262

AZAFENIDIN 200

AZAMETHIPHOS 163

AZAPERONE 60

AZAPROPAZONE 60

AZARIBINE 60

AZATADINE 48, 60, 283

AZATHIOPRINE 60

AZELAIC ACID 33, 61

AZELASTINE 33, 61

*See also* ANTIHISTAMINES 262

AZIMSULFURON 225

AZINPHOS-ETHYL 200

AZINPHOS-METHYL 200

AZITHROMYCIN 61

AZLOCILLIN 61

AZOBENZENE 163

AZOCYCLOTIN 200, 262, 281

AZOXYSTROBIN 134

AZTREONAM 61

B

BACAMPICILLIN 61

BACILLUS SPHAERICUS STRAIN 2362 225

BACILLUS THURINGIENSIS 225

BACILLUS THURINGIENSIS delta endotoxin 134

BACILLUS TOYOI 225

BACITRACIN 61

BACLOFEN 61, 283

BACTERIAL CULTURE MEDIA 219

BACTERIOCIDES 219

BACULOVIRUSCYDIA POMONELLA 225

BALSALAZIDE 61

BAMBERMYCIN (flavophospholipol) 61, 163

BAMBUTEROL 61

BAMETHAN 61

BAMIPINE 61

BARBITURATES 61

BARIUM

*See* BARIUM SALTS 163

BARIUM CHROMATE

*See* CHROMATES 169

*See* CHROMIUM 279

BARIUM metaborate

*See* BARIUM SALTS 279

BARIUM salts 163, 240, 279

BARIUM SELENATE

*See* SELENIUM 193

BARIUM SILICOFLUORIDE 134

*See also* SILICOFLUORIDES 156

BARIUM SULFATE

*See* BARIUM SALTS 163, 240, 279

BASIC ORANGE 31 163, 231

BASIL OIL 22, 135, 240

BASILIXIMAB 61

BATTERIES

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 219

Bay oil 22, 163, 241

BAZEDOXIFENE 61

BDMPEA

*See* 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE 212

BEAUVERIA BASSIANA 135, 164

BECAPLERMIN 61

BECLAMIDE 61

BECLOMETHASONE 33, 61

BEECHWOOD

*See* CREOSOTE 35, 172, 201

BELATACEPT 61

BELIMUMAB 61

BELLADONNA

*See* ATROPA BELLADONNA 33, 60, 277

BEMEGRIDE 61

BENACTYZINE 61

BENALAXYL 135

BENAZEPRIL 61

BENDIOCARB 135, 164, 200

BENDROFLUAZIDE 61

BENETHAMINE PENICILLIN 62

BENFLURALIN 225

BENOMYL 200, 262

BENORYLATE 62

BENOXAPROFEN 62

BENPERIDOL 62

BENQUINOX 164

BENSERAZIDE 62

BENSULFURON-METHYL 225

BENSULIDE 164

BENTAZONE 135

BENTONITE 225

BENZALKONIUM CHLORIDE 135, 164, 241

*See also* QUATERNARY AMMONIUM COMPOUNDS

BENZATHINE PENICILLIN 62

BENZATROPINE

*See* BENZTROPINE 62

Benzene 200, 241, 262, 281

*See also* HYDROCARBONS, LIQUID 145

BENZETHIDINE 212

BENZHEXOL 62

BENZILONIUM 62

BENZOCAINE 33, 62

BENZODIAZEPINE DERIVATIVES 62

BENZOFENAP 135

BENZOYL METRONIDAZOLE

*See* METRONIDAZOLE

BENZOYL PEROXIDE 33, 62, 135, 241, 262

BENZOYLINDOLES 212

BENZPHETAMINE 62

BENZTHIAZIDE 62

BENZTROPINE (benzatropine) 62, 283

BENZYDAMINE 34, 62

6-BENZYLADENINE 164

BENZYL BENZOATE 225

BENZYLMORPHINE 209

BENZYLPENICILLIN 62

BENZYLPIPERAZINE \*(BZP) 212

BEPHENIUM SALTS 34

BEPRIDIL 62

BERACTANT 62

BERGAMOT OIL 135, 241, 262

BERYLLIUM 164, 262

BESIFLOXACIN HYDROCHLORIDE 62

BETACETYLMETHADOL 212

BETACYFLUTHRIN 135, 164, 200

BETA-CYPERMETHRIN 165

BETAHISTINE 62

BETA-HYDROXY-3-METHYLFENTANYL 212

BETA-HYDROXYFENTANYL 212

1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHYLAMINOBENZENE 271

BETAINE HYDROCHLORIDE 225

BETAMEPRODINE 212

BETAMETHADOL 212

BETAMETHASONE 62

BETAPRODINE 212

BETAXOLOL 63

BETHANECHOL CHLORIDE 63

BETHANIDINE 63

BEVACIZUMAB 63

BEVANTOLOL 63

BEXAROTENE 63, 235, 262, 287

BEZAFIBRATE 63

BEZITRAMIDE 209

BHC 165

BICALUTAMIDE 63

BIFENAZATE 225

BIFENTHRIN 165, 200

Bifluorides 136, 165, 200, 241, 262, 281

BIFONAZOLE 34, 63

BIMATOPROST 63

BIOALLETHRIN 136, 165

BIORESMETHRIN 136

BIPERIDEN 63

BISMUTH CITRATE

*See* BISMUTH COMPOUNDS 63

BISMUTH COMPOUNDS 63

BISMUTH FORMIC IODIDE

*See* BISMUTH COMPOUNDS 63

BISMUTH OXYCHLORIDE

*See* BISMUTH COMPOUNDS 63

BISMUTH SUBIODIDE

*See* BISMUTH COMPOUNDS 63

BISMUTH SUBNITRATE 225

BISOPROLOL 63

BISPYRIBAC 136

BISTRIFLURON 225

BIS(TROBUTYLTINOXIDE)

*See* TRIBUTYL TIN OXIDE

BITHIONOL 165, 231, 262

BIURET 225

BIVALIRUDIN 63

BLEACHES

*See* CHLORINATING AGENTS

BLEOMYCIN 63

BLOOD 3

*See also* BLOOD COMPONENTS 3

*See also* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES 219

*See also* HUMAN BLOOD PRODUCTS 219

BOCEPREVIR 63

BOLANDIOL 63

BOLASTERONE 63

BOLAZINE 63

BOLDENONE (dehydrotestosterone) 63

BOLENOL 63

BOLMANTALATE 63

Borage

*See* BORAGO OFFICINALIS 231

BORAGO OFFICINALIS (Borage) 231

BORATES

*See* BORON

BORAX 136, 241

*See* also BORON 64

BORIC ACID 136, 241

*See also* BORON 64

BORON 64

*See also* BORIC ACID 136

BORON COMPOUNDS

*See* BORON

BORON TRIFLUORIDE 136, 165, 200, 241, 262, 281

*See* also BORON

BORTEZOMIB 64

BOSCALID 225

BOSENTAN 64, 236, 263, 287

BOTULINUM TOXINS 64

BOVINE SOMATOTROPHIN 226

BRAGANTIA spp 231

BRETYLIUM TOSYLATE 64

BRIMONIDINE 64

BRINZOLAMIDE 64

BRODIFACOUM 165, 200, 281

BROMACIL 226

BROMADIOLONE 165, 200, 281

BROMAZEPAM 64, 283

BROMETHALIN 166, 200

BROMHEXINE 34

BROMIDES 64

BROMINE 200, 281

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA) 212

BROMO-DRAGONFLY

*See* 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE 212

BROMOCHLORODIMETHYLHYDANTOIN

*See* CHLORINATING COMPOUNDS

BROMOCRIPTINE 64

Bromoform 64, 166, 241, 263

BROMOPHOS 166

BROMOPHOS-ETHYL 166

BROMOPROPYLATE 226

BROMOXYNIL 166

BROMPHENIRAMINE 34, 48, 64, 283

BROMUCONAZOLE 136, 166

BROMVALETONE 64

BROTIANIDE 166

Brucine 200, 241, 281

BRUGMANSIA 64

BUCLIZINE 48, 64, 283

BUCLOSAMIDE 231

BUDESONIDE 34, 64

BUFEXAMAC 64

BUFOTENINE 212

BUMETANIDE 64

BUNAMIDINE 166

BUNIODYL SODIUM 231

BUPHENINE 64

BUPIRIMATE 226

BUPIVACAINE 64

BUPRENORPHINE 209, 283

BUPROFEZIN 136

BUPROPION 64

BUSERELIN 64

BUSPIRONE 65

BUSULPHAN 65

BUTACAINE 65

BUTACARB 166

BUTAFENACIL 226

1,4-BUTANEDIOL 231

BUTHIDAZOLE 136

BUTOBARBITONE 209, 283

BUTOCONAZOLE 48, 65, 278

BUTORPHANOL 209

2-BUTOXY-2’-THIOCYANODIETHYL ETHER 166, 263

BUTOXYCARBOXIM 136, 166

2-BUTOXYETHANOL AND ITS ACETATES 241, 263

BUTOXYPOLYPROPYLENE GYLCOL 226

BUTRACONAZOLE 65

BUTRALIN 136

BUTROXYDIM 136

BUTYL AMINOBENZOATE 65

BUTYL NITRITE 65

BUTYLCHLORAL HYDRATE 65

BUTYPHENONES

*See* HALOPERIDOL

BUTYRIC ACID 166

BZP

*See* BENZYLPIPERAZINE 212

C

C1 ESTERASE INHIBITORS

*See* HUMAN BLOOD PRODUCTS 219

CABAZITAXEL 65

CABERGOLINE 65

CACALIA spp 231

CACODYLIC ACID 166, 200

CADMIUM 279

*See also* CADMIUM COMPOUNDS

CADMIUM ACETATE

*See* CADMIUM COMPOUNDS

CADMIUM CHLORIDE

*See* CADMIUM COMPOUNDS

CADMIUM COMPOUNDS 65, 166, 241

*See also* CADMIUM

CADMIUM NITRATE

*See* CADMIUM COMPOUNDS

CADUSAFOS 166, 200

CAFFEINE

*See* ASPIRIN (+ caffeine) 59

*See* SALICYLAMIDE (+ caffeine) 119

CAJUPUT OIL 22, 166, 241

calamus

*See* ACORUS CALAMUS 231

CALCIFEROL 167, 200, 281

CALCIPOTRIOL 65

CALCITONIN 65

CALCITRIOL 65

CALCIUM CARBIMIDE 65

CALCIUM FOLINATE

*See* FOLINIC ACID

CALCIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS

CALCIUM POLYSTYRENE SULPHONATE 65

CALOMEL

*See* MERCURIC CHLORIDE

CALOTROPIS GIGANTEA 65

CALOTROPIS PROCERA 65

CALUSTERONE 65

CAMBENDAZOLE 167

CAMPHOR 20, 25, 136, 167241, 263

*See also* ESSENTIAL OILS 23, 243

CAMPHOR OIL (white)

*See* CINEOLE 170

CAMPHORATED OIL 65

CAMPHOTAMIDE 65

CANAGLIFLOZIN 65

CANAKINUMAB 65

CANDESARTAN CILEXETIL 65

CANDICIDIN 65

CANINE TICK ANTI-SERUM. 65

CANNABICHROMENE

*See* NABIXIMOLS 210

CANNABICYCLOHEXANOL

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL 214

CANNABIDIOL

*See* NABIXIMOLS 210

CANNABIDIOLIC ACID

*See* NABIXIMOLS 210

CANNABIDIVAROL

*See* NABIXIMOLS 210

CANNABIGEROL

*See* NABIXIMOLS 210

CANNABINOIDS

*See* NABIXIMOLS 210

CANNABINOL

*See* NABIXIMOLS 210

CANNABIS 213

CANNABIS SATIVA

S*ee* HEMP SEED OIL 5

*See* NABIXIMOLS 210

CANTHARIDIN 65, 277

CAPECITABINE 65

CAPREOMYCIN 66

CAPTAFOL 200, 281

CAPTAN 168

CAPTODIAME 66

CAPTOPRIL 66

CAPURIDE 66

CARAMIPHEN 66

CARBACHOL 66

CARBADOX 200, 281

CARBAMATE 15

CARBAMAZEPINE 66

CARBAMIDE PEROXIDE 136, 168, 231, 241, 263

CARBARYL 66, 137, 168

CARBAZOCHROME 66

CARBENDAZIM 200

CARBENICILLIN 66

CARBENOXOLONE 66

CARBETAMIDE 226

CARBETAPENTANE 34

CARBETOCIN 66

CARBIDOPA 66

CARBIMAZOLE 66

CARBOCISTEINE 34

CARBOCROMEN 66

CARBOFURAN 200

CARBON DISULFIDE 168, 242, 263

CARBON TETRACHLORIDE 201, 242, 263, 281

CARBOPHENOTHION 201

CARBOPLATIN 66

CARBOPROST 66

CARBOSULFAN 201

CARBOXIN 226

CARBROMAL 66

CARBUTAMIDE 66

CARBUTEROL 66

CARDIAC GLYCOSIDES

*See* UNDER INDIVIDUAL ENTRIES

CARFENTANYL 209

CARFENTRAZONE-ETHYL 226

CARINDACILLIN 66

CARISOPRODOL 66

CARMUSTINE 66

CARNIDAZOLE 66

CARPROFEN 66

CARVEDILOL 66

CASPOFUNGIN 66

Cassia oil 22, 137, 242, 263

CASTOR OIL, MONOMALEATE 168

CATALIN

*See* PIRENOXINE 112

CATHINE 66

CATHINONE 213

CATUMAXOMAB 66

CEFACETRILE 67

CEFACLOR 67

CEFADROXIL 67

CEFALORIDINE 67

CEFAMANDOLE 67

CEFAPIRIN 67

CEFAZOLIN 67

CEFEPIME 67

CEFETAMET 67

CEFIXIME 67

CEFODIZIME 67

CEFONICID 67

CEFOPERAZONE 67

CEFOTAXIME 67

CEFOTETAN 67

CEFOTIAM 67

CEFOVECIN 67

CEFOXITIN 67

CEFPIROME 67

CEFPODOXIME 67

CEFQUINOME 67

CEFSULODIN 67

CEFTAROLINE FOSAMIL 67

CEFTAZIDIME 67

CEFTIBUTEN 67

CEFTIOFUR 67

CEFTRIAXONE 67

CEFUROXIME 67

CELECOXIB 68

CELIPROLOL 68

CELLULASE DERIVED FROM ASPERGILLUS NIGER 226

CEMENTS, GLUES AND ADHESIVES − MEDICAL AND VETERINARY 220

CEPHACETRILE

*See* CEFACETRILE

CEPHAELIS ACUMINATA (ipecacuanha) 68

CEPHAELIS IPECACUANHA 68

CEPHALEXIN 68

CEPHALONIUM 68

CEPHALORIDINE

*See* CEFALORIDINE

CEPHALOTHIN 68

CEPHAMANDOLE

*See* CEFAMANDOLE

CEPHAPIRIN

*See* CEFAPIRIN

CEPHAZOLIN

*See* CEFAZOLIN

CEPHRADINE 68

CERAMICS 219

CERIVASTATIN 68

CERTOLIZUMAB PEGOL 68

CERULETIDE 68

CETIRIZINE 34, 68, 283

CETRORELIX 68

CETUXIMAB 68

CETYL ALCOHOL 226

CETYL TRANEXAMATE

*See* TRANEXAMIC ACID

CHAMOMILE OIL 226

CHEMISTRY SETS 219

CHENODEOXYCHOLIC ACID 68

CHILD-RESISTANT CLOSURE 22

*See also* NON-ACCESS PACKAGING

CHILD-RESISTANT PACKAGING 22

*See also* NON-ACCESS PACKAGING

CHINA CLAY 226

CHLOPHEDIANOL 34

CHLORAL FORMAMIDE 68

CHLORAL HYDRATE 68, 283

CHLORALOSE 68, 168

CHLORAMBUCIL 68

CHLORAMPHENICOL 48, 68

CHLORANDROSTENOLONE 68

CHLORANTRANILIPROLE 226

CHLORAZANIL 68

CHLORBUTOL 34, 48

CHLORCYCLIZINE 68

CHLORDANE 168

CHLORDECONE 201, 281

CHLORDIAZEPOXIDE 69, 283

CHLORDIMEFORM 201, 281

CHLORFENAC 137

CHLORFENAPYR 168, 201

CHLORFENETHOL 168

CHLORFENSON 137

CHLORFENVINPHOS 201

CHLORFLUAZURON 226

CHLORFLURENOL 226

CHLORHEXIDINE 137, 168, 201

CHLORIDAZON 226

CHLORINATED TERPENES

*See* TERPENES, CHLORINATED 196

CHLORINATING COMPOUNDS 137, 168, 242, 263

chlorine 12, 173, 201, 277, 281

*See also* CHLORINATING COMPOUNDS 137, 168, 242, 263

*See also* DICHLOROISOCYANURATES 265

*See also* DICHLOROISOCYANURIC ACID 141, 173

CHLORINE (gas) 242

CHLORMEQUAT 168

CHLORMERODRIN 69

CHLORMETHIAZOLE 69, 283

CHLORMEZANONE 69

CHLORNIDINE 137

5-CHLORO-3-METHYL-4-NITROPYRAZOLE 201

4-CHLORO-o-TOLUIDINE 201, 281

CHLOROCRESOL 137, 242

CHLOROFORM 34, 69, 168, 242, 264

alpha-CHLOROHYDRIN 169, 264

CHLOROMESTERONE

*See* DEHYDROCHLOROMETHYLTESTOSTERONE

4-CHLOROMETHANDIENONE 69

CHLOROMETHIURON 201, 281

CHLOROPHACINONE 169

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE 69

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) 169

CHLOROPICRIN 169, 201, 281

CHLOROQUINE 69

4-CHLOROTESTOSTERONE

*See* CLOSTEBOL 71

CHLOROTHALONIL 169

CHLOROTHIAZIDE 69

CHLOROTRIANISENE 69

CHLOROXYDIENONE 69

CHLOROXYLENOLS 226

CHLORPHENIRAMINE 35, 48, 69, 283

CHLORPHENTERMINE 69

CHLORPROMAZINE 69, 283

CHLORPROPAMIDE 69

CHLORPROPHAM 137

CHLORPROTHIXENE 69

CHLORPYRIFOS 137, 169

CHLORPYRIFOS-METHYL 169

CHLORQUINALDOL 69

*See also* CLIOQUINOL

CHLORSULFURON 137

CHLORTETRACYCLINE 69, 138

CHLORTHAL-DIMETHYL 138

CHLORTHALIDONE 69

CHLORTHIAMID 169

CHLORTHIOPHOS 201

CHLORZOXAZONE 69

CHOLECALCIFEROL

*See* COLECALCIFEROL

CHOLERA VACCINE 69

CHOLESTYRAMINE (colestyramine) 69

CHOLINE SALICYLATE

*See* SALICYLIC ACID

Chromates iv, 169, 242, 264

*See also* CHROMIUM 279

CHROMIC ACID

*See* CHROMIUM TRIOXIDE

CHROMIUM 279

*See also* CHROMATES 169

CHROMIUM TRIOXIDE 169, 242, 264

chrysanthemic ACID ESTERS

*See* PYRETHRINS 46, 155

CHYMOPAPAIN 69

2C-I

*See* 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE 213

CICLACILLIN 69

CICLESONIDE 69

CICLOPIROX 35, 48, 69

CIDOFOVIR 70

CILASTATIN 70

CILAZAPRIL 70

CILOSTAZOL 70

CIMETIDINE 48, 70, 264

CINACALCET 70

CINCHOCAINE 35, 70

CINCHOPHEN 232

Cineole 22, 169, 242

CINEROLONE

*See* PYRETHRINS 46, 155

CINMETHYLIN 138

CINNAMEDRINE 35

CINNAMON BARK OIL 22, 138, 242, 264

CINNAMON LEAF OIL 23, 170, 242

CINOXACIN 70

CIPROFLOXACIN 70

CISAPRIDE 70

CISATRACURIUM BESYLATE 70

CISPLATIN 70

CITALOPRAM 70

CITRONELLA OIL 226

CLADRIBINE 70

CLANOBUTIN 70

CLARITHROMYCIN 70

CLARY SAGE OIL 226

CLAVULANIC ACID 70

CLEMASTINE 48, 70, 283

CLEMIZOLE 70

CLENBUTEROL 70

CLETHODIM 138

CLEVIDIPINE 70

CLIDINIUM BROMIDE 70

CLIMBAZOLE 138, 170, 242

CLINDAMYCIN 70

CLIOQUINOL 70, 232

CLOBAZAM 70

CLOBETASOL 70

CLOBETASONE (clobetasone-17-butyrate) 48, 70, 264

CLOCORTOLONE 70

CLODINAFOP-PROPARGYL 170

CLODRONIC ACID (includes sodium clodronate) 71

CLOFARABINE 71

CLOFAZIMINE 71

CLOFENAMIDE 71

CLOFENTEZINE 138

CLOFIBRATE 71

CLOMAZONE 170

CLOMIPHENE 71, 235

CLOMIPRAMINE 71, 283

CLOMOCYCLINE 71

CLONAZEPAM 71, 283

CLONIDINE 71, 283

CLONITAZENE 213

CLOPAMIDE 71

CLOPIDOGREL 71

CLOPIDOL 226

CLOPROSTENOL 71

CLOPYRALID 138

CLOQUINTOCET-MEXYL 138

CLORAZEPATE 71, 283

CLOREXOLONE 71

CLORPRENALINE 71

CLORSULON 138

CLOSANTEL 170

CLOSTEBOL (4-chlorotestosterone) 71

CLOTHIANIDIN 138, 170

CLOTRIMAZOLE 35, 48, 71, 170, 264, 278

CLOTTING FACTORS

*See* HUMAN BLOOD PRODUCTS 219

Clove oil 23, 138, 170, 242, 264

CLOXACILLIN 71

CLOZAPINE 71, 235, 283

COAL TAR 232

COBALT 71

COBALT NAPHTHENATE 226

COBICISTAT 71

COCA LEAF 213

COCAINE 209

CODEINE 9, 35, 48, 71, 209, 283

CODEINE-N-OXIDE 209

CO-DERGOCRINE 72

CODOXIME 213

COLASPASE 72

COLCHICINE 72

COLCHICUM AUTUMNALE 72

COLECALCIFEROL 201, 281

*See also* VITAMIN D

COLESTIPOL 72

COLESTYRAMINE

*See* CHOLESTYRAMINE 69

COLFOSCERIL PALMITATE 72

COLISTIN 72

COLLAGEN 72

*See also* MEDICAL DEVICES 220

COLOPHONY 226

COLTSFOOT

*See* TUSSILAGO

COMFREY

*See* SYMPHYTUM spp. 157, 234, 275

COMPOUNDED 4

CONCENTRATE OF POPPY STRAW 209

coniine

*See* CONIUM MACULATUM 232

CONIUM MACULATUM (coniine) 232

CONTAINERS 10

*See also*  IMMEDIATE CONTAINER 5

*See also* SELECTED CONTAINER 7

CONTRAST MEDIA, RADIOGRAPHIC (RADIOPAQUES)

*See* RADIOGRAPHIC CONTRAST MEDIA 221

CONVALLARIA KEISKI 72

CONVALLARIA MAJALIS 72

COPPER ACETATE 138, 171

COPPER CHLORIDE

*See* COPPER NITRATE 171

COPPER-CHROME-ARSENIC

*See* CHROMATES, AND ARSENIC

COPPER COMPOUNDS 72, 138, 171, 219

COPPER HYDROXIDE 138, 171

COPPER NITRATE 171

COPPER OXIDES 138, 171

COPPER OXYCHLORIDE 138, 172

COPPER SALICYLATE

*See* DIMETHYL SULFOXIDE 175

COPPER

*See* COPPER COMPOUNDS 171

COPPER SULFATE 139, 172, 242

CORIFOLLITROPIN ALFA 72, 235

CORONILLA 72

CORROSIVE SUBLIMATE

*See* MERCUROUS CHLORIDE

CORTICOSTERONE 72

CORTICOTROPHIN 72

CORTISONE 72

CORYMBIA CITRIODORA

*See* EXTRACT OF LEMON EUCALYPTUS 143

COTARNINE 232

CO-TRIMOXAZOLE 72

COUMAPHOS 172, 201

COUMARIN 72

COUMATETRALYL 139, 172, 201, 281

CP 47,497 C8 HOMOLOGUE

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL 214

CP 47,497

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL 214

4-CPA 139

CREOSOTE 35, 172, 201, 242

*See also* PHENOL 153, 189

CROFELEMER 72

CROSPOVIDONE 226

CROTALARIA spp 232

CROTON OIL

*See* CROTON TIGLIUM 277

CROTON TIGLIUM (croton oil) 232, 277

CROTOXYPHOS 172

CRUFOMATE 172

CRYOPRECIPITATE

*See* HUMAN BLOOD PRODUCTS 219

CRYSTAL VIOLET 72

CRYSTAL WARE

*See* GLASS 219

2C-T-2

*See* 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE 213

2C-T-7

*See* 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE 213

CUBE

*See* ROTENONE

CULICINOMYCES CLAVOSPORUS 226

CUPRIMYXIN 72

CURARE 72

curing agents FOR EPOXY RESINS

*See* AMINES FOR USE AS CURING AGENTS FOR EPOXY RESIN

*See* Anhydrides, organic acid FOR USE AS CURING AGENTS FOR EPOXY RESINS

*See* EPOXY RESINS

CYANAMIDE 172

CYANATRYN 139

CYANAZINE 172

Cyanides 27, 201, 242, 264

*See also* HYDROCYANIC ACID AND CYANIDES 282

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (PETHIDINE INTERMEDIATE A) 209

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE 213

CYANOACRYLATE ESTERS 139

CYANOACRYLIC ACID ESTERS 242

CYANOGEN 201, 281

CYANTRANILIPROLE 139

CYANURIC ACID 139, 242, 264

CYCLAMIC ACID 226

CYCLANDELATE 72

CYCLANILIDE 172

CYCLIZINE 49, 73, 283

CYCLOBARBITONE 209, 283

CYCLOBENZAPRINE 73

CYCLOFENIL 73, 235

CYCLOHEXANE 226

CYCLOHEXANOL ACETATE 226

CYCLOHEXANONE PEROXIDE 139, 242, 264

CYCLOHEXIMIDE 73

CYCLOHEXYLPHENOLS 213

CYCLOPENTHIAZIDE 73

CYCLOPENTOLATE 73

CYCLOPHOSPHAMIDE 73

CYCLOPROPANE 73

CYCLOPROTHRIN 139

CYCLOSERINE 73, 283

CYCLOSPORIN 73

CYCLOTHIAZIDE 73

CYCLOXYDIM 139

CYCRIMINE 73

CYFLUFENAMID 139

CYFLUTHRIN 139, 172

CYHALOFOP-BUTYL 139

CYHALOTHRIN 201

CYHEXATIN 201, 281

CYMARIN 73

CYMIAZOLE 139

CYNOGLOSSUM spp 232

CYOMETRINIL 172

CYPERMETHRIN 140, 172

*See also* ZETA-CYPERMETHRIN, ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN

ALPHA-CYPERMETHRIN 134, 162, 199

BETA-CYPERMETHRIN 165

ZETA-cypermethrin 198, 208

CYPHENOTHRIN 140, 172

CYPROCONAZOLE 140

CYPRODINIL 140

CYPROHEPTADINE 49, 73, 283

CYPROTERONE 73

CYROMAZINE 226

Cysteamine 73, 140, 173, 242, 264, 283

CYTARABINE 73

CYTHIOATE 140, 173

D

2,4-D 140, 173

DABIGATRAN 73

DACARBAZINE 73

DACLIZUMAB 73

DACTINOMYCIN 73

DALFOPRISTIN 73

DALMATIAN

*See* SAGE OIL 23, 193, 249

DALTEPARIN 73

DAMINOZIDE 140

DANAPAROID 73

DANAZOL 73

DANTHRON 73

DANTROLENE 73, 283

DAPAGLIFLOZIN 73

DAPOXETINE 73

DAPSONE 74

DAPTOMYCIN 74

DARBEPOETIN 74, 236

DARIFENACIN 74

DARUNAVIR 74

DASATINIB 74

DATURA 35, 74

DATURA STRAMONIUM (stramonium) 36, 74

DATURA TATULA (stramonium) 36, 74

DAUNORUBICIN 74

DAZOMET 15, 173

2,4-DB 140

D.D.A.V.P.

*See* DESMOPRESSIN 75

DDT

*See* DICOPHANE 232

DEANOL 74

DEBITTERISED NEEM SEED OIL 4

DEBRISOQUINE 74

DECAMETHONIUM 74

DEET

*See* DIETHYLTOLUAMIDE 142

DEFERASIROX 74

DEFERIPRONE 74

DEFLAZACORT 74

DEGARELIX 74

DEHYDROCHLOROMETHYLTESTOSTERONE 74

DEHYDROCORTICOSTERONE 74

DEHYDROEPIANDROSTERONE

*See* PRASTERONE 114

DEHYDROISOANDROSTERONE

*See* PRASTERONE 114

DEHYDROTESTOSTERONE

*See* BOLDENONE 63

DELAVIRDINE 74

DELAVIRDINE MESYLATE

*See* DELAVIRDINE 74

DELPHINIUM STAPHISAGRIA 36

DELTA-9-TETRAHYDROCANNABINOL

*See* DRONABINOL 210, 235, 283

DELTAMETHRIN 140, 173, 202

DEMBREXINE 74, 140

DEMECARIUM 74

DEMECLOCYCLINE 75

DEMETON 202

DEMETON-O-METHYL 202

DEMETON-S-METHYL 202

DENATONIUM BENZOATE

*See* BENDIOCARB 164

*See* DIETHYLENE GLYCOL 141

*See* ETHYLENE GLYCOL 143

*See* METHOMYL 185

*See* METHYLATED SPIRIT(S) 149

DENOSUMAB 75

DEOXYCORTONE 75

DEOXYRIBONUCLEASE 75

DERACOXIB 75

DERMAL USE 4

DERQUANTEL 173

2,4-DES 140

DESFERRIOXAMINE 75

DESFLURANE 75

DESIGNATED SOLVENT 4

DESIPRAMINE 75, 283

DESIRUDIN 75

DESLANOSIDE 75

DESLORATADINE 36, 75

*See also* ANTIHISTAMINES 261

DESLORELIN 75

DESMOPRESSIN (D.D.A.V.P.) 75

DESOGESTREL 75

DESOMORPHINE 213

DESONIDE 75

DESOXYMETHASONE 75

DESVENLAFAXINE 75

DET

*See* N,N-DIETHYLTRYPTAMINE 213

DETOMIDINE 75

DEXAMETHASONE 75

DEXAMPHETAMINE 209

DEXCHLORPHENIRAMINE 36, 49, 75, 283

DEXFENFLURAMINE 75

DEXMEDETOMIDINE 75

DEXTRANS 219

DEXTROMETHORPHAN 36, 75

DEXTROMORAMIDE 209, 283

DEXTROPROPOXYPHENE 75, 209, 236, 283

DEXTRORPHAN 75

DIAFENTHIURON 140

DIALIFOS 202

DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS

*See* QUATERNARY AMMONIUM COMPOUNDS 155, 192

dialkyl TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

4,4-DIAMINODIPHENYLMETHANE (METHYLENE DIANILINE) 202, 264, 281

DIAMPROMIDE 213

DIAMTHAZOLE 76

DIAVERIDINE 76

DIAZEPAM 76, 283

DIAZINON 140, 173

DIAZOXIDE 76

DIBENZEPIN 76

DIBENZODIOXINS, HALOGENATED

*See* HALOGENATED DIBENZODIOXINS 204, 282

DIBENZOFURANS, HALOGENATED

*See* HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 204

DIBENZOPYRANS 213

DIBOTERMIN 76

1,2-DIBROMO-3-CHLOROPROPANE 202, 281

DIBROMOPROPAMIDINE 36, 76

DIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

DICAMBA 140, 173

DICHLOBENIL 173

DICHLOFENTHION 173

DICHLOFLUANID 173

DICHLONE 140

DICHLORALPHENAZONE 76

1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE

*See* TDE 158, 196

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE 174

DICHLOROETHYL ETHER 173, 243, 265

*See also* CHLORINATING COMPOUNDS

DICHLOROETHYLENE 265

DICHLOROISOCYANURATES 243, 265

DICHLOROISOCYANURIC ACID 141, 173

DICHLOROMETHANE (methylene chloride) 141, 243, 266, 279

DICHLOROPHEN 76, 141, 174

1,2-DICHLOROPROPANE 174

1,3-DICHLOROPROPENE 202, 281

DICHLORPHENAMIDE 76

2,4-DICHLORPROP 174

DICHLORVOS 141, 174, 202

DICHROMATES 243

*See also* CHROMATES 169, 264

DICLAZURIL 226

DICLOBUTRAZOL 141

DICLOFENAC 36, 49, 76, 266, 278

DICLOFOP-METHYL 174

DICLORAN 141

DICLOXACILLIN 76

DICOBALT EDETATE

*See* COBALT 71

*See* EDETIC ACID 80

DICOFOL 141

DICOPHANE (DDT) 232

DICROTOPHOS 202

DICYCLANIL 174

DICYCLOMINE 76

DIDANOSINE 76

DIDECYLDIMETHYLAMMONIUM SALTS 174, 243

DIELDRIN 174

DIENESTROL 76, 266, 287

DIENOGEST 76

DIESEL (DISTILLATE) 243

*See also* HYDROCARBONS, LIQUID 145

DIETHANOLAMINE 141, 174, 243, 266

DIETHAZINE 76

DIETHYL CARBONATE 226

DIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

DIETHYLCARBAMAZINE 76

DIETHYLENE GLYCOL 141, 174, 232

DIETHYLENE GLYCOL MONOBUTYL ETHER 141

DIETHYLHEXYL PHTHALATE 232

DIETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES 189

DIETHYLPHTHALATE 232

DIETHYLPROPION 76

DIETHYLSTILBOESTROL

*See* STILBOESTROL 121

DIETHYLSTILBOESTROL DIPHOSPHATE

*See* FOSFESTROL 86

DIETHYLTHIAMBUTENE 213

DIETHYLTOLUAMIDE (DEET) 142, 266

DIFENACOUM 174, 202, 281

DIFENOCONAZOLE 142

DIFENOXIN 76, 209, 283

DIFENZOQUAT 174

DIFETHIALONE 174, 202

DIFLORASONE 76

DIFLOXACIN 76

DIFLUBENZURON 142

DIFLUCORTOLONE 76

DIFLUFENICAN 226

DIFLUNISAL 76

DIGITALIS LANATA 77

DIGITALIS PURPUREA 77

DIGITOXIN 77

DIGOXIN 77

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F 77

DIHYDRALAZINE 77

DIHYDROCODEINE 37, 49, 77, 209, 283

DIHYDROERGOTOXINE 77

DIHYDROLONE 77

DIHYDROMORPHINE 209

DIHYDROSTREPTOMYCIN 77

DIHYDROTACHYSTEROL 77

5,6-DIHYDROXYINDOLINE 174, 232, 243, 266

DI-IODOHYDROXYQUINOLINE (iodoquinol) 49, 77

*See also* CLIOQUINOL

DIISOPROPYLAMINE DICHLOROACETATE 77

DIKEGULAC-SODIUM 226

DILTIAZEM 77

DIMEFOX 202

DIMENHYDRINATE 37, 49, 77, 278, 283

DIMENOXADOL 213

DIMEPHEPTANOL 213

DIMERCAPROL 77

DIMETAMFETAMINE

*See* N,N-DIMETHYLAMPHETAMINE 213

DIMETHANDROSTANOLONE 77

DIMETHAZINE 77

DIMETHENAMID-P 174

DIMETHICODIETHYLBENZALMALONATE 142

DIMETHICONE 226

DIMETHINDENE 49, 77, 283

DIMETHIPIN 175

DIMETHIRIMOL 142

DIMETHISOQUIN

*See* QUINISOCAINE 117

DIMETHOATE 175

DIMETHOMORPH 142

DIMETHOTHIAZINE 77

DIMETHOXANATE 77

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7) 213

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB) 213

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET) 213

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2) 213

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I) 213

2,5-DIMETHOXYAMPHETAMINE \*(DMA) 213

DIMETHYL ETHER 226

DIMETHYL FUMARATE 77

DIMETHYL SULFATE 202, 266

DIMETHYL SULFONE

*See* DIMETHYL SULFOXIDE 78, 175

DIMETHYL SULFOXIDE 78, 175, 243, 266

DIMETHYL TIN DICHLORIDE

*See* TIN ORGANIC COMPOUNDS

DIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

DIMETHYLACETAMIDE 142, 175

4-DIMETHYLAMINOAZOBENZENE 202, 281

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE OR PSILOTSIN) 213

DIMETHYLFORMAMIDE 142, 175, 243, 266

*See also* DESIGNATED SOLVENT 4

DIMETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES 189

1,3-DIMETHYLAMYLAMINE 232

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(DMHP) 213

DIMETHYLPHTHALATE 232

DIMETHYLTHIAMBUTENE 213

DIMETILAN 202

DIMETRIDAZOLE 78

DINICONAZOLE 142

2,4-DINITROCHLOROBENZENE 78

Dinitrocresols 78, 175, 202, 243, 266, 281

DINITRONAPHTHOLS 78

Dinitrophenols 78, 175, 202. 243, 266, 281

DINITROTHYMOLS 78

DINOCAP 202, 267

DINOPROST 78, 235

DINOPROSTONE 78, 235

DINOSEB 202, 281

DI-N-PROPYL ISOCINCHOMERONATE 142

DIOCTYL SODIUM SULFOSUCCINATE

*See* DOCUSATE SODIUM 227

DIOXACARB 175

Dioxane 175, , 243, 267, 277

DIOXAPHETYL BUTYRATE 214

DIOXINS

*See* HALOGENATED DIBENZODIOXINS

DIPENTENE

*See* LIMONENE 228

DIPERODON 78

DIPHACINONE 175

DIPHEMANIL 78

DIPHENAMID 142

DIPHENHYDRAMINE 37, 49, 78, 283

DIPHENIDOL 78

Diphenoxylate 49, 78, 210, 267, 278, 283

DIPHENYLAMINE 226

DIPHENYLPYRALINE 78, 283

DIPHTHERIA TOXOID 78

DIPIPANONE 210

DIPIVEFRIN 78

DIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

DIPROPYLENE GLYCOL MONOMETHYL ETHER 226

DIPYRIDAMOLE 78

DIQUAT 175, 202

DIRITHROMYCIN 78

DIRLOTAPIDE 78

DISODIUM ETIDRONATE

*See* ETIDRONIC ACID 83

DISODIUM PAMIDRONATE

*See* PAMIDRONIC ACID 108

DISODIUM TILUDRONATE

*See* TILUDRONIC ACID 126

DISOPHENOL 78

DISOPYRAMIDE 78

DISPENSING LABEL 5, 286

DISTIGMINE 78

DISTILLATE (DIESEL)

*See* Diesel 243

*See also* HYDROCARBONS, LIQUID

DISTRIBUTOR 5

DISULFIRAM 78, 175

DISULFOTON 175, 202

DISULPHAMIDE 78

DITHIANON 175

DITHIAZANINE 78, 175

DITHIOCARBAMATES

*See* UNDER INDIVIDUAL ENTRIES

DITHIOPYR 142

DITHRANOL 49

DITIOCARB 79

DIUREDOSAN 175

DIURON 226

DIVIDED PREPARATION 5

DMA

*See* 2,5-DIMETHOXYAMPHETAMINE 213

DMAA

S*ee* 1,3-DIMETHYLAMYLAMINE 232

DMHP

*See* 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN 213

DMT

*See* N,N-DIMETHYLTRYPTAMINE 213

DOB

*See* 2,5-DIMETHOXY-4-BROMOAMPHETAMINE 213

DOBUTAMINE 79

DOCETAXEL 79

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) 226

1-DODECANOL

*See* LAURYL ALCOHOL 228

DODINE 176

DOET

*See* 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE 213

DOFETILIDE 79

DOLASETRON 79

DOM

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE 212

DOMPERIDONE 79

DONEPEZIL 79

DOPAMINE 79

DOPEXAMINE 79

DORAMECTIN 142, 176, 202

DORIPENEM 79

DORNASE 79

DORZOLAMIDE 79

DOSAGE UNIT 5

DOTHIEPIN 79, 283

DOXANTRAZOLE 79

DOXAPRAM 79

DOXAZOSIN 79

DOXEPIN 79, 283

DOXORUBICIN 79

DOXYCYCLINE 79

DOXYLAMINE 37, 49, 79, 283

2,2-DPA 227

d-PHENOTHRIN 229

d-PULEGONE 23, 188, 191, 249

DROMETRIZOLE TRISILOXANE 227

DRONABINOL (delta-9-TETRAHYDROCANNABINOL) 210, 235, 283

*See also* NABIXIMOLS

DRONEDARONE 79

DROPERIDOL 79, 283

DROSPIRENONE 79

DROSTANOLONE 79

DROTEBANOL 210

DROTRECOGIN 79

DRUG 5

DRY CLEANING FLUID

*See* LIQUID HYDROCARBONS 21

*See* HYDROCARBONS, LIQUID23

DSMA 176, 202

DUBOISIA LEICHHARDTII 37, 79

DUBOISIA MYOPOROIDES 37, 79

DULCIN 232

DULOXETINE 79, 284

DUTASTERIDE 80

DYDROGESTERONE 80

E

ECGONINE 214

Econazole 37, 49, 80, 176, 267, 278

ECOTHIOPATE 80

ECOTHIOPATE IODIDE

*See* ECOTHIOPATE

ECTYLUREA 80

ECULIZUMAB 80

EDETIC ACID 80

EDOXUDINE 80

EDROPHONIUM 80

EFALIZUMAB 80

EFAVIRENZ 80

EFLORNITHINE 80

EFORMOTEROL 80

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 219

ELECTRICAL COMPONENTS 219

ELETRIPTAN 80

ELTENAC 80

ELTROMBOPAG OLAMINE 80

ELVTEGRAVIR 80

EMAMECTIN 142, 176, 202

EMEPRONIUM 80

EMETINE 80

*See also* CEPHAELIS ACUMINATA 68

*See also* CEPHAELIS IPECACUANHA 68

EMODEPSIDE 142, 176

EMTRICITABINE 80

ENALAPRIL 80

ENAMELLING PREPARATIONS

*See* FRITTED GLAZING OR ENAMELLING PREPARATIONS 219

ENDOSULFAN 176, 202

ENDOTHAL 176, 202

ENDOTOXIN

*See* BACILLUS THURINGIENSIS 225

ENDRIN 202

ENESTEBOL 80

ENFLURANE 80

ENFUVIRTIDE 80

ENHANCING AGENTS FOR USE IN ULTRASONIC AND MAGNETIC RESONANCE IMAGING 219

ENILCONAZOLE

*See* IMAZALIL

ENOBOSARM 81

ENOXACIN 81

ENOXAPARIN 81

ENOXIMONE 81

ENPROSTIL 81

ENROFLOXACIN 81

ENTACAPONE 81

ENTECAVIR 81

EPHEDRA 81

EPHEDRINE 81, 236, 267

*See also* EPHEDRA 81

EPICHLOROHYDRIN 203, 267, 281

EPICILLIN 81

EPIDERMAL GROWTH FACTOR 203, 281

EPINASTINE 81

EPIRUBICIN 81

EPITIOSTANOL 81

EPLERENONE 81

EPOETINS 81, 236

EPOPROSTENOL 81

EPOXICONAZOLE 142

EPOXY RESINS 14, 142, 267, 243

EPRINOMECTIN 143, 203

EPROSARTAN 81

EPSIPRANTEL 227

EPTC 176

EPTIFIBATIDE 81

EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

*See* IMMUNOGLOBULINS

ERGOCACIFEROL

*See* VITAMIN D

ERGOMETRINE 81

ERGOT 81

ERGOTAMINE 81

ERGOTOXINE 81

ERIBULIN MESYLATE 81

ERLOTINIB 81

ERTAPENEM 81

ERYSIMUM 81, 277

ERYTHRITYL TETRANITRATE 50

ERYTHROMYCIN 81

ERYTHROPOIETIN(S) 82, 236

ESBIOTHRIN 143, 176

ESCITALOPRAM 82

ESFENVALERATE 143, 176

ESMOLOL 82

ESOMEPRAZOLE 82

ESSENTIAL OILS 5, 23, 243

*See* also CAMPHOR 136, 167

ESTRAMUSTINE 82

ESTROPIPATE (piperazine oestrone sulfate) 82

ETACONAZOLE 203, 281

ETAFEDRINE 38

ETANERCEPT 82

ETHACRYNIC ACID 82

ETHAMBUTOL 82

ETHAMETSULFURON-METHYL 227

ETHAMIVAN 82

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and N-METHYLMETHANAMINE 143

ETHANEDINITRILE

*See* CYANOGEN

ETHANOL

*See* METHYLATED SPIRIT(S) 149

*See also* ETHYL ALCOHOL

ETHANOLAMINE 82, 143, 176, 243, 267

ETHCHLORVYNOL 82

ETHEPHON 176

Ether 38, 82, 143, 176, 244, 267

ETHINAMATE 82

ETHINYLOESTRADIOL 82

ETHIOFENCARB 176

ETHION 203

ETHIONAMIDE 82

ETHISTERONE 82

ETHOATE-METHYL 176

ETHOFUMESATE 143

ETHOGLUCID 82

ETHOHEPTAZINE 82

ETHOPABATE 227

ETHOPROPAZINE 82

ETHOPROPHOS 176, 203

ETHOSUXIMIDE 82

ETHOTOIN 82

ETHOXYETHYLMERCURIC CHLORIDE 267

*See* also MERCURY

ETHOXYQUIN 143

*See also* MERCURY

ETHOXYSULFURON 143

ETHOXZOLAMIDE 82

ETHYL ACETATE 227

ETHYL ALCOHOL 227

*See also* ETHANOL

ETHYL BROMIDE 176, 244, 267

ETHYL BUTYRATE 227

ETHYL CHLORIDE 82

ETHYL FORMATE 176

ETHYL LACTATE 227

ETHYL METHACRYLATE 143, 267

ETHYLAMPHETAMINE 210

ETHYLBUTYLACETYL-AMINOPROPIONATE 227

ETHYLDIENOLONE 82

ETHYLENE CHLOROHYDRIN 177, 267

ETHYLENE DIBROMIDE 203, 281

ETHYLENE DICHLORIDE 177

ETHYLENE GLYCOL 23, 143, 177, 232, 244

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES 177, 244, 267, 279

Ethylene oxide 203, 244, 267, 281

ETHYLHEXANEDIOL 82, 232

ETHYLMERCURIC CHLORIDE 267

ETHYLMETHYLTHIAMBUTENE 214

ETHYLMORPHINE 38, 83, 210, 284

ETHYLOESTRENOL 83

ETHYNODIOL 83

ETICYCLIDINE \*(PCE) 214

ETIDOCAINE 83

ETIDRONIC ACID (includes disodium etidronate) 83

ETILEFRIN 83

ETIPROSTON 83

ETODOLAC 83

ETOFENAMATE 38, 83

ETONITAZENE 214

ETONOGESTREL 83

ETOPOSIDE 83

ETORICOXIB 83

ETORPHINE 214

ETOXAZOLE 227

ETOXERIDINE 214

ETRAVINE 83

ETRETINATE 83, 235, 267, 287

ETRIDIAZOLE 143

ETRIMFOS 177

EUCALYPTUS OIL 23, 177, 244

Eugenol 23, 143, 177, 244, 267

EUPATORIUM CANNABINUM (Hemp Agrimony) 232

EVEROLIMUS 83

EXEMESTANE 83

EXENATIDE 83

EXPLOSIVES 219

EXTERNAL 5

EXTRACT OF LEMON EUCALYPTUS 143

EZETIMIBE 83

F

FAMCICLOVIR 50, 83

FAMOTIDINE 38, 83, 267

FAMPHUR 178, 203

FAMPRIDINE

*See* 4-AMINOPYRIDINE

FARFUGIUM JAPONICUM 232

FEBANTEL 178

FELBINAC 38, 83

FELODIPINE 83

FELYPRESSIN 83

FENAMIPHOS 178, 203

FENARIMOL 143

FENAZAFLOR 178

FENBENDAZOLE 143

FENBUCONAZOLE 143

FENBUFEN 83

FENBUTATIN OXIDE 178

*See also* TIN ORGANIC COMPOUNDS

FENCAMFAMIN 84

FENCHLORAZOLE-ETHYL 143

FENCHLORPHOS 178

FENCLOFENAC 84

FENETYLLINE 214

FENFLURAMINE 84, 284

FENFURAM 227

FENHEXAMID 227

FENITROTHION 178

FENOFIBRATE 84

FENOLDOPAM 84

FENOPROFEN 84

FENOPROP 143

FENOTEROL 84, 267

FENOXACRIM 178, 203

FENOXAPROP-ETHYL 143

FENOXAPROP-P-ETHYL 144

FENOXYCARB 227

FENPIPRAMIDE 84

FENPIPRANE 84

FENPROPOREX 84

FENPROSTALENE 84

FENPYROXIMATE 178

FENSON 144

FENSULFOTHION 203

FENTANYL 210

FENTHION 144, 178, 203

FENTHION-ETHYL 203

FENVALERATE 178

FERRICYANIDES

*See* CYANIDES 201

FERROCYANIDES

*See* CYANIDES 201

FEXOFENADINE 38, 84

*See also* Antihistamines 261

FIBRINOGEN

*See* HUMAN BLOOD PRODUCTS 220

FIBRINOLYSIN 84

FIDAXOMICIN 84

FILGRASTIM 84

FILM OR PAPER, PHOTOGRAPHIC

*See* PHOTOGRAPHIC PAPER or FILM 220

FINASTERIDE 84

FINGOLIMOD 84, 287

FIPRONIL 144, 178

FIROCOXIB 84

FIRST SCHEDULE PAINT 5, 272, 279

FLAMPROP-METHYL 144

FLAMPROP-M-METHYL 144

FLAVOPHOSPHOLIPOL

*See* BAMBERMYCIN 61, 163

FLAVOXATE 50

FLAZASULFURON 144

FLECAINIDE 84

FLEROXACIN 84

FLOCOUMAFEN 178, 203

FLOCTAFENINE 84

FLONICAMID 178

FLORASULAM 144

FLORFENICOL 84

FLUANISONE 84

FLUAZIFOP-BUTYL 179

FLUAZIFOP-P-BUTYL 179

FLUAZINAM 179

FLUAZURON 144

FLUBENDAZOLE 144

FLUBENDIAMIDE 144

FLUCHLORALIN 144

FLUCLOROLONE 84

FLUCLOXACILLIN 85

FLUCOFURON 179, 203

FLUCONAZOLE 50, 85, 267, 278

FLUCYTHRINATE 203

FLUCYTOSINE 85

FLUDARABINE 85

FLUDIOXONIL 144

FLUDROCORTISONE 85

FLUFENAMIC ACID 85

FLUFENOXURON 227

FLUMAZENIL 85

FLUMETHASONE 85

FLUMETHIAZIDE 85

FLUMETHRIN 144, 179

FLUMETSULAM 227

FLUMICLORAC PENTYL 144

FLUMIOXAZIN 179, 203

FLUNISOLIDE 85

FLUNITRAZEPAM 210, 284

FLUNIXIN MEGLUMINE 85

FLUOCINOLONE 85

FLUOCINONIDE 85

FLUOCORTIN 85

FLUOCORTOLONE 85

FLUOMETURON 227

FLUORACETAMIDE 281

FLUORESCEIN 85

*See also* METHYLATED SPIRIT(S) 149

FLUORIDES 38, 50, 85, 144, 179, 244, 267

*See also* SILICOFLUORIDES 156, 194

FLUOROACETAMIDE 27, 203

FLUOROACETIC ACID 27, 203, 282

FLUOROMETHOLONE 85

4-FLUORO-N-METHAMPHETAMINE

*See* 4-FLUORO-N-METHYLAMPHETAMINE

4-FLUORO-N-METHYLAMPHETAMINE 214

(1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE) \*(AM-694) 214

FLUOROSILICATES

*See* SILICOFLUORIDES

FLUOROSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

FLUOROURACIL 85

FLUOXETINE 85

FLUOXYMESTERONE 85

FLUPENTHIXOL 85, 284

FLUPHENAZINE 85, 284

FLUPROPANATE 179

FLUPROSTENOL 85

FLUQUINCONAZOLE 179

FLURANDRENOLONE 85

FLURAZEPAM 85, 284

FLURBIPROFEN 39, 85

FLUROXENE 85

FLUROXYPYR 227

FLUSILAZOL 179

FLUSPIRILENE 86

FLUTAMIDE 86

FLUTICASONE 39, 86

FLUTOLANIL 227

FLUTRIAFOL 179

FLUVALINATE 144, 179

FLUVASTATIN 86

FLUVOXAMINE 86

FLUXAPYROXAD 144

FOLIC ACID 39, 86

FOLINIC ACID 39, 86

FOLLICLE STIMULANT, RECOMBINANT

*See* CORIFOLLITROPIN ALFA 235

FOLLICLE-STIMULATING HORMONE 86, 277

FOLLICLE-STIMULATING HORMONE, HUMAN

*See* UROFOLLITROPIN 235

FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN

*See* FOLLITROPIN ALPHA 235

*See* FOLLITROPIN BETA 235

FOLLISTATIN 86, 236

FOLLITROPIN ALPHA 86, 235

FOLLITROPIN BETA 86, 235

FOLPET 203, 282

FOMIVIRSEN 86

FONDAPARINUX 86

FOOD 219

FORAMSULFURON 144

FORCHLORFENURON 227

FORMALDEHYDE 39, 179, 233, 244, 268

*See* *also* METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT 184, 270

*See also* FREE FORMALDEHYDE 5

FORMEBOLONE 86

FORMESTANE 86

FORMETANATE 203

FORMIC ACID 144, 244, 268

FORMOTEROL

*See* EFORMOTEROL

FORMOTHION 179

FOSAMPRENAVIR 86

FOSAPREPITANT 86

FOSCARNET 86

FOSFESTROL (diethylstilboestrol diphosphate) 86

FOSINOPRIL 86

FOSPHENYTOIN 86

FOSPIRATE 144, 179

FOTEMUSTINE 86

FRAMYCETIN 86

FREE FORMALDEHYDE 5

*See also* FORMALDEHYDE 39, 179, 233

*See also* PARAFORMALDEHYDE 44, 188, 233

FRITTED GLAZING OR ENAMELLING PREPARATIONS 219

FRUSEMIDE

*See* FUROSEMIDE 86

FUELS

*See* MOTOR, HEATING or FURNACE FUELS 220

FUELS, HOBBY

*See* MOTOR, HEATING or FURNACE FUELS 220

FUELS, TOY

*See* MOTOR, HEATING or FURNACE FUELS 220

FULLERS EARTH 227

FULVESTRANT 86

FUMAGILLIN 179

FUNGAL PROTEASE DERIVED FROM ASPERGILLUS NIGER 227

FURALAXYL 145

FURALTADONE 86

FURATHIOCARB 145, 203

FURAZABOL 86

FURAZOLIDONE 86

FURETHIDINE 214

FUROSEMIDE (frusemide) 86

FUSIDIC ACID 86

G

GABAPENTIN 87, 284

GALANTAMINE 87

GALANTHUS 87

GALLAMINE 87

GALSULFASE 87

GAMMA HYDROXYBUTYRATE (GHB)

*See* 4-HYDROXYBUTANOIC ACID 214

GAMMA-CYHALOTHRIN 145, 203

GANCICLOVIR 87

GANIRELIX 87

GATIFLOXACIN 87

GEFITINIB 87

GELATIN 219

GELSEMIUM SEMPERVIRENS 39, 277

GEMCITABINE 87, 284

GEMEPROST 87

GEMFIBROZIL 87

GEMIFLOXACIN 87

GEMTUZUMAB OZOGAMICIN 87

GENTAMICIN 87

GENTIAN VIOLET

*See* CRYSTAL VIOLET

GERANIUM OIL 227

GESTODENE 87

GESTONORONE 87

GESTRINONE 87

GHB (GAMMA HYDROXYBUTYRATE)

*See* 4-HYDROXYBUTANOIC ACID 214

GHRH INJECTABLE PLASMID 87

GIBBERELLIC ACID 227

GITALIN 87

GLASS 219

GLATIRAMER ACETATE 87

GLAZED POTTERY 219

GLAZING PREPARATIONS CONTAINING LEAD COMPOUNDS 268

GLIBENCLAMIDE 87

GLIBORNURIDE 87

GLICLAZIDE 87

GLIMEPIRIDE 87

GLIPIZIDE 87

GLISOXEPIDE 87

GLUCAGON 50, 277

GLUCANASE DERIVED FROM ASPERGILLUS NIGER 227

GLUES, CEMENTS AND ADHESIVES − MEDICAL AND VETERINARY 220

GLUFOSINATE-AMMONIUM 145

GLUTARALDEHYDE 39, 145, 180, 244, 268

GLUTATHIONE 87

GLUTETHIMIDE 88, 236, 284

GLYCERYL THIOGLYCOLLATE 180

GLYCERYL TRINITRATE 50, 88, 277

GLYCOLIC ACID 180, 244, 268

GLYCOPYRRONIUM 50, 88

GLYCOSYLATED HYDROQUINONE

*See* HYDROQUINONE

GLYMIDINE 88

GLYPHOSATE 145

GnRH VACCINE 88

GOLIMUMAB 88

GONADORELIN 88

GONADOTROPHIC HORMONES 88

GOSERELIN 88

GRAMICIDIN 88

GRANISETRON 88

GRAPHIC MATERIAL 5

GREPAFLOXACIN 88

GRISEOFULVIN 88

GROWTH HORMONE 277

GUAIPHENESIN 39, 88

*See also* PARACETAMOL (+ guaiphenesin) 44

GUANABENZ 88

GUANACLINE 88

GUANETHIDINE 88

GUANIDINE 88, 180, 244

GUAZATINE 180

H

H5N1 INFLUENZA VIRUS HAEMAGGLUTININ

*See* INFLUENZA AND CORYZA VACCINES

HAEMATIN 88

HAEMOPHILUS INFLUENZAE VACCINE 88

HALCINONIDE 88

HALOFANTRINE 88

HALOFENATE 88

HALOFUGINONE 88, 203, 282

HALOGENATED DIBENZODIOXINS 204, 282

HALOGENATED dibenzofurans 204, 282

HALOPERIDOL 88, 277, 284

HALOSULFURON-METHYL 145

HALOTHANE 89

HALOXON 180

HALOXYFOP 180

HALQUINOL

*See* CLIOQUINOL

HARMALA ALKALOIDS 214

HCB 204, 282

HEIGHT 5

HELICOZEAOCCLUSION BODIES

*See* POLYHEDROSIS VIRUS 229

HELICOVERPA ARMIGERA

*See* NUCLEAR POLYHEDROSIS VIRUS 228

HELIOTROPIUM spp 233

HEMEROCALLIS (Hemerocallis flava) 89

HEMP AGRIMONY

*See* EUPATORIUM CANNABINUM 232

HEMP

*See* CANNABIS 213

HEMP SEED OIL 5

*See also* TETRAHYDROCANNABINOLS 217

HEPARINS 89

HEPATITIS A VACCINE 89

HEPATITIS B VACCINE 89

HEPTACHLOR 180

HEROIN 214

HETACILLIN 89

HEXACHLOROPHANE 39, 89, 180, 244, 268

See also HCB

HEXACONAZOLE 145

HEXAFLUOROSILICATES

*See* SILICOFLUORIDES

HEXAFLUOROSILIC ACID

*See* HYDROSILICOFLUORIC ACID

HEXAFLURON 227

HEXAMETHONIUM 89

HEXAMETHYLMELAMINE

*See* ALTRETAMINE 56

HEXAZINONE 145, 180

HEXETIDINE 89

HEXOBENDINE 89

HEXOCYCLIUM 89

HEXOPRENALINE 89

HEXYL ACETATE 227

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL) 214

HEXYTHIAZOX 227

HISTAMINE 89

HMG-CoA REDUCTASE INHIBITORS (including statins) 89

HOBBY FUELS

*See* MOTOR, HEATING or FURNACE FUELS 220

HOMATROPINE 89

HORMONE, FOLLICLE-STIMULATING 86

*See also* FOLLICLE-STIMULATING HORMONE 277

HORMONE, GROWTH

*See* GROWTH HORMONE 277

HORMONE, HUMAN FOLLICLE-STIMULATING

*See* UROFOLLITROPIN 235

HORMONE, HUMAN GROWTH

*See* SOMATROPIN 121, 236

HORMONE, LUTEINISING 97, 235

HORMONE, RECOMBINANT HUMAN FOLLICLE-STIMULATING

*See* FOLLITROPIN ALPHA 235

*See* FOLLITROPIN BETA 235

HORMONES, ADRENOCORTICAL 55

HORMONES, GONADOTROPHIC 88

HORMONES, PITUITARY 112

HORMONES, SEX 120

HORMONES, STEROID 121

HUMAN BLOOD PRODUCTS 219

See also BLOOD

HUMAN CHORIONIC GONADATROPHIN 89

HUMAN FOLLICLE-STIMULATING HORMONE

*See* UROFOLLITROPIN 235

human growth hormone

*See* SOMATROPIN 121, 236

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) 227

HUMAN PAPILLOMA VIRUS VACCINE 89

HYALURONIC ACID AND ITS POLYMERS 89

HYDRALAZINE 89

HYDRAMETHYLNON 145, 180

HYDRARGAPHEN 89

Hydrazine 180, 244, 268

HYDROCARBONS, LIQUID iv, 14, 23, 145, 244

*See also* DESIGNATED SOLVENT 4

*See also* NAPHTHALENE 186

See alsoLIQUID HYDROCARBONS

HYDROCHLORIC ACID 23, 146, 180, 244, 268

HYDROCARBONS LIQUID AROMATIC 204

*See also* HYDROCARBONS, LIQUID 145

HYDROCHLOROTHIAZIDE 89

HYDROCODONE 210, 284

HYDROCORTISONE 39, 50, 90, 268, 278

HYDROCORTISONE ACETATE 39, 50

HYDROCYANIC ACID 27, 90, 204, 268, , 277, 282

HYDROFLUMETHIAZIDE 90

HYDROFLUORIC ACID 146, 180, 204, 244, 268, 282

HYDROFLUOSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

HYDROGEN FLUORIDE

*See* HYDROFLUORIC ACID 146, 180

HYDROGEN PEROXIDE 146, 181, 233, 245, 269

HYDROGEN SULFIDE 204

HYDROMORPHINOL 210

HYDROMORPHONE 210, 284

HYDROPRENE 227

HYDROQUINONE 40, 90, 181, 245, 269

*See also* MONOBENZONE 102

HYDROSILICOFLUORIC ACID 146, 181, 204, 245, 269, 282

beta-HYDROXY-3-METHYLFENTANYL 212

4-HYDROXYBUTANOIC ACID (GAMMA HYDROXYBUTYRATE (GHB)) 214

HYDROXYCHLOROQUINE 90

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(CANNABICYCLOHEXANOL OR CP 47,497 C8 HOMOLOGUE) 214

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497) 214

HYDROXYEPHEDRINE 90

HYDROXYPETHIDINE 214

beta-HYDROXYFENTANYL 212

HYDROXYPHENAMATE 90

HYDROXYPROGESTERONE 90

HYDROXYPROPYL CELLULOSE 227

8-HYDROXYQUINOLINE 40, 269

*See also* CLIOQUINOL 70, 232

HYDROXYSTENOZOL 90

HYDROXYUREA 90

HYDROXYZINE 90, 284

HYGROMYCIN 90

HYOSCINE 40, 90, 277

HYOSCINE BUTYLBROMIDE 40

*See* *also* HYOSCINE 40

HYOSCYAMINE 40, 90, 277

HYOSCYAMUS NIGER 40, 90, 277

HYPOTHALAMIC RELEASING FACTORS 90, 277

HYPROMELLOSE 90

I

IBAFLOXACIN 90

IBANDRONIC ACID 90

IBOGAINE 90

IBRITUMOMAB 90

IBUFENAC 90

IBUPROFEN 41, 51, 91, 269

*See also* PARACETAMOL (+ ibuprofen) 52, 108

IBUTEROL 91

IBUTILIDE 91

ICATIBANT 91

ICODEXTRIN 227

IDARUBICIN 91

IDOXURIDINE 91

IDURSULFASE 91

IFOSFAMIDE 91

ILOPROST 91

IMATINIB 91

IMAZALIL 146

IMAZAMOX 146

IMAZAPIC 146

IMAZAPYR 146

IMAZETHAPYR 146

IMIDACLOPRID 146, 181

IMIDAPRIL 91

IMIDOCARB 181

IMIGLUCERASE 91

IMIPENIM 91

IMIPRAMINE 91, 284

IMIPROTHRIN 146, 181

IMIQUIMOD 91

IMMEDIATE CONTAINER 5

IMMEDIATE WRAPPER 5

IMMUNOGLOBULINS 91

IMMUNOSERA

*See* ANTISERA 59

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS 220

INDACATEROL 91

INDANAZOLINE 41

INDAPAMIDE 91

INDAZIFLAM 181

INDINAVIR 91

INDOLE-3-ACETIC ACID 227

INDOMETHACIN 41, 91, 277

INDOPROFEN 91

INDORAMIN 91

INDOXACARB 146, 181

INFLIXIMAB 91

INFLUENZA AND CORYZA VACCINES 91

INGENOL MEBUTATE 92

INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS

*See* MEDICAL DEVICES 220

INK ADDITIVES

*See* PRINTING INKS OR INK ADDITIVES 221

INOSITOL NICOTINATE 51

INSULIN-LIKE GROWTH FACTOR I 92

INSULIN-LIKE GROWTH FACTORS 92, 236

INSULINS 92

INTERFERONS 92

INTERLEUKINS 92

INTERNAL USE 5

INTRA-ARTICULAR FLUIDS

*See* MEDICAL DEVICES 220

INTRAOCULAR VISCOELASTIC PRODUCTS 220

Iodine 41, 181, 245, 269

*See also* IODOPHORS 181

3-IODO-2-PROPYNYL BUTYL CARBAMATE (iodocarb) 146, 181

Iodocarb

*See* 3-IODO-2-PROPYNYL BUTYL CARBAMATE 146, 181

IODOMETHANE 204, 282

IODOPHORS 245

IODOPHORS 181

*See also* IODINE 41, 181, 245

iodoquinol

*See* DI-IODOHYDROXYQUINOLINE 49, 77

IODOSULFURON-METHYL-SODIUM 146

IODOTHIOURACIL 92

IOXYNIL 181

IPCONAZOLE 146, 181

IPECACUANHA

*See* CEPHAELIS IPECACUANHA 68

*See* CEPHAELIS ACUMINATA 68

IPILIMUMAB 92

IPRATROPIUM 41, 92

IPRATROPIUM BROMIDE 269

IPRIFLAVONE 92

IPRINDOLE 92

IPRODIONE 227

IPRONIAZID 92

IRBESARTAN 92

IRINOTECAN 92

IRON & IRON COMPOUNDS 41, 92, 146, 182

IRON OXIDES

*See* IRON COMPOUNDS 41, 146, 182

ISOAMINILE 92

ISOAMYL NITRITE 92

ISOBUTYL NITRITE 92

ISOCARBOPHOS 204

ISOCARBOXAZID 92

ISOCONAZOLE 42, 51, 92, 182

Isocyanates (free organic) 182, 245, 269

ISOETARINE 92

ISOEUGENOL 147, 182

ISOFENPHOS 204

ISOFLURANE 92

ISOMETHADONE 214

ISOMETHEPTENE 92

ISONIAZID 92

ISOPHORONE 147, 245

ISOPRENALINE 92, 269

ISOPRENE ALCOHOL 227

ISOPRINOSINE 92

ISOPROPAMIDE 42, 92

ISOPROTURON 204

ISOSORBIDE DINITRATE 51, 92

ISOSORBIDE MONONITRATE 92

ISOSTEARYL ALCOHOL ETHOXYLATE 227

ISOTRETINOIN 93, 235, 269, 287

ISOXABEN 147

ISOXAFLUTOLE 147

ISOXICAM 93

ISOXSUPRINE 93

ISRADIPINE 93

ITRACONAZOLE 93

IVABRADINE 93

IVACAFTOR 93

IVERMECTIN 93, 147, 204

IXABEPILONE 93

J

JAPANESE ENCEPHALITIS VACCINE 93

JASMOLONE

*See* PYRETHRINS 46, 155

JEQUIRITY

*See* ABRUS PRECATORIUS 231

JUNIPERUS SABINE [savin(e)] 233

JWH-018

*See* 1-PENTYL-3-(1-NAPHTHOYL)INDOLE 216

JWH-073

*See* NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE 216

JWH-122

*See* 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. 216

JWH-200

*See* 1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE 215

JWH-250

*See* 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE 215

K

KANAMYCIN 93

KAOLIN 227

KAVA

*See* PIPER METHYSTICUM 112

KAVALACTONES

*See* PIPER METHYSTICUM 112

KEROSENE iv, 245

*See also* LIQUID HYDROCARBONS 21,

*See also* HYDROCARBONS, LIQUID 23, 145

*See also* MOTOR, HEATING or FURNACE FUELS 220

KETAMINE 210

KETANSERIN 93

KETAZOLAM 93

KETOBEMIDONE 214

KETOCONAZOLE 42, 93

KETONE 14

KETOPROFEN 51, 93

KETOROLAC (includes ketoralac trometamol) 93

KETOTIFEN 42, 93

K-HDO

*See* N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM

KHELLIN 93

KITASAMYCIN 93, 147

KRESOXIM-METHYL 227

KUNZEA OIL 227

L

LABELS 6, 10, 287

*See also* DISPENSING LABEL 5, 94

*See also* MAIN LABEL 6

LABETALOL

LACIDIPINE 94

LACOSAMIDE 94

LAMBDA-CYHALOTHRIN 147, 182, 204

LAMIVUDINE 94

LAMOTRIGINE 94, 284

LAMP OIL

*See* LIQUID HYDROCARBONS 21

*See* HYDROCARBONS, LIQUID 23

LAMPS

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 219

LANATOSIDES 94

LANREOTIDE 94

LANSOPRAZOLE 51, 94

LANTHANUM 94

LAPATINIB 94

LARONIDASE 94

LAROPIPRANT 94

LASALOCID 182

LATAMOXEF 94

LATANOPROST 94

LAUDEXIUM 94

LAURETH CARBOXYLIC ACIDS 182, 245

LAURETH-9

*See* LAUROMACROGOL

LAURIC ACID 227

LAUROMACROGOLS 94

LAURYL ALCOHOL (1-DODECANOL) 228

LAURYL ISOQUINOLINIUM BROMIDE 182, 245

LAVANDIN OIL 228

*See also* CAMPHOR 136, 167

LAVENDER OIL 228

LEAD & LEAD COMPOUNDS 17, 94, 147, 183, 233, 245, 270, 279

*See also* PRINTING INKS or INK ADDITIVES 221

*See also* SELENIUM 193

*See also* GLAZING PREPARATIONS 268

LEAD METALLIC 228

LEFETAMINE 94

LEFLUNOMIDE 94, 270, 287

LEMON EUCALYPTUS OIL

*See* EXTRACT OF LEMON EUCALYPTUS 143

LEMON OIL 147, 245, 270

LEMONGRASS OIL 228

LENALIDOMIDE 94, 235, 270, 287

LENOGRASTIM 94

LEPIDOPTEROUS SEX PHEROMONES 228

LEPIRUDIN 94

LEPTAZOL 94

LEPTOPHOS 204

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) 23, 183, 245

LERCANIDIPINE 94

LETROZOLE 94

LEUPRORELIN 94

LEVALLORPHAN 95

LEVAMISOLE 95, 148, 183

LEVAMPHETAMINE 210

LEVETIRACETAM 95, 284

LEVOBUNOLOL 95

LEVOBUPIVACAINE 95

Levocabastine 42, 95, 270, 284, 287

LEVOCETIRIZINE

*See* CETIRIZINE

LEVODOPA 95

LEVOMEPROMAZINE 95

LEVOMETHAMPHETAMINE 210

LEVOMETHORPHAN 214

LEVOMORAMIDE 210

LEVONORGESTREL 51, 95

LEVOPHENACYLMORPHAN 214

LEVORPHANOL 210

LEVOSIMENDAN 95

LIDOCAINE

*See* LIGNOCAINE

LIGHT MINERAL OILS

*See* HYDROCARBONS, LIQUID 145

LIGNOCAINE 42, 95

LIGULARIA DENTATA 233

Lime oil 148, 245, 270

LIMONENE (dipentene) 228

LINAGLIPTIN 95

LINCOMYCIN 95

LINDANE 42, 95, 148, 183

See also BHC 165

LINEZOLID 95

LINOLEIC ACID 228

LINSEED FATTY ACIDS 228

LINSEED OIL

*See* ETHOPROPHOS 176

LINURON 228

LIOTHYRONINE 95

LIPASE

*See* PANCREATIC ENZYMES 108

LIQUID 204

LIQUID AROMATIC HYDROCARBONS

*See* HYDROCARBONS, LIQUID 145

LIQUID EPOXY RESINS 14

LIQUID Hydrocarbons 14, 23

*See also* HYDROCARBONS, LIQUID

*See also* NAPHTHALENE

LIQUORICE, DEGLYCYRRHISINISED 228

LIRAGLUTIDE 95

LISINOPRIL 95

LISURIDE 95

LITHIUM 42, 96

LITHIUM PERFLUOROOCTANE SULFONATE 204

LIXISENATIDE 96

LOBELIA INFLATA 42

LOBELINE 42

LODOXAMIDE 42, 96

LOFEXIDINE 96

LOGIPARIN 96

LOMEFLOXACIN 96

LOMUSTINE 96

LOPERAMIDE 42, 96, 270

LOPINAVIR 96

LOPRAZOLAM 96

LORACARBEF 96

LORATADINE 42, 96

*See also* ANTIHISTAMINES 261

LORAZEPAM 96, 284

LORMETAZEPAM 96

LOSARTAN 96

LOXAPINE 96

LUBRICANTS 220

LUFENURON 148

LUMEFANTRINE 96

LUMIRACOXIB 97

LUTEIN

*See* XANTHOPHYLL 230

LUTEINISING HORMONE 97, 235

LYE WATER

*See* ALKALINE SALTS, SODIUM HYDROXIDE OR POTASSIUM HYDROXIDE

LYMECYCLINE 97

LYSERGIC ACID 214

LYSERGIDE 214

M

MACROGOLS 51

MADURAMICIN 148, 204, 282

MAFENIDE 97, 183

MAGNESIUM CHLORATE 148, 245, 270

MAGNESIUM FLUOSILICATE

*See* FLUORIDES

MAGNESIUM PHOSPHIDE

*See* PHOSPHIDES, METALLIC

MAGNESIUM SULFATE 51

MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS 219

MAIN LABEL 6

MALACHITE GREEN 148, 204

Malathion 51, 148, 184, 246

*See also* ORGANOPHOSPHORUS COMPOUNDS 106

MALDISON

*See* MALATHION

MALEIC HYDRAZIDE 228

MANCOZEB 15, 148

*See also* DITHIOCARBAMATES

MANDIPROPAMID 148

MANDRAGORA OFFICINARUM 97

MANGANESE DIOXIDE 228

MANNITYL HEXANITRATE 51

MANNOMUSTINE 97

MANUFACTURER 6

MANUKA oil

*See* LEPTOSPERMUM SCOPARIUM OIL 23, 183, 245

MAPROTILINE 97

MARAVIROC 97

MARBOFLOXACIN 97

MARJORAM OIL 23, 148, 246

MAROPITANT 97

MATCHES 220

MAVACOXIB 97

MAZIDOX 204

MAZINDOL 97, 284

MBDB

*See* N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE 215

MCPA 149, 184

MCPB 149

MDA

*See* 3,4-METHYLENEDIOXYAMPHETAMINE 215

MDMA

*See* N,-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE 213

MDPV

*See* 3,4-METHYLENEDIOXYPYROVALERONE 215

MEASLES VACCINE 97

MEASURE PACK 6

MEBANAZINE 97

MEBENDAZOLE 43, 149, 184

MEBEVERINE 97

MEBHYDROLIN 97, 284

MEBOLAZINE 97

MEBUTAMATE 97

MECAMYLAMINE 97

MECARBAM 204

MECASERMIN 97

MECILLINAM 97

MECLOCYCLINE 97

MECLOFENAMATE 97

MECLOFENAMIC ACID 149

MECLOFENOXATE 97

MECLOQUALONE 214

MECLOZINE 43, 97, 284

MECOPROP 149, 184

MECOPROP-P 184

MEDAZEPAM 97, 284

MEDETOMIDINE 97

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS 220

MEDICAL DEVICES 220

MEDICINE 6

MEDIGOXIN (methyldigoxin) 97

MEDROXYPROGESTERONE 97

MEDRYSONE 98

MEFENAMIC ACID 43, 98, 270

MEFENOREX 98

MEFENPYR-DIETHYL 149

MEFLOQUINE 98

MEFLUIDIDE 184

MEFRUSIDE 98

MEGESTROL 98

MELAGATRAN 98

MELALEUCA OIL (tea tree oil) 23, 184, 246

MELANOCYTE STIMULATING HORMONE

*See* AFAMELANOTIDE

MELATONIN 98

MELENGESTROL 98

MELENGESTROL ACETATE 184

MELIA AZEDARACH 233

MELOXICAM 98

MELPHALAN 98

MEMANTINE 98

MENAZON 184

MENINGOCOCCAL VACCINE 98

MENOTROPHIN 98

5-MeO-AMT

*See* 5-METHOXY--METHYLTRYPTAMINE 215

MEPACRINE 98

MEPENZOLATE 98

MEPHEDRONE

*See* 4-METHYLMETHCATHINONE 215

MEPHENESIN 98

MEPHENTERMINE 98

MEPINDOLOL 98

MEPIQUAT 149

MEPITIOSTANE 98

MEPIVACAINE 98

MEPROBAMATE 98, 284

MEPTAZINOL 98

MEPYRAMINE 43, 51, 98, 284

MEQUITAZINE 98

2-MERCAPTOETHANOL 184

MERCAPTOMERIN 98

MERCAPTOPURINE 98

MERCURIC CHLORIDE 204, 246

MERCURIC IODIDE 246

MERCURIC NITRATE 246

MERCURIC OXIDE 184, 246

MERCURIC POTASSIUM IODIDE 246

MERCURIC THIOCYANATE 246, 270

MERCUROCHROME 43, 184, 246

MERCUROUS CHLORIDE 246

MERCURY 9, 43, 99, 205, 277, 282

*See also* PHENYLMERCURIC ACETATE 206

MERCURY METALLIC 246

MERCURY, ORGANIC COMPOUNDS 246

MEROPENEM 99

MERSALYL 99

MESABOLONE 99

MESALAZINE 99

MESCALINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE 217

MESNA 99

MESOLSULFURON-METHYL 228

MESOTRIONE 149

MESTANOLONE (androstalone) 99

MESTEROLONE 99

MESTRANOL 99

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT 184, 270

METAFLUMIZONE 149

METALAXYL 149, 185

METALDEHYDE 149, 185, 246

METANDIENONE 99

METARAMINOL 99

METARHIZIUM ANISOPLIAE 228

METAZOCINE 215

METENOLONE 99

METERGOLINE 99

METFORMIN 99

METHABENZTHIAZURON 149

METHACHOLINE 99

METHACRIFOS 185, 205, 282

METHACYCLINE 99

METHADONE 210, 284

METHADONE INTERMEDIATE

*See* 4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE

METHALLENOESTRIL 99

METHAM 185

METHAM SODIUM

*See* METHAM

METHAMIDOPHOS 205

METHAMPHETAMINE

*See* METHYLAMPHETAMINE

METHANDRIOL 99

METHANOL 4, 149, 185, 246, 270

*See also* MOTOR, HEATING or FURNACE FUELS 220

METHANTHELINIUM 99

METHAPYRILENE 205

METHAQUALONE 215

METHAZOLAMIDE 99

METHAZOLE 205

METHCATHINONE 215

METHDILAZINE 51, 99, 284

METHENOLONE 99

METHICILLIN 99

METHIDATHION 205

METHIMAZOLE 99

METHIOCARB 149, 185, 205

METHISAZONE 99

METHIXENE 99

METHOCARBAMOL 99, 284

METHOHEXITONE 100

METHOIN 100

METHOMYL 185, 205

METHOPRENE 228

METHOTREXATE 100

METHOTRIMEPRAZINE

*See* LEVOMEPROMAZINE

METHOXAMINE 43, 100, 270

METHOXSALEN 100

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA) 215

4-METHOXY--METHYLPHENYLETHYLAMINE \*(PMA) 215

5-METHOXY--METHYLTRYPTAMINE \*(5-MeO-AMT) 215

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

*See* EPOETINS

METHOXYCHLOR 149

METHOXYETHYLMERCURIC ACETATE 205, 282

METHOXYETHYLMERCURIC CHLORIDE 205, 282

METHOXYFENOZIDE 228

METHOXYFLURANE 100

METHOXYPHENAMINE 43

*See also* 3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) 217

METHOXYPHENETHYLAMINE 212

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250) 215

METHOXY-PHENYLETHYLAMINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE 217

METHSUXIMIDE 100

METHYCLOTHIAZIDE 100

METHYL (*2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE \*(SALVINORIN A) 215

METHYL ACETATE 228

METHYL AMINOLEVULINATE 100

METHYL BENZOQUATE 228

METHYL BROMIDE 205, 282

METHYL CHAVICOL

*See* BASIL OIL 135

METHYL CHLORIDE 270

METHYL ETHYL KETONE 149, 246, 270

*See also* DESIGNATED SOLVENT 4

METHYL ETHYL KETONE PEROXIDE 149, 246, 270

METHYL ISOAMYL KETONE 149, 246, 270

*See also* DESIGNATED SOLVENT 4

METHYL ISOBUTYL KETONE 150, 246, 270

*See also* DESIGNATED SOLVENT 5

*See also* METHYLATED SPIRIT(S) 149

METHYL ISOTHIOCYANATE 185, 270

METHYL MERCURY 100

METHYL METHACRYLATE 185, 233, 270

METHYL NEODECANAMIDE 185

METHYL p-HYDROXYBENZOATE 228

METHYL SALICYLATE 23, 100, 150, 185

*See also* DIMETHYL SULFOXIDE 175

METHYL SALICYLATE LIQUID 247

1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHYLAMINOBENZENE 271

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (MORAMIDE INTERMEDIATE) 215

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP) 215

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (PETHIDINE INTERMEDIATE C) 210

4-METHYLAMINOREX 215

METHYLAMPHETAMINE 210

METHYLANDROSTANOLONE 100

METHYLATED SPIRIT 23, 149, 246

METHYLCLOSTEBOL 100

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL 185, 205

1-METHYLCYCLOPROPENE 228

METHYLDESORPHINE 215

METHYLDIBROMO GLUTARONITRILE 185, 233, 270

METHYLDIGOXIN

*See* MEDIGOXIN 97

METHYLDIHYDROMORPHINE 210

METHYLDOPA 100

METHYLENE BISTHIOCYANATE 185, 270

METHYLENE BLUE 100, 149, 205

METHYLENE chloride

*See* DICHLOROMETHANE 141, 243, 266, 279

METHYLENE dianiline

*See* 4,4-DIAMINODIPHENYLMETHANE 202, 264, 281

METHYLENE GLYCOL

*See* FREE FORMALDEHYDE 5

*See* FORMALEDHYDE

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA) 205, 282

3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE

*See* N,A-DIMETHYL-3,4-(METHYLENEDIOXYL)PHENYLETHYLAMINE

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA) 215

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV) 215

METHYLEPHEDRINE 43

METHYLERGOMETRINE 100

METHYLEUGENOL 185, 246, 270

ALPHA -METHYLFENTANYL 212

3-METHYLFENTANYL 215

4-METHYLHEXANE-2-AMINE

*See* 1,3-DIMETHYLAMYLAMINE

METHYLMERCURY 277

4-METHYLMETHCATHINONE \*(MEPHEDRONE) 215

METHYLNALTREXONE 100

METHYLNORBORNYLPYRIDINE 185, 271

METHYLPENTYNOL 100

METHYLPHENIDATE 210

METHYLPHENOBARBITONE 100, 284

*See also* BARBITURATE METHYLPREDNISOLONE 100

METHYLSULFONYLMETHANE

*See* DIMETHYL SULFOXIDE

METHYLTESTOSTERONE 100

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE 150

4-METHYLTHIOAMPHETAMINE 215

ALPHA -METHYLTHIOFENTANYL 212

3-METHYLTHIOFENTANYL 215

METHYLTHIOURACIL 100

METHYLTRIENOLONE 100

METHYPRYLONE 100

METHYSERGIDE 100

METIRAM 15, 150

METOCLOPRAMIDE 51, 100

METOFLUTHRIN 186

METOLACHLOR 150

METOLAZONE 101

METOPON 215

METOPROLOL 101

METOSULAM 186

METRAFENONE 150, 186

METRIBOLONE 101

METRIBUZIN 186

METRIFONATE (trichlorfon) 101

*See also* TRICHLORFON 197

METRONIDAZOLE 101

METSULFURONMETHYL 228

METYRAPONE 101

MEVINPHOS 205

MEXILETINE 101

MEZLOCILLIN 101

Mianserin 101, 284

MIBEFRADIL 101

MIBOLERONE 101

MICAFUNGIN 101

Miconazole 43, 51, 101, 186, 271, 278

MIDAZOLAM 101

MIDODRINE 101

MIFEPRISTONE 101

MIGLITOL 101

MIGLUSTAT 101

MILBEMECTIN 150, 186

MILBEMYCIN OXIME 101, 150

MILRINONE 101

MINERAL OILS

*See* HYDROCARBONS, LIQUID

MINERAL OILS, LIGHT

*See* HYDROCARBONS, LIQUID 145

MINERAL TURPENTINE

*See* LIQUID HYDROCARBONS 21

*See* HYDROCARBONS, LIQUID 23, 145

MINOCYCLINE 101

MINOXIDIL 43, 101

MIPAFOX 205

Mirex 205, 282

MIRTAZAPINE 101, 284

Misoprostol 101, 271, 287

MITOBRONITOL 101

MITOMYCIN 101

MITOTANE 101

MITOXANTRONE 102

MITRAGYNA SPECIOSA 215

MITRAGYNINE 215

MITRATAPIDE 102

MIVACURIUM CHLORIDE. 102

MMDA

*See* 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE 215

MOCA

*See* 4-DIMETHYLAMINOAZOBENZENE 205

MOCLOBEMIDE 102

MODAFINIL 102

MOLGRAMOSTIM 102

Molinate 205, 282

MOLINDONE 102

MOMETASONE 43, 102

MONENSIN 102, 150, 186

MONEPANTEL 150

MONOBENZONE 102

*See also* HYDROQUINONE 40

MONOCLONAL ANTIBODIES 102

MONOCROTOPHOS 205

MONOMALEATE, CASTOR OIL 168

MONTELUKAST 102

MOPERONE 102

MORAMIDE

*See* DEXTROMORAMIDE

MORAMIDE INTERMEDIATE

*See* 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID 215

MORANTEL 150, 186

MORAZONE 102

MORICIZINE 102

MORPHERIDINE 215

Morphine 210, 284

MORPHINE METHOBROMIDE 210

MORPHINE-N-OXIDE 210

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200) 215

MOTOR, HEATING or FURNACE FUELS 220

MOTRAZEPAM 102

MOTRETINIDE 102

MOXIDECTIN 102, 150, 186, 205

MOXIFLOXACIN 102

MOXONIDINE 102

MPPP

*See* 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE 215

MSMA 186, 205

MUMPS VACCINE. 102

MUPIROCIN 102

MURAGLITAZAR 102

MUROMONAB 102

MUSCIMOL 215

MUSTINE (nitrogen mustard) 103

MYCLOBUTANIL 150

MYCOPHENOLATE MOFETIL

*See* MYCOPHENOLIC ACID 103

MYCOPHENOLIC ACID (includes mycophenolate mofetil) 103

MYRISTIC ACID 228

MYROPHINE 215

N

N-(N-DODECYL)-2-PYRROLIDONE 142, 176, 243

*See also* DESIGNATED SOLVENT 4

*See also* N-(N-OCTYL)-2-PYRROLIDONE 151

*See also* N-METHYL-2-PYRROLIDONE 150

N-(N-octyl)-2- PYRROLIDONE 151, 187, 247

*See also* DESIGNATED SOLVENT 5

*See also* N-(N-DODECYL)-2-PYRROLIDONE 142

*See also* N-METHYL-2-PYRROLIDONE 150

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE 165, 248, 272

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE 165

N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE 165, 248, 272

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE 165

N,N-DIALLYLDICHLOROACETAMIDE 140

N,N-DIETHYLTRYPTAMINE \*(DET) 213

N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE

*See* 4-DIMETHYLAMINOAZOBENZENE 202

N,N-DIMETHYLAMPHETAMINE (DIMETAMFETAMINE) 213

N,N-DIMETHYLTRYPTAMINE \*(DMT) 213

N,-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) 213

NAA 150

NABILONE 210

Nabiximols 210, 235, 284

NABUMETONE 103

NADOLOL 103

NADROPARIN 103

NAFARELIN 103

NAFTIDROFURYL 103

NALBUPHINE 284

NALBUPHINE 103

NALED 150, 186

NALIDIXIC ACID. 103

NALORPHINE 103

NALOXONE 103

NALTREXONE 103

NAME AND ADDRESS 6

NANDROLONE 103

NAPHAZOLINE 43, 271

naphthalene 20, 25, 186, 206, 247, 271, 277

NAPTHALENEACETIC ACID

*See* NAA

NAPHTHALOPHOS 186,

NAPHTHOYLINDOLES 216

NAPHTHOYLPYRROLES 216

NAPHTHYLMETHYLINDENES 216

NAPHTHYLMETHYLINDOLES 216

NAPROPAMIDE 228

Naproxen 43, 103, 271

NAPTALAM 151

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE \*(JWH-073) 216

NAPTHYL ACETAMIDE 228

NARASIN 103, 186

NARATRIPTAN 103

NATALIZUMAB 103

NATAMYCIN 103

NATEGLINIDE 103

n-BUTYL BUTYRATE 226

n-BUTYL LACTATE 226

N-COCO-1,3-DIAMINOPROPANE 171

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM 172

NEBACUMAB 103

NEBIVOLOL 103

NEDOCROMIL 103

NEEM

*See* DEBITTERISED NEEM SEED OIL 4

*See* Azadirachta indica 134, 163, 231, 240, 262

NEFAZODONE 103

NEFOPAM 103

NELFINAVIR (includes nelfinavir mesylate) 103

NEOMYCIN 103

NEOSTIGMINE 104

NEPAFENAC 104

NERIUM OLEANDER 104, 277

NEROLI OIL 228

NESIRITIDE 104

N-ETHYL MDA

*See* N-ETHYL--METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE 214

N-ETHYL--METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE \*(N-ETHYL MDA) 214

NETILMICIN 104

NETOBIMIN 151, 186

NEVIRAPINE 104

N-HYDROXY MDA

*See* N--[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE 215

NIALAMIDE 104

NICARBAZIN 228

NICARDIPINE 104

NICERGOLINE 104

NICKEL SULFATE 186

NICLOSAMIDE 43

NICOCODINE 216

NICODICODINE 216

NICOFURANOSE 104

NICOMORPHINE 216

NICORANDIL 104

NICOTINAMIDE

*See* NICOTINIC ACID 51, 104

Nicotine 104, 186, 206, 271, 282

NICOTINIC ACID 51, 104

NICOTINYL ALCOHOL 51

NICOUMALONE 104

NIFEDIPINE 104

NIFENAZONE 104

NIKETHAMIDE 104

NILOTINIB 104

NILUTAMIDE 104

NIMESULIDE 104

NIMIDANE 186, 206

NIMODIPINE 104

NIMORAZOLE 104

NIRIDAZOLE 104

NISIN 228

*See also* ANTIBIOTIC SUBSTANCES 59

NISOLDIPINE 104

NITENPYRAM 186

NITISINONE 104

NITRAZEPAM 105, 284

NITRENDIPINE 105

Nitric acid 151, 186, 247, 271

NITRIC OXIDE 105

Nitrobenzene 187, 247, 271

Nitrofen 206, 282

NITROFURANTOIN 105

NITROFURAZONE 105

nitrogen mustard

*See* MUSTINE 103

Nitrophenols 187, 247, 271

Nitroprussides 187, 206, 247, 271

NITROSCANATE 151

NITROUS OXIDE 105

NITROXOLINE 105

NITROXYNIL 187

Nizatidine 43, 105, 271

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE \*(MBDB) 215

N-METHYL-2-PYRROLIDONE 150, 185, 247

*See also* DESIGNATED SOLVENT 5

*See also* N-(N-DODECYL)-2-PYRROLIDONE 142

*See also* N-(N-OCTYL)-2-PYRROLIDONE 151

N-METHYLMETHANAMINE

*See* 1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and N-METHYLMETHANAMINE 143

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE 151

N-OLEYL-1,3-DIAMINOPROPANE 187

NOMEGESTROL 105

NOMIFENSINE 105

NON-ACCESS PACKAGING 105

*See also* CHILD-RESISTANT CLOSURE

*See also* CHILD-RESISTANT PACKAGING

Nonoxinol 9 151, 187, 247

NON-VOLATILE CONTENT 6

NORACYMETHADOL 216

NORADRENALINE 105, 271

19-NORANDROSTENEDIOL 105

19-NORANDROSTENEDIONE. 105

NORANDROSTENOLONE 105

NORBOLETHONE 105

NORBORMIDE 151

NORCLOSTEBOL 105

NORCODEINE 210

NORELGESTROMIN 105

NORETHANDROLONE 105

NORETHISTERONE 105

NORFLOXACIN 105

NORFLURAZON 228

NORGESTREL 105

NORIBOGAINE 105

NORLEVORPHANOL 216

NORMETHADONE 211, 284

NORMETHANDRONE 105

NORMORPHINE 216

NORPIPANONE 216

NORTRIPTYLINE 105, 284

NOSCAPINE 43

*See also* OPIUM 211, 284

NOVALURON 228

NOVOBIOCIN 105

NOXIPTYLINE 105

N-PHENETHYL-4-PIPERIDONE 216

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE 195

NUCLEAR POLYHEDROSIS VIRUS 228

Nutmeg oil 23, 151, 247

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION 220

NUX VOMICA

*See* STRYCHNINE

Nystatin 43, 52, 105, 271, 278

N--[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(N-HYDROXY MDA) 215

O

OCITHILINONE

*See* 2-OCTYL-4-ISOTHIAZOLIN-3-ONE 247

OCTAMYLAMINE 105

OCTATROPINE 105

1-OCTEN-3-OL 187

OCTHILINONE 187

OCTREOTIDE 106

OCTYL ALCOHOLS 228

OCTYL NITRITE 106

2-OCTYL-4-ISOTHIAZOLIN-3-ONE (OCITHILINONE) 247

OESTRADIOL 106, 151, 277

OESTRIOL 106

OESTROGENS 106

OESTRONE 106, 277

OFATUMUMAB 106

OFLOXACIN 106

OIL OF LEMON EUCALYPTUS (Corymbia citriodora)

*See* EXTRACT OF LEMON EUCALYPTUS 143

OIL OF TANSY

*See* TANACETUM VULGARE 123

OIL OF turpentine 23

OLANZAPINE 106, 284

OLAQUINDOX 187

OLEANDOMYCIN 106, 151

OLEANDRIN 106

OLEIC ACID 228

OLMESARTAN 106

OLODATEROL 106

OLOPATADINE 106

OLSALAZINE 106

OMALIZUMAB 106

OMEGA-3-ACID ETHYL ESTERS 106

OMEPRAZOLE 52, 106

OMETHOATE 151, 187, 206

ONDANSETRON 106

OPIPRAMOL 106

Opium 211, 284

ORANGE OIL (BITTER) 151, 247, 271

ORANGE OIL, SWEET 228

ORBIFLOXACIN 106

ORCIPRENALINE 106, 271

ORGANO TIN-COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

ORGANOPHOSPHORUS COMPOUNDS 15, 106

ORLISTAT 52, 106

ORNIDAZOLE 107

ORNIPRESSIN 107

OROMUCOSAL USE 6

ORPHENADRINE 107

ORTHO-Dichlorobenzene 173, 242, 264

ORTHO-PHENYLPHENOL 153, 248, 272

ORTHO-PHTHALALDEHYDE 153, 190, 248, 272

ORTHOPTERIN 107

ORTHO-Tolidine 208, 251, 282

OSELTAMIVIR 107

OUABAIN 107

OVANDROTONE 107

OXABETRINIL 228

OXABOLONE 107

OXACILLIN 107

OXADIARGYL 152

OXADIAZON 187

OXADIXYL 152

OXALATES, METALLIC 271

Oxalic acid vi, 187, 247, 271

OXALIPLATIN 107

OXALONITRILE

*See* CYANOGEN

OXAMYL 206

OXANDROLONE 107

OXANTEL EMBONATE 152

OXAPROZIN 107

Oxazepam 107, 284

OXCARBAZEPINE 107

OXEDRINE 107

OXETACAINE (oxethazaine) 43, 107

OXETHAZAINE

*See* OXETACAINE 43, 107

OXFENDAZOLE 152

OXIBENDAZOLE 152

OXICONAZOLE 43, 52, 107

OXITROPIUM 107

OXOLAMINE 107

OXOLINIC ACID 107

OXPENTIFYLLINE (pentoxifylline) 107

OXPRENOLOL 107

OXYBUPROCAINE 107

OXYBUTYNIN 107

OXYCARBOXIN 152

OXYCLOZANIDE 187

Oxycodone 211, 284

OXYDEMETON METHYL 206

OXYFLUORFEN 228

OXYMESTERONE 107

OXYMETAZOLINE 43, 272

OXYMETHOLONE 107

OXYMORPHONE 211

OXYPHENBUTAZONE 108

OXYPHENCYCLIMINE 108

OXYPHENISATIN 233

OXYPHENONIUM 108

OXYTETRACYCLINE 108, 152

OXYTHIOQUINOX 152

OXYTOCIN 108, 277

P

PACKAGING

S*ee* LABELS & CONTAINERS

S*ee also* PRIMARY PACK 7

S*ee also* MEASURE PACK 6

PACLITAXEL 108

PACLOBUTRAZOL 152

PAECILOMYCES LILACINUS Strain 251 187

Paint 7, 279

PAINT, FIRST SCHEDULE 5, 272, 279

PAINT, SECOND SCHEDULE 7, 272, 279

PAINT, THIRD Schedule 8, 279

PALIFERMIN 108

PALIPERIDONE 108, 284

PALIVIZUMAB 108

PALMAROSA OIL 228

PALMITIC ACID 228

PALONOSETRON 108

PAMAQUIN 108

PAMIDRONIC ACID (includes disodium pamidronate) 108

PANCREATIC ENZYMES 108

PANCURONIUM 108

PANITUMUMAB 108

PANTOPRAZOLE 52, 108

PAPAVERETUM 284

PAPAVERINE 43, 108

*See also* OPIUM 211, 284

PAPER 220

*See also* PHOTOGRAPHIC PAPER or FILM 220

Paracetamol 43, 52, 108, 272

*See also* ASPIRIN (+ paracetamol) 59

*See also* METOCLOPRAMIDE (+ paracetamol) 51

*See also* SALICYLAMIDE (+ paracetamol) 119

PARA-DICHLOROBENZENE (pdb) 141, 242, 264

PARAFFIN OILS

*See* HYDROCARBONS, LIQUID 145

PARA-FLUOROFENTANYL 216

Paraformaldehyde 44, 188, 233, 247

PARAHEXYL

*See* 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN 214

PARALDEHYDE 108

PARAMETHADIONE 109

PARAMETHASONE 109

PARAQUAT 206

PARATHION 206

PARATHION-METHYL 188, 206

PARBENDAZOLE 188

PARECOXIB 109

PARICALCITOL 109

PAROMOMYCIN 109

PAROXETINE 109

PASIREOTIDE 109

PASIREOTIDE DIASPARTATE 109

PATCHOULI OIL 228

PAZOPANIB 109

PCBS

*See* POLYCHLORINATED BIPHENYLS

PCE

*See* ETICYCLIDINE 214

PCP

*See* PHENCYCLIDINE 216

PCPY

See ROLICYCLIDINE 217

PDB

*See* PARA-Dichlorobenzene 242

PEBULATE 188

PECAZINE 109

PECTINASE 228

PEFLOXACIN 109

PEGAPTANIB 109

PEGFILGRASTIM 109

PEGINTERFERON 109

PEGVISOMANT 109

PEMETREXED 109

PEMOLINE 109

PEMPIDINE 109

PENBUTOLOL 109

PENCICLOVIR 44, 109

PENCONAZOLE 152

PENCYCURON 228

PENDIMETHALIN 152

PENETHAMATE 109

PENFLUFEN 152

PENICILLAMINE 109

PENNYROYAL OIL 23, 188, 247

PENTACHLORONITROBENZENE

*See* QUINTOZENE

PENTACHLOROPHENOL 188, 206, 272

PENTADECANOIC ACID 229

PENTAERYTHRITYL TETRANITRATE 109

PENTAGASTRIN 109

PENTAMETHONIUM 109

PENTAMIDINE (includes pentamidine isethionate) 109

PENTAZOCINE 211, 284

PENTHIENATE 109

PENTHIOPYRAD 152

Pentobarbitone 109, 211, 284

PENTOLINIUM 109

PENTOSAN POLYSULFATE SODIUM 110

PENTOXIFYLLINE

*See* OXPENTIFYLLINE 107

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018) 216

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE \*(JWH-122) 216

PEPAP

*See* 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE 216

PEPPERMINT OIL 229

Peracetic acid 152, 188, 247, 272

PERFLUIDONE 188

PERGOLIDE 110

PERHEXILINE 110

PERICYAZINE 110, 284

PERINDOPRIL 110

PERMANGANATES 188, 272

PERMETHRIN 110, 152, 189

PERPHENAZINE 110, 284

PERTUSSIS ANTIGEN 110

PESTICIDE 7

PETASITES 233

Pethidine 211, 284

PETHIDINE INTERMEDIATE A

*See* 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE 209

PETHIDINE INTERMEDIATE B

*See* 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER 211

PETHIDINE INTERMEDIATE C

*See* 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID 210

Petrol 21, 152, 247

*See also* BENZENE 200

*See also* MOTOR, HEATING or FURNACE FUELS 220

PETROLEUM OILS

*See* HYDROCARBONS, LIQUID

PHEDRAZINE 44

PHENACEMIDE 110

PHENACETIN 110

PHENADOXONE 216

PHENAGLYCODOL 110

PHENAMPROMIDE 216

PHENAZOCINE 216

PHENAZONE 44, 110, 152

PHENAZOPYRIDINE 110

PHENCYCLIDINE \*(PCP) 216

PHENDIMETRAZINE 211

PHENELZINE 110, 284

PHENETICILLIN 110

PHENFORMIN 110

PHENGLUTARIMIDE 110

PHENINDIONE 110

Pheniramine 44, 52, 110, 284

PHENISATIN 110

PHENISOPHAM 152

PHENMEDIPHAM 229

PHENMETRAZINE 211

PHENOBARBITONE 110, 284

PHENOLS 45, 110, 153, 189, 248, 272

*See also* CREOSOTE 172

PHENOLPHTHALEIN 110

PHENOMORPHAN 216

PHENOPERIDINE 211, 284

PHENOTHIAZINE 189

PHENOXYBENZAMINE 110

PHENOXYMETHYLPENICILLIN 110

PHENSUXIMIDE 110

PHENTERMINE 110, 236

PHENTHIMENTONIUM 110

PHENTOLAMINE 111

PHENYL MERCURIC CHLORIDE

*See* MERCURY

PHENYL METHYL KETONE 153, 248

*See also* DESIGNATED SOLVENT 5

PHENYLACETYLINDOLES 216

PHENYLBUTAZONE 111

PHENYLENEDIAMINES 189, 233, 248, 272

Phenylephrine 45, 111, 272

*See also* CODEINE (+ phenylephrine) 35

*See also* PARACETAMOL (+ phenylephrine) 44

*See also* IBUPROFEN (+ phenylephrine) 41

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP) 216

PHENYLMERCURIC ACETATE 206, 282

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (PETHIDINE INTERMEDIATE B) 211

111, 272

PHENYLTOLOXAMINE 111, 284

Phenytoin 111, 272

Pholcodine 45, 111, 211, 284

PHORATE 206

PHOSALONE 189

PHOSFOLAN 206

PHOSMET 189

PHOSPHIDES, METALLIC 206, 282

Phosphine 206, 282

PHOSPHODIESTERASE TYPE 5 INHIBITORS 111

PHOSPHONIC ACID 153, 248, 272

Phosphoric acid 153, 189, 248, 272

PHOSPHORUS 277

PHOSPHORUS, YELLOW 206, 248, 272

PHOSPHOURUS ACID

*See* PHOSPHONIC ACID

PHOTOGRAPHIC PAPER or FILM 220

PHOXIM 190

PHP

*See* ROLICYCLIDINE 217

PHTHALYLSULFATHIAZOLE 111

PHYSOSTIGMINE 111

PHYTASE 229

PHYTOMENADIONE

*See* VITAMIN K

PICARIDIN 153

PICLORAM 229

PICOLINAFEN 229

PICRIC ACID 248, 273

PICROTOXIN 111

PIGEON POX VACCINE 130

PIGMENTS 220

PILOCARPINE 111

PIMARCIN

*See* NATAMYCIN

PIMECROLIMUS 111

PIMELIC ACID 229

PIMINODINE 216

PIMOBENDAN 111

Pimozide 111, 284

PINACIDIL 111

PINDOLOL 111

PINDONE 190

PINE OILs 153, 190

PINOXADEN 153, 190

PIOGLITAZONE 111

PIPECURONIUM 111

PIPEMIDIC ACID 111

PIPENZOLATE 111

PIPER METHYSTICUM (kava) 112

PIPERACILLIN 112

PIPERAZINE 45, 153

PIPERAZINE OESTRONE SULFATE

*See* ESTROPIPATE 82

PIPERIDINE 112

PIPERIDOLATE 112

PIPERONYL BUTOXIDE 229

PIPEROPHOS 190

PIPOBROMAN 112

PIPOTHIAZINE 112

PIPRADROL 112

PIRACETAM 112

PIRBUTEROL 112

PIRENOXINE (catalin) 112

PIRENZEPINE 112

PIRETANIDE 112

PIRIMICARB 153, 190

PIRIMIPHOS-ETHYL 190

PIRIMIPHOS-METHYL 190

PIRITRAMIDE 211

PIROXICAM 112

PIRPROFEN 112

PITAVASTATIN 112

PITUITARY HORMONES 112

PIVAMPICILLIN 112

Pizotifen 112, 284

PLASMA

*See* BLOOD COMPONENTS 3

*See* HUMAN BLOOD PRODUCTS 219

PLASMA SUBSTITUTES

*See* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES 219

PLASMA-DERIVED THERAPEUTIC PROTEINS

*See* HUMAN BLOOD PRODUCTS 219

PLATELETS

*See* BLOOD COMPONENTS 3

*See* HUMAN BLOOD PRODUCTS 219

PLERIXAFOR 112

PLICAMYCIN 112

PMA

*See* 4-METHOXY--METHYLPHENYLETHYLAMINE 215

PNEUMOCOCCAL VACCINE 113

PODOPHYLLIN 273

*See also* PODOPHYLLUM EMODI 45, 52, 113

*See also* PODOPHYLLUM PELTATUM 45, 52, 113

*See also* PODOPHYLLUM RESIN 277

Podophyllotoxin 45, 52, 113, 273

PODOPHYLLUM EMODI (podophyllin) 45, 52, 113

PODOPHYLLUM PELTATUM (podophyllin) 45, 52, 113

PODOPHYLLUM RESIN (podophyllin) 277

POISON 7

POLIDEXIDE 113

POLIHEXANIDE 153, 273

POLIOMYELITIS VACCINE 113

POLIXETONIUM SALTS 153, 190

POLOXALENE 229

POLY (GNRF) OVALBUMIN 229

POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE 229

POLY(OXY-1,2-ETHANEDIYL) 153, 248, 273

POLYACRYLAMIDE 113

POLYDADMAC

*See* POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE 229

POLYESTRADIOL 113

POLYETHANOXY (15) TALLOW AMINE 153, 248, 273

POLYHEDROSIS VIRUS OF *HELICO ZEA* OCCLUSION BODIES 229

POLYLACTIC ACID 113

POLYMYXIN 113

POLYSILICONE-15

*See* DIMETHICODIETHYLBENZALMALONATE

POLYSORBATE 20 229

POLYSULFATED GLYCOSAMINOGLYCANS 113

POLYTHIAZIDE 113

POPPY STRAW CONCENTRATE 209

PORACTANT 113

PORCELAIN 220

PORCINE SOMATOTROPHIN 229

POSACONAZOLE 113

POTASSIUM AZELOYL DIGLYCINATE 190

POTASSIUM BICARBONATE 229

POTASSIUM BROMATE 190, 249

POTASSIUM BROMIDE 113

POTASSIUM CARBONATE

*See* ALKALINE SALTS

POTASSIUM CHLORATE 45, 153, 249

POTASSIUM CHLORIDE 114

POTASSIUM CHROMATE iv

*See* CHROMATES 169

*See* CHROMIUM 279

POTASSIUM CYANATE 190, 249

Potassium hydroxide 23, 153, 190, 233, 249, 273

POTASSIUM METABISULPHITE 153, 249, 273

Potassium nitrite 154, 190, 206, 249, 273

POTASSIUM PERCHLORATE 114

POTASSIUM PERMANGANATE

s*ee* PERMANGANATES 188

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT 154, 191, 249

POTASSIUM PERSULFATE 191, 249, 273

POTASSIUM PHOSPHATE

*See* ALKALINE SALTS

POTASSIUM SALTS

*See* ALKALINE SALTS 133, 161, 231

*See* BIFLUORIDES 136, 165, 200, 241, 262, 281

POTASSIUM SILICATE

*See* ALKALINE SALTS

POTASSIUM SORBATE 229

POTASSIUM SULFIDE 154, 249, 273

POULTRY VACCINES 130

PRACTOLOL 114

PRALIDOXIME 114

PRALLETHRIN 154, 191

PRAMIPEXOLE 114

PRAMOCAINE 114

PRAMPINE 114

PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone) 114

PRASUGREL 114

PRAVASTATIN 114

Prazepam 114, 284

PRAZIQUANTEL 114

PRAZOSIN 114

PREDNISOLONE 114

PREDNISONE 114

PREGABALIN 114, 284

PREGNENOLONE 114

PRENALTEROL 114

PRENYLAMINE 114

PREPARATIONS, DIVIDED 5

PRILOCAINE 45, 114

PRIMAQUINE 114

PRIMARY PACK 7

PRIMIDONE 114

PRINTING INKS OR INK ADDITIVES 221

PROBENECID 114

PROBUCOL 114

PROCAINAMIDE 114

PROCAINE 115

PROCAINE PENICILLIN 115

PROCARBAZINE 115

PROCHLORAZ 191

PROCHLORPERAZINE 52, 115, 284

PROCYCLIDINE 45, 115

PROCYMIDONE 206

PROFENOFOS 191

PROFOXYDIM 154

PROGESTERONE 115, 154, 277

PROGESTOGENS 115

PROGLUMIDE 115

PROGUANIL 115

PROHEPTAZINE 216

PROHEXADIONE CALCIUM 154

PROLINTANE 115

PROMACYL 191

Promazine 115, 285

Promethazine 45, 52, 115, 285

PROMETRYN 154

PROMOXOLANE 115

PROPACHLOR 191

PROPAFENONE 115

PROPAMIDINE 46, 115

PROPAMOCARB 154

PROPANIDID 115

PROPANIL 154

PROPANTHELINE 115

PROPAQUIZAFOP 154

PROPARGITE 191

PROPENTOFYLLINE 115

PROPERIDINE 216

PROPETAMPHOS 191

PROPETANDROL 115

PROPICONAZOLE 154, 191

propineb 15, 191

*See also* DITHIOCARBAMATES

PROPIONIBACTERIUM ACNES 115

Propionic acid 154, 191, 249, 274

PROPIRAM 211

PROPOFOL 115

PROPOXUR 154, 191

PROPRANOLOL 115, 277

PROPYL ACETATES 229

PROPYLENE GLYCOL 229

2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER 229

PROPYLENE OXIDE 206, 282

PROPYLHEXEDRINE 115

PROPYLTHIOURACIL 115

PROPYPHENAZONE 115

PROPYZAMIDE 155

PROQUAZONE 115

PROQUINAZID 191

PROSCILLARIDIN 115

PROSTAGLANDINS 115

PROSTIANOL 116

PROSULFOCARB 191

PROSULFURON 191

PROTAMINE 116

PROTEIN C

*See* HUMAN BLOOD PRODUCTS 220

ALPHA1-PROTEINASE INHIBITOR (HUMAN) 56

PROTHIOCONAZOLE 229

PROTHIOCONAZOLE-DESCHLORO 155

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE 155

PROTHIOFOS 191

PROTHIONAMIDE 116

PROTHIPENDYL 116

PROTHROMBIN COMPLEX CONCENTRATE (PCC)

*See* HUMAN BLOOD PRODUCTS 220

PROTIRELIN 116

PROTOVERATRINES 116

PROTRIPTYLINE 116, 285

PROXYMETACAINE 116

PRUCALOPRIDE 116

PSEUDOEPHEDRINE 52, 116

PSEUDOMONAS FLUORESCENS 229

PSILOCINE

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE 213

PSILOCYBINE 216

PSILOTSIN

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE 213

PTERIDIUM spp 233

PULMONARIA spp 233

PYMETROZINE 155

PYRACLOFOS 192

PYRACLOSTROBIN 155

PYRAFLUFEN-ETHYL 155

PYRANTEL 46

PYRASULFOTOLE 155

PYRAZINAMIDE 116

PYRAZOPHOS 192

PYRETHRIC ACIDS

*See* PYRETHRINS 46, 155

PYRETHRINS 46, 155

PYRETHROLONE

*See* PYRETHRINS 46, 155

PYRIDABEN 155, 192

PYRIDALYL 192

PYRIDATE 192

PYRIDINOLCARBAMATE 116

PYRIDOSTIGMINE 116

PYRIDOXAL 116

PYRIDOXAMINE 116

PYRIDOXINE 116

PYRIFENOX 155

PYRIMETHAMINE 116

PYRIMETHANIL 229

Pyrinuron 206, 282

PYRIPROLE 192

PYRIPROXYFEN 229

PYRITHIOBAC SODIUM 155

PYRITHIONE COPPER 192

Pyrithione ZINC 46, 155, 192, 249

PYROVALERONE 116

PYROXASULFONE 192, 207

PYROXSULAM 192

PYRVINIUM 116

Q

QUASSIA 229

QUATERNARY AMMONIUM COMPOUNDS 14, 155, 192, 249

QUAZEPAM 116

QUETIAPINE 116, 285

QUINAGOLIDE 116

QUINALBARBITONE 211, 285

QUINAPRIL 116

QUINBOLONE 116

QUINCLORAC 155

QUINETHAZONE 116

QUINIDINE 116

QUININE 116, 155, 207

QUINISOCAINE (dimethisoquin) 117

QUINOXYFEN 229

QUINTOZENE 155

QUINUPRISTIN 117

QUIZALOFOP ETHYL. 192

QUIZALOFOP ETHYL (D + ISOMER)

*See* QUIZALOFOP ETHYL

QUIZALOFOP-P-ETHYL 156, 192

QUIZALOFOP-P-TEFURYL 192

R

RABEPRAZOLE 52, 117

RABIES VACCINE 117

RACEMETHORPHAN 216

RACEMORAMIDE 211

RACEMORPHAN 216

RACTOPAMINE 117, 156

RADIOGRAPHIC CONTRAST MEDIA (RADIOPAQUES) 221

RADIOISOTOPES 221

RADIOPAQUES

*See* RADIOGRAPHIC CONTRAST MEDIA 221

RALOXIFENE 117

RALTEGRAVIR 117

RALTITREXED 117

RAMIPRIL 117

RANIBIZUMAB 117

Ranitidine 46, 117, 274

RAPACURONIUM 117

RASAGILINE 117

RASBURICASE 117

RASML

*See* REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS 7

RAUWOLFIA SERPENTINA. 117

RAUWOLFIA VOMITORIA 117

RAZOXANE 117

REBOXETINE 117

RECOMBINANT FOLLICLE STIMULANT

*See* CORIFOLLITROPIN ALFA 235

RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE

*See* FOLLITROPIN ALPHA 235

*See* FOLLITROPIN BETA 235

RED CELLS

*See* BLOOD COMPONENTS 3

*See* HUMAN BLOOD PRODUCTS 219

RED YEAST RICE 117

REDUCERS

*See* HYDROCARBONS, LIQUID 21

*See* LIQUID HYDROCARBONS 23

REMIFENTANIL 211

REMOXIPRIDE 117

REPAGLINIDE 117

REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS 7

RESERPINE 117

RESMETHRIN 156, 192

RESTRICTED FLOW INSERT 7

RETAPAMULIN 117

RETEPLASE 117

RETIGABINE 117, 285

RIBAVIRIN 117

RIDAFOROLIMUS 118

RIFABUTIN 118

RIFAMPICIN 118

RIFAMYCIN 118

RIFAPENTINE 118

RIFAXIMIN 118

RILPIVIRINE 118

RILUZOLE 118

RIMEXOLONE 118

RIMITEROL 118

RIMONABANT 118

RIMSULFURON 156

RISEDRONIC ACID 118

RISPERIDONE 118, 285

RITODRINE 118

RITONAVIR 118

RITUXIMAB 118

RIVAROXABAN 118

RIVASTIGMINE 118

RIZATRIPTAN 118

ROBENACOXIB 118

ROBENIDINE 156

ROCURONIUM 118

ROFECOXIB 118

ROFLUMILAST 118

ROLICYCLIDINE \*(PHP or PCPY) 217

ROLITETRACYCLINE 118

ROMIFIDINE 118

ROMIPLOSTIM 118

RONIDAZOLE 118

ROPINIROLE 118

ROPIVACAINE 119

ROSEMARY OIL 229

*See also* CAMPHOR 136, 167

*See also* CINEOLE 170

ROSIGLITAZONE 119

ROSOXACIN 119

ROSUVASTATIN 119

ROTENONE 192

ROTIGOTINE 119, 285

ROXIBOLONE 119

ROXITHROMYCIN 119

RUBELLA VACCINE 119

RUBOXISTAURIN 119

RUPATADINE 119, 285

S

s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE

*See* TRIBUFOS 208

SABADILLA

*See* SCHOENOCAULON OFFICINALE 119

SAFLUFENACIL 156, 207

Safrole 193, 234, 249, 274

*See also* SASSAFRAS OIL 193

Sage oil (Dalmatian) 23, 193, 249

SAGE OIL (Spanish) 229

*See also* CAMPHOR 136, 167

Salbutamol 52, 119, 274

SALCATONIN 119

SALE OR SUPPLY 26

Salicylamide 46, 119, 274

*See also* ASPIRIN (+ salicylamide) 59

*See also* PARACETAMOL(*+* salicylamide) 108

SALICYLANILIDE 156

SALICYLIC ACID 53

SALINOMYCIN 119, 193

SALMETEROL 119

SALVIA DIVINORUM 217

SALVINORIN A

*See* METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE 215

SANDALWOOD OIL 229

SANTONIN 53

SAPROPTERIN 119

SAQUINAVIR 119

SARM

*See* SELECTIVE ANDROGEN RECEPTOR MODULATORS 119, 236

Sassafras oil 193, 249, 274

SAVIN(E)

*See* JUNIPERUS SABINE 233

SAXAGLIPTIN 119

SCABBY MOUTH VACCINE 130

SCHOENOCAULON OFFICINALE (sabadilla) 119

SCHRADAN 207

SCOPOLIA CARNIOLICA 119

SEAWEED & UNFRACTIONED SEAWEED EXTRACTS 229

SECBUTOBARBITONE 211, 285

SECOBARBITAL

*See* QUINALBARBITONE

SECOND SCHEDULE PAINT 7, 272, 279

SEDAXANE 156

SEEDS 221

SELAMECTIN 156

SELECTED CONTAINER 7

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) 119, 236

SELEGILINE 119

selenium v, 46, 119, 193, 207, 277, 279

SELENIUM ARSENIDE

*See* ARSENIC 199

*See* SELENIUM 207

SELENIUM COMPOUNDS 249, 274, 279

SELENIUM SULFIDE

*See* SELENIUM 46

SEMDURAMICIN 194, 207

SENECIO spp 234

SERMORELIN 120

SERTINDOLE 120

SERTRALINE 120

SETHOXYDIM 156

SEVELAMER 120

SEVOFLURANE 120

SEX HORMONES 120

SHUI OIL

*See* CAMPHOR

SIBUTRAMINE 120

SIDURON 156

SILANDRONE 120

SILDENAFIL 120

SILICOFLUORIC ACID

*See* HYDROSILICOFLUORIC ACID

SILICOFLUORIDES 156, 194, 249

*See also* FLUORIDES 267

SILICONES 120, 234

Silver 46, 274

SILVER NITRATE 194

SILVER SALTS 250

*See also* SILVER NITRATE 194

SILVER SULFADIAZINE 120

SIMAZINE 229

SIMVASTATIN 120

SINBIOALLETHRIN 156, 194

SINGLE-USE TUBES FOR THE ESTIMATION OF ALCOHOL CONTENT OF BREATH 221

SIROLIMUS 120

SISOMICIN (sisomycin) 120

SITAGLIPTIN 120

Sitaxentan 120, 236, 274, 287

SLIMICIDES 219

SODIUM ALUMINATE 194, 250, 274

SODIUM BICARBONATE 229

SODIUM BROMATE 194, 250

SODIUM BROMIDE 120

SODIUM CARBONATE

*See* ALKALINE SALTS

SODIUM CELLULOSE PHOSPHATE 120

SODIUM CHLORATE 156, 250, 274

SODIUM CHROMATE

*See* CHROMATES 169

*See* CHROMIUM 279

SODIUM CLODRONATE

*See* CLODRONIC ACID 71

SODIUM CROMOGLYCATE 46, 120

SODIUM DIACETATE 156, 250

SODIUM DICHLOROISOCYANURATE 250

*See also* DICHLOROISOCYANURATES 265

SODIUM 2,2-DICHLOROPROPIONATE

*See* 2,2-DPA

SODIUM DODECYLBENZENE SULFONATE 156, 250, 274

SODIUM FLUORIDE 274

SODIUM HYDROGEN SULFATE 156, 250, 274

SODIUM HYDROSULFITE 156, 250, 274

Sodium hydroxide 24, 156, 194, 234, 250, 274

SODIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS 137, 168

SODIUM LAURETH-6 CARBOXYLATE 156, 250, 275

SODIUM LAURYL SULFATE 194, 250

SODIUM METABISULPHITE 157, 250, 275

SODIUM MORRHUATE 120

Sodium nitrite 46, 157, 195, 207, 250, 275

SODIUM NITROPRUSSIDE 120

SODIUM OXYBATE

*See* 4-HYDROXYBUTANOIC ACID

SODIUM PERCARBONATE 157, 195, 250

SODIUM PERSULFATE 195, 250, 275

SODIUM PHOSPHATE 53, 120

SODIUM PICOSULFATE 53

SODIUM POLYSTYRENE SULPHONATE 120, 157

SODIUM propionate 229

SODIUM SALICYLATE 121

SODIUM SALTS

*See* ALKALINE SALTS 133, 161, 231

*See* BIFLUORIDES 136, 165, 200, 241, 262, 281

SODIUM SILICATE(S)

*See* ALKALINE SALTS

SODIUM STANNATE 157, 250

Sodium sulfide 157, 195, 250, 275

SODIUM TETRADECYLSULFATE 121

SODIUM TRICHLOROACETATE 250

SOLASODINE 121

SOLID 7

SOLIFENACIN 121

SOMATOSTATIN 121

SOMATOTROPIN EQUINE 121

SOMATROPIN (human growth hormone) 121, 236

SONTOQUINE 121

SORAFENIB 121

SOTALOL 121

SPARFLOXACIN 121

SPARTEINE 121

SPECTINOMYCIN 121

SPINETORAM 157

SPINOSAD 157

SPIRAMYCIN 121

SPIRAPRIL 121

SPIRONOLACTONE 121

SPIROTETRAMAT 195

SPIROXAMINE 195

SQUILL 46

STABAXOL

*See* 2,2',6'6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE

STANOLONE 121

STANOZOLOL 121

STAPHISAGRIA

*See* DELPHINIUM STAPHISAGRIA 36

STAR ANISE OIL 157

STATINS

*See* HMG-CoA REDUCTASE INHIBITORS 89

STAVUDINE 121

STEM CELLS

*See* BLOOD COMPONENTS 3

*See also* HUMAN BLOOD PRODUCTS

STENBOLONE 121

STERIC ACID 229

STEROID HORMONES 121

STEROIDAL AGENTS

*See* ANABOLIC STEROIDAL AGENTS 236

*See* ANDROGENIC STEROIDAL AGENTS 236

STILBOESTROL (diethylstilboestrol) 121

STORAGE 28

STP

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE 212

STRAMONIUM

*See* DATURA STRAMONIUM 36, 74

*See* DATURA TATULA 36, 74

STREPTODORNASE 121

STREPTOKINASE 121

STREPTOMYCIN 121

STRONTIUM CHROMATE

*See* CHROMATES 169

*See* CHROMIUM 279

STRONTIUM RANELATE 121

STROPHANTHINS 121

STROPHANTHUS spp 121, 277

Strychnine 27, 121, 207, 250, 277, 282

STRYCHNOS spp 122

STYRAMATE 122

Styrene 157, 250, 275

*See also* DESIGNATED SOLVENT 5

SUBSTANCE 8

SUCCIMER 122

SUCCINYLATED & ETHERIFIED STARCHES 219

SUCRALFATE 229

SUFENTANIL 211

SUGAMMADEX 122

SULBACTAM 122

Sulcofuron 195, 207, 250, 282

SULCONAZOLE 46, 122

SULESOMAB 229

SULFACETAMIDE 53, 122, 157

*See also* SULFONAMIDES

SULFADIAZINE 122, 157

SULFADIMETHOXINE 122

SULFADIMIDINE 122, 157

SULFADOXINE 122

SULFAFURAZOLE 122

SULFAGUANIDINE 122

SULFAMERAZINE 122, 157

SULFAMETHIZOLE 122

SULFAMETHOXAZOLE 122

SULFAMETHOXYDIAZINE 122

SULFAMETHOXYPYRIDAZINE 122

SULFAMETROLE 122

Sulfamic acid 157, 195, 251, 275

SULFAMONOMETHOXINE 122

SULFAMOXOLE 122

SULFAPHENAZOLE 122

SULFAPYRIDINE 122

SULFAQUINOXALINE 122

SULFASALAZINE 122

SULFATHIAZOLE 122, 157

SULFATROXAZOLE 122

SULFENTRAZONE 207

SULFINPYRAZONE 122

SULFLURAMID 195

SULFOMETURON-METHYL 157

SULFOMYXIN 123

SULFONAL

*See* SULFONMETHANE 123

SULFONAMIDES 123

SULFONMETHANE (sulfonal and alkyl sulfonals) 123

SULFOSULFURON 229

SULFOTEP 207

Sulfuric acid 195, 251, 275

SULFURYL FLUORIDE 195

SULINDAC 123

SULPHANILAMIDE

*See* SULFONAMIDES

SULPHATED POLYSACCHARIDES 229

SULPROFOS 195

SULTAMICILLIN 123

SULTHIAME 123

SUMATRIPTAN 123

SUNITINIB 123

SUPPLY OR SALE 26

SUPROFEN 123

SUTILAINS 123

SUXAMETHONIUM 123

SUXETHONIUM 123

SYMPHYTUM spp. (Comfrey) 157, 234, 275

SYNEPHRINE

*See* OXEDRINE

SYNTHETIC CANNABINOMIMETICS 217

T

2,3,6-TBA 158

2,4,5-T 195

TACRINE 123

TACROLIMUS 123

TADALAFIL 123

TAFLUPROST. 123

TALIGLUCERASE ALFA 123

TALLOW ALKYLAMINE ACETATES 195

TAMOXIFEN 123

TAMSULOSIN 123

TANACETUM VULGARE 123

TANNIC ACID 229

TANNIC ACID/BENZYL ALCOHOL 230

TANSY OIL

*See* TANACETUM VULGARE 123

TAPENTADOL 211, 285

TAR

*See* PHENOL

TAR ACIDS 195

TASONERMIN 123

TAZAROTENE 123, 275

TAZOBACTAM 123

TBTO

*See* TRI-ALKYL TIN COMPOUNDS/SALTS

T-CELL RECEPTOR ANTIBODY 123

TCMTB (2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE) 195

TCP

*See* TENOCYCLIDINE 217

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) 158, 196

TEA TREE OIL

*See* MELALEUCA OIL 23, 184

TEBUCONAZOLE 158

TEBUFENOZIDE 158

TEBUFENPYRAD 196

TEBUTHIURON 196

TEFLUTHRIN 158, 207

TEGAFUR 123

TEGASEROD 123

TEICOPLANIN 124

TELAPREVIR 124

TELBIVUDINE 124

TELITHROMYCIN 124

TELMISARTAN 124

Temazepam 124, 285

TEMEPHOS 158, 196

TEMOZOLOMIDE 124

TEMPERATURE - BOILING OR DISTILLATION 9

TEMSIROLIMUS 124

TENECTEPLASE 124

TENIPOSIDE 124

TENOCYCLIDINE \*(TCP) 217

TENOFOVIR 124

TENOXICAM 124

TEPOXALIN 124

TEPP 207

TEPRALOXYDIM 158

TERAZOSIN 124

TERBACIL 230

TERBINAFINE 46, 124

TERBUCONAZOLE

*See* TEBUCONAZOLE

TERBUFOS 207

Terbutaline 53, 124, 275

TERBUTHYLAZINE 196

TERBUTRYN 158

TERFENADINE 124, 275

*See also* ANTIHISTAMINES 261

TERIFLUNOMIDE 124, 275, 287

TERIPARATIDE 124, 235

TERLIPRESSIN 124

TERMITE BARRIERS 221

TERODILINE 124

TEROPTERIN 124

TERPENES, CHLORINATED 196, 251, 275

TESTOLACTONE 124

TESTOSTERONE 124, 196, 277

TETANUS ANTITOXIN 124

TETANUS TOXOID 124

TETRABENAZINE 125

TETRACAINE

*See* AMETHOCAINE

Tetrachloroethane 208, 251, 275, 282

Tetrachloroethylene 46, 158, 196, 251, 275

*See also* DESIGNATED SOLVENT 5

TETRACHLORVINPHOS 158

TETRACONAZOLE 158, 196

TETRACOSACTRIN 125

TETRACYCLINE 125, 158

TETRADIFON 196

TETRAETHYLAMMONIUM 125

TETRAHYDROCANNABINOLIC ACID

*See* NABIXIMOLS 210

TETRAHYDROCANNABINOLS 217

*See also* NABIXIMOLS 210

TETRAHYDROCANNABIVAROL

*See* NABIXIMOLS 210

TETRAHYDROZOLINE 46, 275

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE 196, 208, 282

TETRAMETHRIN 158

TETRAMISOLE 196

TETRAPION

*See* FLUPROPANATE

TETROXOPRIM 125

TFMPP

*See* 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE 217

Thalidomide 125, 235, 275, 288

Thallium 27, 208, 282

THALLIUM SULFATE

*See* THALLIUM

THAUMATIN 230

THEBACON 211

THEBAINE 211

THENYLDIAMINE 125, 285

THEOPHYLLINE 53, 125

THERAPEUTIC GOOD 7

THERAPEUTIC USE 7

THEVETIA PERUVIANA 125

THEVETIN 125

THIABENDAZOLE 46, 158

THIACETARSAMIDE 125

*See also* ARSENIC 162

THIACLOPRID 196

THIAMBUTOSINE 125

THIAMAZOLE

*See* METHIMAZOLE

THIAMETHOXAM 158, 196

THIAZAFLURON 196

THIAZOPYR 158

THIAZOSULFONE 125

THIDIAZURON 230

THIETHYLPERAZINE 125, 285

THIFENSULFURON 158

THINNERS

*See* HYDROCARBONS, LIQUID 21

*See* LIQUID HYDROCARBONS 23

THIOACETAZONE 125

THIOBENCARB 159

THIOCARLIDE 125

2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

*See* TCMTB 195

THIODICARB 159, 196

THIOFANOX 208

THIOFENTANYL 217

THIOGUANINE 125

THIOMESTERONE (tiomesterone) 125

THIOMETON 196

THIOPENTONE 125

THIOPHANATE-METHYL 159, 196

THIOPROPAZATE 125, 285

THIOPROPERAZINE 125

THIORIDAZINE 125, 285

THIOSTREPTON 125

THIOTEPA 125

THIOTHIXENE 125, 285

THIOURACIL 125

Thiourea 125, 251, 275

THIOUREA AND ALKYL THIOUREAS 196

thiram 15, 196

*See also* DITHIOCARBAMATES

THIRD SCHEDULE PAINT 8, 279

THROMBIN

*See* HUMAN BLOOD PRODUCTS 220

Thujone 24, 196, 251

*See also* SAGE OIL 193

Thyme oil 24, 159, 251

THYMOL 196

THYMOXAMINE (includes thymoxamine hydrochloride 125

THYROID 125

THYROTROPHIN 126

THYROXINE 126, 277

TIAGABINE 126

TIAMULIN 126

TIAPROFENIC ACID 126

TIARAMIDE 126

TIBOLONE 126

TICAGRELOR 126

TICARCILLIN 126

TICLOPIDINE 126

TIEMONIUM 126

TIENILIC ACID 126

TIGECYCLINE 126

TIGLOIDINE 126

TILDIPIROSIN 126

TILETAMINE 126

TILIDINE 211

TILMICOSIN 126

TILUDRONIC ACID (includes disodium tiludronate) 126

TIMBER or WALLBOARD 221

TIMOLOL 126

TIN ORGANIC COMPOUNDS 208

TINIDAZOLE 126

TINTER 8

TINZAPARIN (includes tinzaparin sodium) 126

TIOCARBAZIL 159

TIOCONAZOLE 46, 53, 126

TIOMESTERONE

*See* THIOMESTERONE 125

TIOTROPIUM 126

TIPEPIDINE 126

TIPRANAVIR 126

TIRILAZAD 126

TIROFIBAN 127

TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS − INJECTABLE

*See* MEDICAL DEVICES 220

TMA

*See* 3,4,5-TRIMETHOXY--METHYLPHENYLETHYLAMINE 217

TOBRAMYCIN 127

TOCAINIDE 127

TOCERANIB 127

TOCILIZUMAB 127

TOLAZAMIDE 127

TOLAZOLINE 127

TOLBUTAMIDE 127

TOLCAPONE 127

TOLCLOFOS-METHYL 159

TOLFENAMIC ACID 127

TOLMETIN 127

TOLONIUM 127

TOLPROPAMINE 127

TOLRESTAT 127

TOLTERODINE 127

TOLTRAZURIL 159

TOLUENE 22, 197, 251, 275, 279

*See also* HYDROCARBONS, LIQUID 145

*See also* XYLENE 198

Toluenediamine 197, 234, 251, 275

TOLVAPTAN 127

TOLYLFLUANID 197

TOPICAL USE 8

TOPIRAMATE 127

TOPOTECAN 127

TORASEMIDE 127

TOREMIFENE 127

TOXOIDS 127

TOY 8

TOY FUELS

*See* MOTOR, HEATING or FURNACE FUELS 220

TRALKOXYDIM 159

Tramadol 127, 285

TRAMAZOLINE 46, 275

TRANDOLAPRIL 127

TRANEXAMIC ACID 127

TRANSDERMAL USE 8

TRANSFLUTHRIN 197

TRANYLCYPROMINE 127, 285

TRASTUZUMAB 127

TRAVOPROST 127

TRAZODONE 127

TRENBOLONE 159

TRENBOLONE (trienbolone, trienolone) 128

TREOSULPHAN 128

TREPROSTINIL 128

TRESTOLONE 128

TRETAMINE 128

Tretinoin 128, 235, 276, 288

TRIACETYLOLEANDOMYCIN 128

TRIADIMEFON 159, 197

TRIADIMENOL 159

TRIALKYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRI-ALLATE 15, 159

Triamcinolone 46, 53, 128, 276

TRIAMIPHOS 208

TRIAMTERENE 128

TRIASULFURON 230

TRIAZBUTIL 208

TRIAZIQUONE 128

TRIAZOLAM 128

TRIBENURON-METHYL 159

TRIBUFOS (s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE) 208

TRIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRICHLORFON 197

*See* *also* METRIFONATE 101

TRICHLORMETHIAZIDE 128

Trichloroacetic acid 128, 159, 197, 251, 276

TRICHLOROACETIC acid alkali salts 251

1,1,1-TRICHLOROETHANE 159, 234, 251, 276

*See also* DESIGNATED SOLVENT 5

TRICHLOROETHENE

*See* TRICHLOROETHYLENE

Trichloroethylene 128, 197, 251, 276

TRICHLOROISOCYANURIC ACID 251, 282

*See also* CHLORINATING COMPOUNDS 264

TRICHLOROPHENOL 197, 276

TRICHODERMA HARZIANUM 230

TRICHODESMA AFRICANA 234

TRICLABENDAZOLE 197

TRICLOFOS 128

TRICLOPYR 197

TRICLOSAN 197

TRICOSENE

*See* (Z)-9-TRICOSENE 230

TRICYCLAMOL 128

TRIDEMORPH 198

TRIDIHEXETHYL 128

TRIDIPHANE 160

TRIENBOLONE

*See* TRENBOLONE 128

TRIENOLONE

*See* TRENBOLONE 128

TRIETAZINE 160

TRIETHANOLAMINE 160, 251, 276

TRIETHYL PHOSPHATE 198, 251, 276

TRIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRIETHYLENE GLYCOL 230

TRIETHYLENE THIOPHOSPHORAMIDE

*See* THIOTEPA

TRIFLOXYSTROBIN 160

TRIFLOXYSULFURON 230

TRIFLUMIZOLE 160

TRIFLUMURON 160

TRIFLUOPERAZINE 128, 285

TRIFLUOROMETHANESULFONIC ACID 198, 251, 276

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP) 217

TRIFLUPERIDOL 128

TRIFLUPROMAZINE 128

TRIFLURALIN 230

TRIFORINE 230

TRIIODOTHYRONINE

*See* LIOTHYRONINE SODIUM

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE 160, 251, 276

TRILOSTANE 128

TRIMEPERIDINE 217

Trimeprazine 47, 53, 128, 285

TRIMETAPHAN 128

TRIMETHOPRIM 128

3,4,5-TRIMETHOXY--METHYLPHENYLETHYLAMINE \*(TMA) 217

3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) 217

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE 217

TRIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRIMIPRAMINE 128, 285

TRIMUSTINE 128

TRINEXAPAC-ETHYL 160

TRINITROPHENOL 128, 198

3,6,9-TRIOXAUNDECANEDIOIC ACID 160, 276

TRIOXYSALEN 128

TRIPARANOL 234

TRIPELENNAMINE 129

TRIPHENYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRIPLE ANTIGEN VACCINE 129

Triprolidine 47, 53, 129, 285

TRIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 208

TRIPTORELIN 129

TRISODIUM NITRILOTRIACETATE 198

TRITICONAZOLE 160

TROGLITAZONE 129

TROMETAMOL 129

TROPICAMIDE 129

TROPISETRON 129

TROVAFLOXACIN 129

TROXIDONE 129

TRYPTOPHAN 129

TSH

*See* THYROTROPHIN

TUAMINOHEPTANE 47

TUBERCULIN 129

TUBOCURARINE 129

TULATHROMYCIN 129

TULOBUTEROL 129

TURPENTINE (MINERAL) 251

TURPENTINE OIL 160, 251

*See* *also* OIL OF TURPENTINE 23

TUSSILAGO FARFARA 234

TYLOSIN 129, 160

TYMAZOLINE 47, 276

TYPHOID VACCINE 129

U

ULOCLADIUM OUDEMANSII 230

ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS 219

UNICONAZOLE-P

*See* (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL 169

UNOPROSTONE 129

URACIL 129

URAPIDIL 129

UREA 230

13C-UREA 230

URETHANE 129

URINARY CATHETERS

*See* MEDICAL DEVICES 220

UROFOLLITROPIN 129, 235

UROKINASE 130

URSODEOXYCHOLIC ACID 130

USTEKINUMAB 130

V

VACCINE, CHOLERA 69

VACCINE, HAEMOPHILUS INFLUENZAE 88

VACCINE, HEPATITIS A 89

VACCINE, HEPATITIS B 89

VACCINE, HUMAN PAPILLOMAVIRUS 89

VACCINE, JAPANESE ENCEPHALITIS 93

VACCINE, MEASLES 97

VACCINE, MENINGOCOCCAL 98

VACCINE, MUMPS 102

VACCINE, PIGEON POX 130

VACCINE, PNEUMOCOCCAL 113

VACCINE, POLIOMYELITIS 113

VACCINE, RABIES 117

VACCINE, RUBELLA 119

VACCINE, SCABBY MOUTH 130

VACCINE, TRIPLE ANTIGEN 129

VACCINE, TYPHOID 129

VACCINE, VACCINIA VIRUS 130

VACCINE, VARICELLA 130

VACCINE, GnRH 88

VACCINES FOR HUMAN THERAPEUTIC USE 130

VACCINES, INFLUENZA AND CORYZA 91

VACCINES, POULTRY 130

VACCINES, VETERINARY LIVE VIRUS 130

VACCINIA VIRUS VACCINE 130

VALACICLOVIR 130

VALDECOXIB 130

VALGANCICLOVIR 130

VALNOCTAMIDE 130

VALPROIC ACID 130

VALSARTAN 130

VAMIDOTHION 198

VANCOMYCIN 130

VARDENAFIL 130

VARENICLINE 130

VARICELLA VACCINE 130

VASOPRESSIN 130

VECURONIUM 130

VEDAPROFEN 130

VELAGLUCERASE ALFA 130

VEMURAFENIB 130

VENLAFAXINE 130

VERAPAMIL 130

VERATRUM spp. 130

VERNAKALANT 130

VERNOLATE 160

VERTEPORFIN 130

VETERINARY AND MEDICAL ADHESIVES, GLUES AND CEMENTS 220

VETERINARY CHEMICAL 8

VETERINARY CHEMICAL PRODUCT 8

VETERINARY LIVE VIRUS VACCINES 130

VETIVER OIL 230

VIDARABINE 131

VIGABATRIN 131

VILANTEROL 131

VILANTEROL TRIFENATATE 131

VILDAGLIPTIN 131

VILOXAZINE 131

VINBLASTINE 131

VINCA ALKALOIDS

*See* UNDER INDIVIDUAL ENTRIES

VINCAMINE 131

VINCLOZOLIN 208, 276

VINCRISTINE 131

VINDESINE 131

VINFLUNINE 131

VINORELBINE 131

VINYL CHLORIDE 208, 282

VINYL ETHER 131, 230

VIPRYNIUMA

*See* PYRVINIUM

VIRGINIAMYCIN 131, 160

VISNADINE 131

VITAMIN A 131

VITAMIN D 53, 131

VITAMIN K 230

VITREOUS ENAMELS 221

VORICONAZOLE 131

VORINOSTAT 131

W

WALLBOARD

*See* TIMBER 221

WARFARIN 131, 160, 198

WHITE CELLS

*See* BLOOD COMPONENTS 3

*See* HUMAN BLOOD PRODUCTS 219

WHITE LEAD

*See* BASIC LEAD CARBONATE

WHITE MINERAL OILS

*See* HYDROCARBONS, LIQUID 145

WHITE PETROLEUM SPIRIT

*See* LIQUID HYDROCARBONS 23

*See* HYDROCARBONS, LIQUID 21,145

WHITE SPIRIT 252

*See also* HYDROCARBONS, LIQUID

WHOLE BLOOD

*See* HUMAN BLOOD PRODUCTS 219

WOOD

*See* CREOSOTE 35, 172

WRAPPER, IMMEDIATE 5

WRITING 8

WRITING CORRECTION PENS 221

X

XAMOTEROL 131

XANTHINOL NICOTINATE 131

XANTHOPHYLL (lutein) 230

XIMELAGATRAN 132

XIPAMIDE 132

XYLANASE 230

XYLAZINE 132

Xylene 22, 198, 252, 276, 279

*See also* HYDROCARBONS, LIQUID 145

*See also* TOLUENE 197

XYLENOLS 252

*See also* PHENOL 153, 189

XYLOMETAZOLINE 47, 276

Y

YELLOW PHOSPHORUS

*See* PHOSPHORUS, YELLOW 248, 272

YLANG YLANG OIL 230

YOHIMBINE 132

Z

ZAFIRLUKAST 132

ZALCITABINE 132

ZALEPLON 132

ZANAMIVIR 132

ZERANOL 132, 198

ZETA-cypermethrin 198, 208

ZIDOVUDINE 132

ZILPATEROL 132

ZIMELDINE 132

ZINC BORATE 198

Zinc chloride 47, 198, 252, 276

ZINC CHROMATE

*See* CHROMATES 169

*See* CHROMIUM 279

ZINC COMPOUNDS 132

ZINC NAPHTHENATE 230

ZINC PARA-PHENOLSULFONATE 198

ZINC PHOSPHIDE

*See* PHOSPHIDES METALLIC

Zinc sulfate 198, 252, 276

zineb 15, 160

*See also* DITHIOCARBAMATES

ZIPRASIDONE 132, 285

ziram 15, 198, 208

ZOLAZEPAM 132

ZOLEDRONIC ACID 132

ZOLMITRIPTAN 132

Zolpidem 132, 285

ZONISAMIDE 132, 285

Zopiclone 132, 285

ZOXAZOLAMINE 132

ZUCLOPENTHIXOL 132